Browse Biomarkers Based on Type

This page shows data for Prognostic type biomarker.
Total Entries Retrieved: 902
IDBiomarkerBiomoleculeSubjectsRegulationTypeExperimentLevel of SignificanceSourcePMID
14 MGC5466+Wnt5A+KIAA0476+ITPR1+TCF2 mRNA Humans Differentially Expressed in Recurrent Cancer Prognostic Recurrence Vs No Recurrence p<0.0001 Tissue 15067324
15 MGC5466+CHAF1A+CDS2+IER3 mRNA Humans Differentially Expressed in Recurrent Cancer Prognostic Recurrence Vs No Recurrence p<0.0001 Tissue 15067324
16 PPFIA3+COPEB+FOS+JUNB+ZFP36 mRNA Humans Differentially Expressed in Recurrent Cancer Prognostic Recurrence Vs No Recurrence p=0.001 Tissue 15067324
17 MGC5466+Wnt5A+KIAA0476+ITPR1+TCF2+CHAF1A+CDS2+IER3+PPFIA3+COPEB+FOS+JUNB+ZFP36 mRNA Humans Differentially Expressed in Recurrent Cancer Prognostic Recurrence Vs No Recurrence p<0.0001 Tissue 15067324
18 Insulin Like Growth Factor-1 (IGF-1) Protein Mice Downregulated in SPI (soy protein isolate) diet: [Control: (223 ±61ng/ml; SPI Diet: 349 ±40 ng/ml ) Prognostic PCa Mice fed Control Diet Vs PCa Mice fed soy protein isolate Diet p<0.05 Serum 10460196
23 XLKD1/LYVE1+CGA+ F2R/PAR1+ BCL-G mRNA Humans Differentially Expressed Prognostic Patients with Relapse Vs Without Relapse p<0.05 Tissue 14654526
24 Caveolin-1 Protein Humans Upregulated in African American Men (AA: 39% vs WA: 17%) Prognostic African Americans vs White American men with Prostate Cancer p=0.0048 Tissue 10999725
27 BCL-2 Protein Humans Upregulated in High Gleason Score Prognostic High (8-10) vs Low (2-4) Gleason Score p<0.001 Tissue 11500787
28 Insulin Protein Humans Upregulated in High Risk Group Prognostic High vs (Medium and Low) Risk p= 0.05 Serum 11757030
34 Triiodothyronine Protein Humans Upregulated in High Risk Group Prognostic High vs Moderate Risk Group p=0.041 Serum 12497024
35 Triiodothyronine Protein Humans Upregulated in High Risk Group Prognostic High vs Low Risk Group p=0.013 Serum 12497024
38 Annexin 1 Protein Humans Downregulated in Metastatic hormone refractory PCa (2.23 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p<0.001 Tissue 12507908
39 Annexin 2 Protein Humans Downregulated in Metastatic hormone refractory PCa (1.51 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p=0.009 Tissue 12507908
40 Annexin 4 Protein Humans Downregulated in Metastatic hormone refractory PCa (1.3 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p=0.001 Tissue 12507908
41 Annexin 7 Protein Humans Downregulated in Metastatic hormone refractory PCa (1.42 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p<0.001 Tissue 12507908
42 Annexin 11 Protein Humans Downregulated in Metastatic hormone refractory PCa (1.81 fold) Prognostic Localized Prostate Cancer VS Metastatic Hormone Refractory Prostate cancer p<0.001 Tissue 12507908
44 Fatty Acid Synthase (FAS) mRNA Humans Upregulated in Metastatic PCa (12 fold) [Mean Value: GS7 :149.2 Vs Metastatic: 1960.8] Prognostic Gleason Score 7 Vs Metastatic Tumor p<0.00000029 Tissue 12939396
48 phosphorylated Akt (pAkt) Protein Humans Upregulated in PSA failures (PSA Failure: [222.18±33.9 vs PSA Non-Failure: 108.79±104.57) Prognostic PSA failure versus PSA non failure p<0.001 Tissue 15289328
49 phosphorylated Akt (pAkt) + phosphorylated ERK (extracellular signal-regulated kinase) (pERK) Protein Humans pAKT: Upregulated in PSA failures; pERK: Downregulated in PSA failures Prognostic PSA failure versus PSA non failure NA Tissue 15289328
60 BCL-2 Protein Humans Upregulated in PCa Patients: PSA >10 ng/ml Prognostic PSA ≤10 ng/ml Vs PSA >10 ng/ml p<0.01 Tissue 15655565
61 COX-2 Protein Humans Upregulated in PCa Patients: PSA >10 ng/ml Prognostic PSA ≤10 ng/ml Vs PSA >10 ng/ml p<0.01 Tissue 15655565
62 BCL-2 Protein Humans Upregulated in Patients with relapse Prognostic PCa Relapse Vs No Relapse p<0.01 Tissue 15655565
63 COX-2 Protein Humans Upregulated in Patients with relapse Prognostic PCa Relapse Vs No Relapse p<0.01 Tissue 15655565
95 E-cadherin Protein Humans Upregulated in Metastatic PCa: (Localised PCa: 9.46; Metastatic PCa: 27.49) Prognostic Localised PCa Vs Metastatic PCa p<0.001 Serum 15870707
96 E-cadherin Protein Humans Iincreased risk of late biochemical failure with high expression Prognostic Biochemical Faliure Vs No Biochemical Faliure p<0.05 Serum 15870707
102 Methylation status of GSTP1 mRNA Humans Hypermethylated in Patients who relapsed Prognostic Time to Progression p<0.03 Tissue 16322291
103 Methylation status of GSTP1 mRNA Humans Hypermethylated in Patients who relapsed Prognostic Time to Progression P = 0.004 Tissue 16322291
104 Methylation status of APC mRNA Humans Hypermethylated in Patients who relapsed Prognostic Time to Progression P = 0.004 Tissue 16322291
105 Methylation status of GSTP1 mRNA Humans Hypermethylated in Patients who relapsed Prognostic Time to Progression P = 0.01 Tissue 16322291
106 Methylation status of Cyclin D2 + APC mRNA Humans Hypermethylated in Patients who relapsed Prognostic Time to Progression 0.01 Tissue 16322291
114 PCDH7, NRXN3, TPTE/ PTEN2, EPHA3, TSPY, HGF, PKIA, PRLR, NR2F1, TNS, MET, CALN1, ADAM-TS3, NPL4, MYO3A, GNA11, GAGEB1/PA GE1, AKAP9, TCF4, MYLK, KLK2, HOXA10, DDR2, EGF, TEM8, XAGE-1, GAS2. mRNA Humans Upregulated (Log2 fold change: 2-7.9 fold) Prognostic Androgen Independent PCa Vs Androgen Dependent PCa NA Cell Lines 17977648
115 ANGPT2, THBS1, CCL5, PTK6, CXCL11, S100P, PSMD5, CDKN2B, PEG3, HTATIP2, CXCL2, RND1, NK4, ACPP, ICAM1, FOSL2, SFN, PLAT, INHBE, CDKN1C, TP73, SOCS2, BMPR1B, CCL2, VIM, SPRY2, CXCL10, LCN2, AKAP12, KLF4, ATF3, FBN1, TWIST1, ALCAM, MSX2, LOX, BTG1, SOCS1, PPP3CA, PPP3CA mRNA Humans Downregulated (Log2 fold change: 1.3-7.8 fold) Prognostic Androgen Independent PCa Vs Androgen Dependent PCa NA Cell Lines 17977648
117 ααCTX Protein Humans Upregulated in Bone Metastatis PCa Prognostic Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer p<0.05 Urine 16434583
118 ββCTX Protein Humans Upregulated in Bone Metastatis PCa Prognostic Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer p<0.05 Urine 16434583
119 NTx Protein Humans Upregulated in Bone Metastatis PCa Prognostic Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer p<0.05 Urine 16434583
120 ICTP Protein Humans Upregulated in Bone Metastatis PCa Prognostic Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer p<0.05 Serum 16434583
121 BSAP Protein Humans Upregulated in Bone Metastatis PCa Prognostic Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer p<0.05 Serum 16434583
122 TRAP5b Protein Humans Upregulated in Bone Metastatis PCa Prognostic Bone Metastatis Prostate Cancer Vs No Bone Metastatis Prostate Cancer p<0.05 Serum 16434583
125 Neuropeptide Y (NPY) Protein Humans Upregulated in Gleason Pattern 4 Prognostic Gleason Pattern 3 Vs Gleason Pattern 4 p=0.042 Tissue 16614113
126 Neuropeptide Y (NPY) Protein Humans Upregulated in Gleason Pattern 5 Prognostic Gleason Pattern 4 Vs Gleason Pattern 5 p=0.037 Tissue 16614113
127 Neuropeptide Y (NPY) Protein Humans Increased expression with increase in relapse Prognostic Relapse Vs No Relapse after Radical Prosteactomy p=0.037 Tissue 16614113
130 Macrophage Inhibitory Cytokine-1 (MIC-1) Protein Humans Increased expression with increase in relapse Prognostic Relapse Vs No Relapse after Radical Prosteactomy p=0.037 Tissue 16614113
133 PTGS2 Other Humans Increased expression with increase in relapse Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p = 0.0395 Serum 17764114
134 Fusion Status of TMPRSS2-ERG mRNA Humans Fusion of the genes in Positive Biopsy PCa Prognostic Positive Vs Negative Biopsies for PCa NA Urine 17785564
135 PCA3 mRNA Humans Upregulated in Positive Biopsy PCa Prognostic Positive Vs Negative Biopsies for PCa NA Urine 17785564
139 CCNE2+CDC6+FBP1+HOXC6+MKI67+MYBL2+PTTG1+DTL+UBE2C+WNT5A+ALCAM+AZGP1+CCK+MYLK+PPAP2B+PROK1 mRNA Humans Increased GEX Score with relapse Prognostic Relapse Vs No Relapse p=0.007 Tissue 17459658
215 Endothelial cell-specific molecule 1; Protein tyrosine phosphatase receptor type-Q, CD24 antigen; Gap junction membrane channel protein alpha 1; Transmembrane 4 superfamily member 3; Serpine2; Activated leukocyte cell adhesion molecule; Fibromodulin; Plasminogen activator inhibitor 2 type A; Kelch repeat and BTB (POZ) domain containing 10 (krp1); Preproenkephalin, related sequence; Sialophorin; Thymosin beta-4; Glutamate receptor interacting protein 1; Synuclein, gamma; Hypoxanthine guanine phosphoribosyl transferase; Phosphoribosyl pyrophosphate synthetase 1; Phosphoribosyl pyrophosphate synthetase 2; UDP-Gal:betaGlcNAc beta1,4-galactosyltransferase, polypeptide 6; Dual specificity phosphatase 5; Cytochrome P450, family 3, subfamily a, polypeptide 13; 3-hydroxy-3-methylglutaryl-Coenzyme A reductase ; Branched chain keto acid dehydrogenase E1, beta polypeptide; Cytochrome P450, subfamily 24; Plasminogen activator, urokinase; Caveolin 1; Cyclin D1; High mobility group AT-hook 1; Cxxc5; HNF-3/forkhead homolog-1; Fatty acid binding protein 4, adipocyte; Fatty acid binding protein 5, epidermal; Rabin 3; Phospholipase C, delta 4; Decay-accelarating factor; Coagulation factor II (thrombin) receptor-like 1; Nerve growth factor receptor associated protein 1; Asparagine synthetase; Dual specificity phosphatase 6; Protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform; Protein tyrosine phosphatase, receptor type, N1; UDP glycosyltransferase 1 family polypeptide A2; Adenosine monophosphate deaminase 3; Stearoyl-Coenzyme A desaturase 1; Hypothetical LOC290595 (LOC290595), mRNA; Similar to Tubulin alpha-4 chain (Alpha-tubulin 4) (LOC316531), mRNA; Similar to chromosome 14 open reading frame 50 (LOC299153), mRNA; Guanine nucleotide binding protein beta 4 subunit mRNA, partial cds; mRNA Rat Upregulated (Endothelial cell-specific molecule 1 (26.5 fold); Protein tyrosine phosphatase receptor type Q (19.72 fold); CD24 antigen (15.56 fold); Gap junction membrane channel protein alpha 1 (10.53 fold); Transmembrane 4 superfamily member 3 (10.4 fold); Serpine2 (8.61 fold); Activated leukocyte cell adhesion molecule (6.65 fold) ; Fibromodulin (2.62 fold); Plasminogen activator inhibitor 2 type A (2.11 fold); Kelch repeat and BTB (POZ) domain containing 10 (krp1) (36.21 fold); Preproenkephalin, related sequence (24.63 fold); Sialophorin1 (24.14 fold); Thymosin beta-4 (19.82 fold) ; Glutamate receptor interacting protein 1 (8.4 fold) ; Synuclein, gamma (6.62 fold); Hypoxanthine guanine phosphoribosyl transferase (11.45 fold); Phosphoribosyl pyrophosphate synthetase 1 (8.25 fold) ; Phosphoribosyl pyrophosphate synthetase 2 (5.37 fold); UDP-Gal:betaGlcNAc beta1,4-galactosyltransferase, polypeptide 6 (3.4 fold); Dual specificity phosphatase 5 (2.35 fold); Cytochrome P450, family 3, subfamily a, polypeptide 13 (14.28 fold); 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (3.49 fold) ; Branched chain keto acid dehydrogenase E1, beta polypeptide (2.14 fold); Cytochrome P450, subfamily 24 (2.11 fold); Plasminogen activator, urokinase (4.68 fold); Caveolin 1 (31.05 fold) ; Cyclin D1 (7.95 fold); High mobility group AT-hook 1 (15.41 fold) ; Cxxc5 (4.25 fold); HNF-3/forkhead homolog-1 (3.08 fold); Fatty acid binding protein 4, adipocyte (34.02 fold); Fatty acid binding protein 5, epidermal (15.38 fold) ; Rabin 3 (6.46 fold); Phospholipase C, delta 4 (2.64 fold); Decay-accelarating factor (4.02 fold); Coagulation factor II (thrombin) receptor-like 1 (4.96 fold); Nerve growth factor receptor associated protein 1 (8.75 fold); Asparagine synthetase (14.65 fold); Dual specificity phosphatase 6 (11.08 fold); Protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform (2.31 fold) ; Protein tyrosine phosphatase, receptor type, N1 (2.22 fold); UDP glycosyltransferase 1 family polypeptide A21 (5.93 fold); Adenosine monophosphate deaminase 3 (2.14 fold); Stearoyl-Coenzyme A desaturase 1 (25.92 fold); Hypothetical LOC290595 (LOC290595), mRNA (8.46 fold); Similar to Tubulin alpha-4 chain (Alpha-tubulin 4) (LOC316531), mRNA (4.76 fold); Similar to chromosome 14 open reading frame 50 (LOC299153), mRNA (3.58 fold); Guanine nucleotide binding protein beta 4 subunit mRNA, partial cds (3.38 fold); Prognostic MAT-LyLu Vs G Cell Lines p<0.005 Cell Lines 17713630
216 Procollagen, type XII, alpha 1; Glycoprotein Ib (platelet), beta polypeptide; Macrophage stimulating 1 (hepatocyte growth factor-like); Alpha-2-macroglobulin; Hyaluronan and proteoglycan link protein 1; Glycoprotein 38; Decorin; Vascular cell adhesion molecule 1; Clusterin; Elastin; Biglycan; Selenoprotein P, plasma, 1; T-cell receptor gamma chain; Myxovirus (influenza virus) resistance 2; Major histocompatibility complex, class II, DM alpha; MHC class Ib RT1.S3; RT1 class Ib, locus Aw2; Similar to interferon regulatory factor 7 (LOC293624), mRNA; Late gestation lung protein 1; Transgelin; Ectonucleoside triphosphate diphosphohydrolase 2; Dual specificity phosphatase 1; Cytochrome b-245, alpha polypeptide; 3-alpha-hydroxysteroid dehydrogenase; Cathepsin S; Alanyl (membrane) aminopeptidase; Dipeptidase 1 (renal); Caspase 1; B-cell translocation gene 3; CD 81 antigen; Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA; Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA; LIM homeobox protein 2; Lectin, galactose binding, soluble 9; apolipoprotein E; Ubiquitin carboxy-terminal hydrolase L1; Parvalbumin; Purkinje cell protein 4; Carboxylesterase 1; O-6-methylguanine-DNA methyltransferase; UDP glycosyltransferase 1 family, polypeptide A6; Endothelial differentiation, sphingolipid G-protein-coupled 29415 -2.27 0.003533 receptor, 5; Growth hormone receptor; Insulin-like growth factor 1; Insulin-like growth factor binding protein 5; Peripherin 1; Arginosuccinate synthetase; Lactate dehydrogenase B; Calcium/calmodulin-dependent serine protein kinase; Aminolevulinic acid synthase 1; 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2; Alcohol Dehydrogenase 1; Phosphodiesterase 3B; Similar to kelch domain containing 3; testis intracellular 363192 -2.17 0.03046 mediator protein (LOC363192), mRNA; Similar to cornichon-like protein (LOC361705), mRNA; Similar to RNA-binding protein with multiple splicing 361161 -2.81 0.024735 (RBP-MS) (LOC361161), mRNA; Similar to CLN6 protein (LOC315746), mRNA; Reticulocalbin 3; Similar to CG31613-PA (LOC364716), mRNA; mRNA Rat Downregulated (Procollagen, type XII, alpha 1 (2.18 fold); Glycoprotein Ib (platelet), beta polypeptide (2.5 fold); Macrophage stimulating 1 (hepatocyte growth factor-like) (2.61 fold); Alpha-2-macroglobulin (3.8 fold); Hyaluronan and proteoglycan link protein 1 (3.82 fold); Glycoprotein 38 (3.87 fold); Decorin (5.74 fold); Vascular cell adhesion molecule 1 (7.82 fold); Clusterin (8.84 fold); Elastin (12.76 fold); Biglycan (13.23 fold); Selenoprotein P, plasma, 1 (23.08 fold); T-cell receptor gamma chain (2.2 fold); Myxovirus (influenza virus) resistance 2 (2.22 fold) ; Major histocompatibility complex, class II, DM alpha (2.37 fold); MHC class Ib RT1.S3 (4.8 fold) ; RT1 class Ib , locus Aw2 (5.18 fold); Similar to interferon regulatory factor 7 (LOC293624), mRNA (6.14 fold); Late gestation lung protein 1 (2.26 fold); Transgelin (5.72); Ectonucleoside triphosphate diphosphohydrolase 2 (2.7 fold); Dual specificity phosphatase 1 (2.3 fold); Cytochrome b-245, alpha polypeptide (3.64 fold); 3-alpha-hydroxysteroid dehydrogenase (4.86 fold); Cathepsin S (2.33 fold); Alanyl (membrane) aminopeptidase (3.18 fold); Dipeptidase 1 (renal) (6.82 fold); Caspase 1 (11.12 fold); B-cell translocation gene 3 (17.35 fold); CD 81 antigen (36 fold); Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA (2.28 fold); Similar to RIKEN cDNA 4930415K17 (LOC291670), mRNA (2.62 fold); LIM homeobox protein 2 (5.43 fold); Lectin, galactose binding, soluble 9 (2.46 fold); apolipoprotein E (29.52 fold); Ubiquitin carboxy-terminal hydrolase L1 (16.29 fold); Parvalbumin (3.85 fold); Purkinje cell protein 4 (6.82 fold); Carboxylesterase 1 (2.16 fold); O-6-methylguanine-DNA methyltransferase (4.62 fold); UDP glycosyltransferase 1 family, polypeptide A6 (3.25 fold); Endothelial differentiation, sphingolipid G-protein-coupled 29415 -2.27 0.003533 receptor, 5 (2.27 fold); Growth hormone receptor (3.12 fold); Insulin-like growth factor 1 (4.85 fold); Insulin-like growth factor binding protein 5 (5.25 fold); Peripherin 1 (7.17 fold); Arginosuccinate synthetase (12.75 fold); Lactate dehydrogenase B (15.07 fold); Calcium/calmodulin-dependent serine protein kinase (4.13 fold); Aminolevulinic acid synthase 1 (2.39 fold); 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (3.17 fold); Alcohol Dehydrogenase 1 (6.38 fold); Phosphodiesterase 3B (4.76 fold); Similar to kelch domain containing 3 testis intracellular 363192 -2.17 0.03046 mediator protein (LOC363192), mRNA (2.17 fold); Similar to cornichon-like protein (LOC361705), mRNA (2.35 fold); Similar to RNA-binding protein with multiple splicing 361161 -2.81 0.024735 (RBP-MS) (LOC361161), mRNA (2.81 fold); Similar to CLN6 protein (LOC315746), mRNA (3.68 fold); Reticulocalbin 3 (3.94 fold); Similar to CG31613-PA (LOC364716), mRNA (8.61 fold); Prognostic MAT-LyLu Vs G Cell Lines p<0.005 Cell Lines 17713630
217 Kelch repeat and BTB (POZ) domain containing 10 (krp1) mRNA Rat Upregulated in MAT-LyLu (48 fold) Prognostic MAT-LyLu Vs G Cell Lines p=0.01816 Cell Lines 17713630
218 Endothelial cell-specific molecule 1 mRNA Rat Upregulated in MAT-LyLu (23 fold) Prognostic MAT-LyLu Vs G Cell Lines p=0.00995283 Cell Lines 17713630
219 Caveolin 1 mRNA Rat Upregulated in MAT-LyLu (45 fold) Prognostic MAT-LyLu Vs G Cell Lines p=0.0009527 Cell Lines 17713630
234 Metaclassifier: ENC1+GJB1+MYO6+AMACR+TSPAN13+PRKCBP+C20ORF74+DAPK1+IMAGE:396839 + ENC1 mRNA Humans Differentially Expressed Prognostic Benign Prostate Vs Prostate Cancer p<0.0005 Tissue 17460773
235 ARL6IP+MYH11 mRNA Humans Differentially Expressed Prognostic Primary Vs Metastatic Prostate Cancer NA Tissue 17460773
248 PI3-K p85 α mRNA Humans Downregulated in Gleason Score 7-10 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
249 ILK mRNA Humans Downregulated in Gleason Score 7-11 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
250 PTEN mRNA Humans Downregulated in Gleason Score 7-12 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
251 PHLPP mRNA Humans Downregulated in Gleason Score 7-13 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
252 FOXO1A mRNA Humans Downregulated in Gleason Score 7-14 Prognostic Gleason Score 5-6 Vs Gleason Score 7-10 p<0.05 Tissue 18336616
254 C-reactive protein (CRP) Protein Humans Increased in Overall Survival Prognostic Overall Survival Vs No Survival p<0.0001 Plasma 18428198
255 C-reactive protein (CRP) Protein Humans Increased in Overall Survival Prognostic PSA Decline Vs No PSA decline p=0.0068 Plasma 18428198
258 NRP1 mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p=0.007 Tissue 18347174
259 TOP2A mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p<0.0001 Tissue 18347174
260 RRM2 mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p<0.0001 Tissue 18347174
261 KHRDSB3 mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p=0.015 Tissue 18347174
262 SSTR1 mRNA Humans Upregulated in Aggressive Prostate Cancer Prognostic Non Aggressive Vs Aggressive prostate cancer phenotype p=0.006 Tissue 18347174
276 Fusion Status of TMPRSS2:ERG mRNA Humans Increased fusion in patients with biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence p=0.0523 Tissue 18500259
277 Mutation of PTEN mRNA Humans Deletion found in patients with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence p=0.0009 Tissue 18500259
278 Fusion Status of TMPRSS2:ERG + PTEN deletion mRNA Humans Fusion + Deletion Prognostic Biochemical Recurrence Vs no Recurrence p=0.001 Tissue 18500259
279 Fusion Status of TMPRSS2:ERG + PTEN deletion mRNA Humans Fusion + Deletion Prognostic Biochemical Recurrence Vs no Recurrence p=0.036 Tissue 18500259
350 Transforming growth factor-β1 (TGF-β1) Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years p<0.001 Plasma 18559597
351 soluble IL-6 receptor (sIL-6R) Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years p<0.001 Plasma 18559597
352 IL-6 Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years p<0.001 Plasma 18559597
353 Vascular endothelial growth factor (VEGF) Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years Univariate: p= 0.002; Multivariate: p=0.008 Plasma 18559597
354 Vascular cell adhesion molecule-1 (VCAM-1) Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years p<0.001 Plasma 18559597
355 Endoglin Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years Univariate: p<0.001Multivariate: p=0.002 Plasma 18559597
356 Urokinase-type plasminogen activator (uPA) Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years p<0.001 Plasma 18559597
357 uPA receptor (uPAR) Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years Univariate: p<0.001; Multivariate: p=0.05 Plasma 18559597
358 TGF-β1 + sIL-6R + IL-6 + VCAM-1 + VEGF + endoglin + uPA + PAI-1 + uPAR Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years NA Plasma 18559597
359 TGF-β1 + sIL-6R + IL-6 + VCAM-1 + VEGF + endoglin + uPA Protein Humans Increased with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence in 5 years NA Plasma 18559597
360 IL-8 Protein Humans Upregulated in Recurrent Group (Recurrent Group: 181.1 ± 89.3; Non Recurrent Group: 96.4 ± 85.6) Prognostic Reccurance Free Survival Vs Recurrance in 5 years p<0.001 Tissue 18593988
361 Osteopontin Protein Humans Upregulated in Recurrent Group (Recurrent Group: 203.2 ± 78.4; Non Recurrent Group: 127.76 ± 76.6) Prognostic Reccurance Free Survival Vs Recurrance in 5 years p<0.001 Tissue 18593988
362 IL8 + Osteopontin Protein Humans Upregulated in Recurrent Group Prognostic Reccurance Free Survival Vs Recurrance in 5 years p<0.001 Tissue 18593988
365 CD31 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.009 Tissue 18767028
366 Ki67 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.003 Tissue 18767028
367 Her-2/neu Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.006 Tissue 18767028
368 CD31 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.001 Tissue 18767028
369 Ki67 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.03 Tissue 18767028
370 PCNA Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.03 Tissue 18767028
371 Her-2/neu Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.049 Tissue 18767028
372 CD31 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.028 Tissue 18767028
373 Her-2/neu Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.025 Tissue 18767028
374 Ki67 Protein Humans Differentially Expressed Prognostic Progression Vs No Progression p=0.027 Tissue 18767028
375 Her-2/neu Protein Humans Negative Staining in Patients with Progression Free Survival Prognostic Progression Free Survival Vs No Progression Survival p=0.001 Tissue 18767043
376 Her-2/neu Protein Humans Negative Staining in Patients with Metastatic Free Survival Prognostic Metastatic Vs Non Metastatic Prostate cancer p=0.002 Tissue 18767043
377 Her-2/neu Protein Humans Negative Staining in Patients with PCa Death Free Survival Prognostic PCa Specific Death Vs No PCa Specific Death p=0.021 Tissue 18767043
385 TMPRSS2:ERG mRNA Humans Fused in Prostate Cancer Prognostic (Benign Samples + Gleason sums < 7) Vs ≥ 7 p<0.05 Expressed Prostatic Secretion 18948370
394 Ornithine Decarboxylase (ODC) + Ornithine Decarboxylase antizyme (OAZ) +Adenosylmethionine Decarboxylase (AdoMetDC)+ Spermidine/Spermine N(1)-acetyltransferase (SSAT)+ histone H3 (H3)+ growth arrest specific gene (GAS1)+glyceraldehyde 3-phosphate dehydrogenase (GAPDH) + Clusterin (CLU) mRNA Humans Downgregulated in PCa: (GAS1,SSAT, CLU, OAZ, GAPDH); Upregulated in PCa (H3, ODC) Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 NA Tissue 18974881
395 CCL4 Protein Humans Differentially Expressed Prognostic Biochemical Recurrence Vs No Recurrence p=0.011 Tissue 19047106
396 CX3CL1 Protein Humans Differentially Expressed Prognostic Biochemical Recurrence Vs No Recurrence p<0.0001 Tissue 19047106
397 CCL4 Protein Humans Differentially Expressed Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p=0.04 Tissue 19047106
398 CX3CL1 Protein Humans Differentially Expressed Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p<0.0001 Tissue 19047106
399 PSA+Surgical Margins+ seminal vesicle invasion+ Gleason Score+CX3CL1+CCL4+IL-15 Protein Humans Differentially Expressed Prognostic Biochemical Recurrence Vs No Recurrence NA Tissue 19047106
406 Androgen Receptor (AR) mRNA Humans Upregulated in Hormone Refactory Prostate Cancer (11 fold) Prognostic Hormone Naive Vs Hormone Refractory Prostate Cancer p<0.0001 Tissue 19117982
407 Androgen Receptor AR-V1 mRNA Humans Upregulated in Hormone Refactory Prostate Cancer (22 fold) Prognostic Hormone Naive Vs Hormone Refractory Prostate Cancer p<0.0001 Tissue 19117982
408 Androgen Receptor AR-V7 mRNA Humans Upregulated in Hormone Refactory Prostate Cancer (20 fold) Prognostic Hormone Naive Vs Hormone Refractory Prostate Cancer p<0.0001 Tissue 19117982
409 Androgen Receptor AR-V7 mRNA Humans Higher expression in patients with biochemical recurrence Prognostic PSA Recurrence Vs No PSA Recurrence p=0.012 Tissue 19117982
410 Methylation Status of RARB2 Methylation Humans Methylated in Stage IV PCa Prognostic PCa stage I-III VS PCa Stage IV p=0.027 Serum 19131636
411 Methylation Status of GSTP1 Methylation Humans Methylated in Stage IV PCa Prognostic PCA stage I-III VS PCA Stage IV p=0.019 Serum 19131636
412 Methylation Status of GSTP1+RARB2 Methylation Humans Methylated in Stage IV PCa Prognostic PCA stage I-III VS PCA Stage IV p=0.019 Serum 19131636
413 PSA +C4a lacking the C-terminal arginine (C4a des-Arg) + N-terminal fragment of PCI Protein Humans Upregulated in PCa: [C4a lacking the C-terminal arginine (C4a des-Arg)];Downregulated in PCa: [N-terminal fragment of PCI] Prognostic Recurrence Vs No recurrence for 5 years Training: p=0.012 Testing: p=0.011 Serum 19157448
417 Transforming growth factor-b1 Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years Univariate: p<0.001; Multivariate: p=0.003 Plasma 19229851
418 Interleukin-6 soluble receptor ((IL-6sR) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years Univariate: p<0.001; Multivariate: p=0.001 Plasma 19229851
419 Interleukin-6 (IL-6) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years Univariate: p<0.001 Plasma 19229851
420 Vascular cell adhesion molecular 1 (VCAM 1) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years p<0.001 Plasma 19229851
421 Vascular endothelial growth factor (VEGF) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years p=0.002 Plasma 19229851
422 Endoglin Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years p<0.001 Plasma 19229851
423 Urokinase-type plasminogen activator (uPA) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years Univariate: p<0.001; Multivariate: p=0.036 Plasma 19229851
424 Urokinase-type plasminogen activator receptor (uPAR) Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years p<0.001 Plasma 19229851
425 Gleason sum +TGFB1+ IL-6sR +VCAM1+uPA Protein Humans Increased Expression with Biochemical Recurrence Prognostic Recurrence Vs No recurrence for 5 years NA Plasma 19229851
426 p53 Protein Humans Increased Expression with PCa Specific Death Prognostic Prostate Cancer Specific Survival Vs No Survival Univariate: p<0.001; Multivariate: p=0.03; Tissue 19239456
427 p53 Protein Humans Increased Expression with Overall Death Prognostic Overall Survival Vs No Survival Univariate: p<0.001; Multivariate: p=0.001; Tissue 19239456
428 p53 Protein Humans Increased Expression with PCa Specific Death Prognostic Prostate Cancer Specific Survival Vs No Survival Univariate: p=0.01; Multivariate: p=0.01; Tissue 19239456
429 p53 Protein Humans Increased Expression with Overall Death Prognostic Overall Survival Vs No Survival Univariate: p=0.001; Multivariate: p=0.004; Tissue 19239456
431 TMPRSS2 mRNA Humans Upregulated (Clinical Stage 1&2: 3.43 ± 0.62 ; Vs Clinical Stage 3: 5.45 ± 0.92) Prognostic Clincal Stage (1-2) Vs Clinical Stage 3 p=0.02 Tissue 19242826
432 TMPRSS2 mRNA Humans Upregulated (GS<6 4.64 ± 0.35 vs GS>6: 8.34 ± 1.53) Prognostic Gleason Score ≤6, Vs Gleason Score>6 p=0.008 Tissue 19242826
433 TMPRSS2 mRNA Humans Upregulated (Tumor Grade 1-2: 2.35 ± 1.45 vs Tumor Grade 3: 3.41 ± 2.31) Prognostic Tumor Grade (1-2) Vs Tumor Grade 3 p=0.016 Tissue 19242826
435 KLK11 mRNA Humans Upregulated (CS: (1-2) 6.05 ± 1.34 vs CS 3: 3.93 ± 0.45) Prognostic Clincal Stage (1-2) Vs Clinical Stage 3 p=0.009 Tissue 19242826
436 KLK11 mRNA Humans Upregulated (GS<6 4.64 ± 0.35 vs GS>6: 8.34 ± 1.53) Prognostic Gleason Score ≤6, Vs Gleason Score>6 p=0.01 Tissue 19242826
437 KLK11 mRNA Humans Upregulated (Tumor Grade 1-2 : 2.35 ± 1.45 vs Tumor Grade 3: 3.41 ± 2.31) Prognostic Tumor Grade (1-2) Vs Tumor Grade 3 p=0.006 Tissue 19242826
439 Methylation Status of: Ventral anterior homeobox 1 (VAX1); Homeobox D3 (HOXD3); CAP-GLY domain containing linker protein family (CLIP4); Calcium channel, voltage dependent, T-type, alpha 1G 2.0 subunit (CACNA1G) ; Glycoprotein V (GP5); Somatostatin receptor 1 (SSTR1); Methylthioadenosine phosporylase (MTAP); NK2 homeobox 2 (NKX2-2); Homeobox C11 (HOXC11); Ladybird homeobox 1 (LBX1); Motor neuron and pancreas homeobox 1 (MNX1); Glutamate receptor, metabotropic 1 (GRM1); LIM homeobox 9 (LHX9); Microtubule-associated protein tau (MAPT); Galactosidase, beta 1-like (GLB1L) Methylation Humans Hypermethylated in Progression (PP4): [Ventral anterior homeobox 1 (VAX1) (2.7 fold); Homeobox D3 (HOXD3) (2.3 fold); CAP-GLY domain containing linker protein family (CLIP4) (2.1 fold); Calcium channel, voltage dependent, T-type, alpha 1G 2.0 subunit (CACNA1G) (2.0 fold); Glycoprotein V (GP5) (1.9 fold); Somatostatin receptor 1 (SSTR1) (1.8 fold); Methylthioadenosine phosporylase (MTAP) (1.8 fold); NK2 homeobox 2 (NKX2-2) (1.7 fold); Homeobox C11 (HOXC11) (1.6 fold); Ladybird homeobox 1 (LBX1) (1.6 fold); Motor neuron and pancreas homeobox 1 (MNX1) (1.6 fold); Glutamate receptor, metabotropic 1 (GRM1) (1.6 fold); LIM homeobox 9 (LHX9) (1.6 fold); Microtubule-associated protein tau (MAPT) (1.5 fold); Galactosidase, beta 1-like (GLB1L) (1.5 fold)] Prognostic Gleason Score 6 (Pure pattern 3) vs Gleason Score 8 (Pure Pattern 4) p<0.05 Tissue 19283074
440 Ki-67 Protein Humans Differentially Expressed Prognostic Cause Specific Survival Vs No Survival p<0.001 Tissue 19293807
441 Ki-67 Protein Humans Differentially Expressed [Cause Specific Survial (Δχ2 = 24.6) and overall survival (Δχ2 = 20.5)] Prognostic Overall Survival Vs No Survival p<0.001 Tissue 19293807
442 ACPP; AD-017; AMIGO2; APPBP2; ASNS; ATAD2; ATP6V0E; ATXN1; AURKB; B3GALT4; BANK1; BCAP29; BIRC5; BM039 (CENPN); BRE; BUB1; BUB1B; C18orf10; C1orf9; C22orf18 (CENPM); C5orf13; C6orf111; C6orf210; C9orf116; C9orf127; CATSPER2; CCNA2; CCNB1; CCNB2; CCNE2; CD24; CDC16; CDC2; CDC20; CDC25C; CDC6; CDC7; CDKN3; CENPA; CENPC1; CENPF; CHEK1; CHEK1; CITED2; CITED2; CLUL1; COH1; CPT2; CRADD; CTSL2; CYFIP2; DEPDC1; DGKA; DMXL1; DSCR1L1; EFNB2; ESPL1; F2R; FEN1; FLJ10036; FLJ10534; FLJ22624; GABARAPL1; GALNT7; GFPT1; GGA2; GTSE1; GTSE1; H2AFX; H2AFY; HCAP-G; HCAP-G; HECA; HMGB2; HMMR; HMMR; HPS1; IL13RA1; INSIG1; KIAA0999; KIAA1608; KIF14; KIF20A; KIF4A KLK2; KLK2; KLK3; KNS2; KNTC2; LAMB2; LMAN1; LOC54103; MAC30; MALT1; MAPK8IP1; MCM5 ; MID1; MLF1IP; MLLT3; MTHFD2; MTMR1; MYCBP2; MYH10; MYRIP; NAP1L3; NAV3; NEK2; NEK2 NLGN1; NUSAP1; OIP5; OSR2; PBEF1; PCLO; PDE9A; PDIR; PER3; PIK3R1;PINK1; PIR51; PLCB4; PLK1; PMAIP1; PMS2L11; PMSCL1; PRC1; PRKWNK1; PTBP1; PTBP2; PTCD1 ; PTPN13; PTPRR; RAB3B; RACGAP1; RBM30; RFC3; RRM1 ; RRM2; RRM2; SAS; SDC2 ; SDC2 ; SDC4; SEC6L1; SHCBP1 ; SI; SLC29A1; SLC7A6; SMARCA2; SMC4L1; SMC4L1; SOCS2; SOD2; SOS1; Spc25; SS18; STC2; STK3; STK6 ; TM4SF1; TMPO; TNFRSF10B ; TNFSF13; TNFSF12-TNFSF13; TWE-PRIL; TOPK; TPBG; TPX2; TRIB1; TTC3; TUBA3; TYMS; UAP1; UBE3B; USP3; VEGF; ZNF175; ZNF292; ZNF45; ZWINT mRNA Humans Differentially Expressed Prognostic Metastatic Vs Localised Prostate Cancer p=0.0000121714 Cell Lines 19351846
443 ACPP; AD-017 ; AMIGO2; APPBP2; ASNS ; ATAD2; ATP6V0E; ATXN1; AURKB; B3GALT4; BANK1; BCAP29; BIRC5; BM039 (CENPN); BRE; BUB1; BUB1B; C18orf10 ; C1orf9; C22orf18 (CENPM) ; C5orf13; C6orf111 ; C6orf210; C9orf116 ; C9orf127; CATSPER2 ; CCNA2; CCNB1; CCNB2; CCNE2; CD24; CDC16; CDC2 ; CDC20; CDC25C ; CDC6 ; CDC7; CDKN3; CENPA; CENPC1; CENPF; CHEK1; CHEK1; CITED2; CITED2; CLUL1; COH1; CPT2; CRADD; CTSL2; CYFIP2; DEPDC1; DGKA; DMXL1; DSCR1L1 ; EFNB2 ; ESPL1; F2R; FEN1; FLJ10036; FLJ10534; FLJ22624; GABARAPL1 ; GALNT7; GFPT1 ; GGA2; GTSE1; GTSE1 ; H2AFX ; H2AFY; HCAP-G; HCAP-G ; HECA; HMGB2; HMMR ; HMMR; HPS1; IL13RA1; INSIG1; KIAA0999; KIAA1608; KIF14; KIF20A; KIF4A; KLK2 ; KLK2 ; KLK3; KNS2 KNTC2 LAMB2; LMAN1; LOC54103; MAC30; MALT1; MAPK8IP1; MCM5; MID1; MLF1IP; MLLT3; MTHFD2; MTMR1; MYCBP2; MYH10 MYRIP; NAP1L3; NAV3 ; NEK2; NEK2; NLGN1; NUSAP1; OIP5; OSR2; PBEF1; PCLO; PDE9A ; PDIR; PER3 ; PIK3R1 ; PINK1 ; PIR51; PLCB4; PLK1; PMAIP1; PMS2L11; PMSCL1; PRC1; PRKWNK1; PTBP1; PTBP2; PTCD1 ; PTPN13; PTPRR; RAB3B ; RACGAP1;RBM30; RFC3; RRM1; RRM2; RRM2; SAS ; SDC2; SDC2 ; SDC4; SEC6L1; SHCBP1; SI; SLC29A1; SLC7A6; SMARCA2; SMC4L1; SMC4L1; SOCS2; SOD2; SOS1; Spc25; SS18; STC2 ; STK3; STK6; TM4SF1 ; TMPO; TNFRSF10B; TNFSF13; TNFSF12-TNFSF13; TWE-PRIL; TOPK ; TPBG; TPX2; TRIB1 ; TTC3; TUBA3; TYMS; UAP1;UBE3B; USP3; VEGF; ZNF175; ZNF292; ZNF45; ZWINT mRNA Humans Differentially Expressed Prognostic Androgen Dependent Vs Androgen Independent Prostate Cancer p=0.0056 Cell Lines 19351846
447 CTC (Circulating Tumor Cells) Others Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
448 Alkaline Phosphatase Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
449 LDH Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
450 Prostatic Acid Phosphatase (PAP) Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
451 Total Acid Phosphatase (TAP) Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
452 Albumin Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p=0.002 Blood 19505924
453 Hemoglobin Metabolites Humans Increased expression in overall survival Prognostic Overall Survival Vs No Survival p<0.001 Blood 19505924
460 IGF1 Protein Humans Higher concentrations in patients with decreased risk of advanced prostate cancer Prognostic Localised Vs Advanced Prostate Cancer p<0.001 NA 19491931
461 IGFBP3 Protein Humans Higher concentrations in patients with decreased risk of advanced prostate cancer Prognostic Localised Vs Advanced Prostate Cancer p=0.004 NA 19491931
468 DNA Ploidy - Diploid Mutation Humans DIPLOID: 5 year disease free survival - (80.5% ); 10 year disease free survival - (72.9%) Prognostic 5 and 10 years disease free survival Vs no survival p<0.001 Tissue 19633362
469 DNA Ploidy - Tetraploid Mutation Humans TETRAPLOID: 5 year disease free survival - (67.8% ); 10 year disease free survival - (61.6%) Prognostic 5 and 10 years disease free survival Vs no survival p<0.001 Tissue 19633362
470 DNA Ploidy - Aneploid Mutation Humans ANUEPLOID: 5 year disease free survival - (49.5% ); 10 year disease free survival - (31.8%) Prognostic 5 and 10 years disease free survival Vs no survival p<0.001 Tissue 19633362
471 DNA Ploidy - Diploid Mutation Humans DIPLOID: 5 year disease free survival - (88.7% ); 10 year disease free survival - (84.8%) Prognostic 5 and 10 years disease free survival Vs no survival for Gleason Score=7 p<0.001 Tissue 19633362
472 DNA Ploidy - Tetraploid Mutation Humans TETRAPLOID: 5 year disease free survival - (74.3% ); 10 year disease free survival - (64.7%) Prognostic 5 and 10 years disease free survival Vs no survival for Gleason Score=7 p<0.001 Tissue 19633362
473 DNA Ploidy - Anueploid Mutation Humans ANUEPLOID: 5 year disease free survival - (25.0% ); 10 year disease free survival - (0%) Prognostic 5 and 10 years disease free survival Vs no survival for Gleason Score=7 p<0.001 Tissue 19633362
476 GLUT1 Protein Humans Increased expression in Biochemical Recurrence Prognostic PSA recurrence Vs No PSA recurrence p=0.005 Tissue 19854473
477 PHD1 (prolyl-4-hydroxylases 1) Protein Humans Increased expression in Biochemical Recurrence Prognostic PSA recurrence Vs No PSA recurrence p <0.001 Cell Lines 19854473
479 Clusterin & Clusterin Density Protein Humans Upregulated: Clusterin [(No Metastasis 131.1 ± 32.1) Vs (Metastasis: 151.3 ± 34.6 )]; Clusterin Density [(No Metastasis: 5.1 ± 2.3 ) Vs (Metastasis: 6.2 ± 2.7 )] Prognostic No Metastasis Vs Metastasis p<0.001 Serum 19854485
480 Clusterin Density Protein Humans Upregulated: Clusterin Density [(ExtraProstatic 6.2 ± 2.4) Vs (Organ-confined disease: 5.4 ± 2.2 )]; Prognostic Organ-confined disease Vs Extraprostatic disease p=0.033 Serum 19854485
481 Clusterin Density Protein Humans Decreased expression in Patients with Biochemical Recurrence free Survival Prognostic Biochemical Recurrence Free Survival Vs No Survial p=0.034 Serum 19854485
492 ezrin; lamin B1; succinate dehydrogenase complex, subunit A, flavoprotein precursor; succinate dehydrogenase complex, subunit A, flavoprotein precursor; acute morphine dependence related protein 2; methylcrotonoyl Coenzyme A carboxylase 2 (beta); 3-oxoacid CoA transferase 1 precursor; CCT2; CCT2; CCT2; keratin 8; lamin A/C transcript variant 1; Chain A, X-ray Structure Of The Human mitogen activated protein kinase kinase 2 (Mek2)in A Complex; Stomatin (EPB72)-like 2; Heterogeneous nuclear ribonucleoprotein C (C1/C2), hnRNP; Heterogeneous nuclear ribonucleoprotein C (C1/C2); SEC13 homologue (S. cerevisiae); HSPC124; Enoyl Coenzyme A hydratase 1, peroxisomal; Chain A, Structure Of Inositol Monophosphatase the Putative Target Of Lithium Therapy; cathepsin D preproprotein; chloride intracellular channel 4; endoplasmic reticulum protein 29 isoform 1 precursor; heat shock 27 kDa protein 1; Chain A, Native Human Lysosomal Beta-Hexosaminidase Isoform B; thioredoxin peroxidase, peroxiredoxin 4; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor; hypothetical protein LOC79017; ATP synthase, H+ transporting, mitochondrial F0; Ferritin, light polypeptide; nonmetastatic cells 1, protein (NM23A) expressed in isoform a; keratin-10; ubiquitin-conjugating enzyme E2N; fatty acid binding protein 5 (psoriasis-associated); Protein Humans Upregulated ratio in LNMPCA: ezrin [2.4]; lamin B1 [2.76]; succinate dehydrogenase complex, subunit A, flavoprotein precursor [2.22]; succinate dehydrogenase complex, subunit A, flavoprotein precursor [1.86]; acute morphine dependence related protein 2 [1.94]; methylcrotonoyl Coenzyme A carboxylase 2 (beta) [5.27]; 3-oxoacid CoA transferase 1 precursor [1.90]; CCT2 [2.74]; CCT2 [2.22]; CCT2 [1.82]; keratin 8 [4.19]; lamin A/C transcript variant 1 [3.66]; Chain A, X-ray Structure Of The Human mitogen activated protein kinase kinase 2 (Mek2)in A Complex [2.95]; Stomatin (EPB72)-like 2 [2.10]; Heterogeneous nuclear ribonucleoprotein C (C1/C2), hnRNP [2.25]; Heterogeneous nuclear ribonucleoprotein C (C1/C2) [2.01]; SEC13 homologue (S. cerevisiae) [2.62]; HSPC124 [4.70]; Enoyl Coenzyme A hydratase 1, peroxisomal [3.79]; Chain A, Structure Of Inositol Monophosphatase the Putative Target Of Lithium Therapy [2.39]; cathepsin D preproprotein [2.49]; chloride intracellular channel 4 [2.16]; endoplasmic reticulum protein 29 isoform 1 precursor [2.54]; heat shock 27 kDa protein 1 [3.47]; Chain A, Native Human Lysosomal Beta-Hexosaminidase Isoform B [4.62]; thioredoxin peroxidase, peroxiredoxin 4 [2.12]; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor [4.19]; Chain A, Human Glyoxalase I With Benzyl-Glutathione inhibitor [4.56]; hypothetical protein LOC79017 [3.15]; ATP synthase, H+ transporting, mitochondrial F0 [2.46]; Ferritin, light polypeptide [2.49]; nonmetastatic cells 1, protein (NM23A) expressed in isoform a [2.99]; keratin-10 [3.84]; ubiquitin-conjugating enzyme E2N [2.23]; fatty acid binding protein 5 (psoriasis-associated) [20.86]; Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.05 Tissue 19894759
493 collagen, type VI, alpha 1 precursor; vinculin isoform meta-VCL; FLNA protein; gelsolin isoform b; transferrin; transferrin; lamin A/C transcript variant 1; archain; Dihydropyrimidinase-like 3; mutant desmin; PREDICTED: similar to actin, alpha 1, skeletal muscle isoform 2; Chain A, human B lactate dehydrogenase complexed with NAD+ and Hydroxy-1,2,5-Oxadiazole-3-Carbox; splicing factor, arginine/ serine-rich 1 isoform 1; Unknown (protein for IMAGE:3906970); ubiquitin carboxy-terminal hydrolase L1; Chain A, Ligand-Free Human Glutathione S-Transferase M2–2; Chain A, Crystal Structure Of Human Glutathione S-Transferase P1-1 Complexed With (9r,10r)-9; regulatory myosin light chain long version; smooth muscle protein (SM22); haptoglobin-related protein precursor; smooth muscle protein (SM22); smooth muscle protein (SM22); Chain A, X-ray Crystal Structure Of Human Galectin-1; Protein Humans Downregulated ratio in LNMPCA: collagen, type VI, alpha 1 precursor [2.15]; vinculin isoform meta-VCL [3.47]; FLNA protein [1.99]; gelsolin isoform b [2.15]; transferrin [2.04]; transferrin [2.15]; lamin A/C transcript variant 1 [2.06]; archain [1.63]; Dihydropyrimidinase-like 3 [1.86]; mutant desmin [2.38]; PREDICTED: similar to actin, alpha 1, skeletal muscle isoform 2 [2.89]; Chain A, human B lactate dehydrogenase complexed with NAD+ and Hydroxy-1,2,5-Oxadiazole-3-Carbox [2.68]; splicing factor, arginine/ serine-rich 1 isoform 1 [2.6]; Unknown (protein for IMAGE:3906970) [2.04]; ubiquitin carboxy-terminal hydrolase L1 [2.78]; Chain A, Ligand-Free Human Glutathione S-Transferase M2–2 [3.32]; Chain A, Crystal Structure Of Human Glutathione S-Transferase P1-1 Complexed With (9r,10r)-9 [2.85]; regulatory myosin light chain long version [4.25]; smooth muscle protein (SM22) [13.98]; haptoglobin-related protein precursor [6.16]; smooth muscle protein (SM22) [5.08]; smooth muscle protein (SM22) [3.30]; Chain A, X-ray Crystal Structure Of Human Galectin-1 [2.46]; Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.05 Tissue 19894759
496 e-FABP5 Protein Humans Upregulated in LNM PCa Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.01 Serum 19894759
498 e-FABP5, MCCC2, PPA2, Ezrin, and SLP2 Protein Humans Upregulated in LNM PCa Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.01 Tissue 19894759
499 SM22 Protein Humans Downregulated in LNM PCa Prognostic Lymph Node Metastatic Prostate Cancer Vs Localised PCA p<0.01 Tissue 19894759
500 Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP)[Fixed DNA (Gene) Humans Differentially Expressed Prognostic Biochemical recurrence (within 1 year ) Vs No recurrence (24 months) NA Tissue 20028763
501 Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) [Floating] DNA (Gene) Humans Differentially Expressed Prognostic Biochemical recurrence (within 1 year ) Vs No recurrence (24 months) NA Tissue 20028763
502 Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) [Integrated] DNA (Gene) Humans Differentially Expressed Prognostic Biochemical recurrence (within 1 year ) Vs No recurrence (24 months) NA Tissue 20028763
503 ANXA5; APLP2; COL1A2; CRIM1; ECHS1; HMGB1; MAP3K5; NGFRAP1; NPM1; NUB1; PDIA3; PLA2G2A; ROCK1; TEGT; TMEM16G; TMEM69; TRAF4; VCAN; VCP; VDAC1; mRNA Humans Differentially Expressed: ANXA5 [1.47 fold]; APLP2 [1.22 fold]; COL1A2 [1.18 fold]; CRIM1 [1.20 fold]; ECHS1 [1.18 fold]; HMGB1 [1.40 fold]; MAP3K5 [1.35 fold]; NGFRAP1 [1.32 fold]; NPM1 [1.30 fold]; NUB1 [1.12 fold]; PDIA3 [1.43 fold]; PLA2G2A [1.75 fold]; ROCK1 [1.17 fold]; TEGT [1.32 fold]; TMEM16G [0.66 fold]; TMEM69 [1.08 fold]; TRAF4 [1.26 fold]; VCAN [1.31 fold]; VCP [1.18 fold]; VDAC1 [1.51 fold]; Prognostic Gleason Score 6 Vs Gleason Score (8-10) p<0.05 Tissue 20035634
504 ANXA5; APLP2; COL1A2; CRIM1; ECHS1; HMGB1; MAP3K5; NGFRAP1; NPM1; NUB1; PDIA3; PLA2G2A; ROCK1; TEGT; TMEM16G; TMEM69; TRAF4; VCAN; VCP; VDAC1; mRNA Humans Differentially Expressed: ANXA5 [4.28 fold]; APLP2 [2.83 fold]; COL1A2 [2.02 fold]; CRIM1 [3.23 fold]; ECHS1 [1.89 fold]; HMGB1 [4.68 fold]; MAP3K5 [2.98 fold]; NGFRAP1 [3.95 fold]; NPM1 [3.07 fold]; NUB1 [1.62 fold]; PDIA3 [2.40 fold]; PLA2G2A [3.00 fold]; ROCK1 [9.76 fold]; TEGT [2.77 fold]; TMEM16G [0.35 fold]; TMEM69 [2.77 fold]; TRAF4 [2.59 fold]; VCAN [2.92 fold]; VCP [2.75 fold]; VDAC1 [5.41 fold]; Prognostic Gleason Score 6 Vs Gleason Score (8-10) p<0.05 Tissue 20035634
505 MAP3K5 mRNA Humans Upregulated in Gleason Score 8-10 Prognostic Gleason Score 6 Vs Gleason Score (8-10) qRT-PCR: p=0.0129 Tissue 20035634
506 PDIA3 mRNA Humans Upregulated in Gleason Score 8-10 Prognostic Gleason Score 6 Vs Gleason Score (8-10) qRT-PCR: p=0.00167 Tissue 20035634
511 TMPRSS2–ERG mRNA Humans Fusion Positive in Recurrence Prognostic Biochemical recurrence Vs No recurrence p=0.0000000354 Tissue 20068566
512 ERG expression in TMPRSS2–ERG mRNA Humans Upregulated in Fusion (3.07-fold) Prognostic ERG Fusion Vs No Fusion p=3.48E-11 Tissue 20068566
513 CSPG2+ WNT10B+E2F3+CDKN2A+TYMS+TGFB3+ALOX12+CD44+LAF4 mRNA Humans Upregulated with Biochemical Recurrence Prognostic Biochemical recurrence Vs No recurrence Univariate: p=0.0000002; Multivariate: p=0.0270 Tissue 20068566
514 Enhancer of Zeste 2 (EZH2) mRNA Humans Overexpression leads to aggressive behaviour in Cell Lines Prognostic Overexpression Vs No Overexpression in Cell Lines NA Cell Lines 20087897
519 EGFR [SNP rs884419] Mutation Humans AG And GG Phenotypes associated with decreased risk of recurrence Prognostic Biochemical recurrence Vs No recurrence A/G Phenotype: p= 0.0018; G/G Phenotype: p = 0.0016 Tissue 20303520
523 hsa-miR-375-4373027; hsa-miR-9*-4395342; hsa-miR-141-4373137; hsa-miR-516a-3p-4373183; hsa-miR-629-4395547; hsa-miR-203-4373095; hsa-miR-429-4373203; hsa-miR-618-4380996; hsa-miR-212-4373087; hsa-miR-21-4373090; hsa-miR-545-4395378; hsa-miR-218-4373081; hsa-miR-422a-4395408; hsa-miR-656-4380920; hsa-miR-655-4381015; hsa-miR-29c-4395171; hsa-miR-200b-4395362; hsa-miR-200c-4395411; hsa-miR-502-5p-4373227; miRNA Humans Upregulated in Metastatis (Log Fold Change): hsa-miR-375-4373027 [-4.3]; hsa-miR-9*-4395342 [-3.8]; hsa-miR-141-4373137 [-4.5]; hsa-miR-516a-3p-4373183 [-3.9]; hsa-miR-629-4395547 [-2.1]; hsa-miR-203-4373095 [-2.5]; hsa-miR-429-4373203 [-3.4]; hsa-miR-618-4380996 [-3.7]; hsa-miR-212-4373087 [-2.6]; hsa-miR-21-4373090 [-1.8]; hsa-miR-545-4395378 [-2.3]; hsa-miR-218-4373081 [-2.8]; hsa-miR-422a-4395408 [-2.1]; hsa-miR-656-4380920 [-2.8]; hsa-miR-655-4381015 [-2.4]; hsa-miR-29c-4395171 [-1.7]; hsa-miR-200b-4395362 [-3.1]; hsa-miR-200c-4395411 [-1.8]; hsa-miR-502-5p-4373227 [-3.1]; Prognostic Localised Vs Metastatic Prostate Cancer p<0.0098 Serum 20473869
524 miRNA-375, miRNA-141 and miRNA-200b miRNA Humans Differentially Expressed Prognostic Pathoglical Stage pt3 vs pt2 p<0.05 Serum 20473869
525 miRNA-375, miRNA-141 and miRNA-200b miRNA Humans Upregulated Prognostic Gleason Score 6 Vs Gleason Score 7 p<0.05 Serum 20473869
526 miRNA-375 miRNA Humans Upregulated in PCa Prognostic Lymph Node Status: NO Vs N1 p<0.01 Serum 20473869
527 miRNA-141 miRNA Humans Upregulated in PCa Prognostic Lymph Node Status: NO Vs N1 p<0.05 Serum 20473869
528 miRNA-141 miRNA Humans Upregulated in PCa Prognostic Gleason Score >8 Vs Gleason Score 7 p<0.01 Serum 20473869
532 KLK15 (kallikrein-related peptidase) Protein Humans High levels associated with shorter progression-free survival. Prognostic PSA recurrence Vs No PSA recurrence Univariate: p = 0.002; Multivariate: p=0.037; StepWise Inclusion: p=0.032 Tissue 20473923
536 PSA (G/G Genotype) Mutation Humans Increases risk of Gleason Score >=7 with G/G Genotype compared with the G/A & A/A genotype Prognostic Gleason ≤7 Vs Gleason Score >7 p= 0.0122 Blood 20632874
537 AR: (Short CAG) Mutation Humans Increased RIsk of GS (4+3) with Short CAG Repeats Prognostic Gleason Score 7 (4+3) Vs Gleason Score 7 (3+4) p = 0.045 Blood 20632874
540 MMP-9 % Protein Humans Increased expression in Recurrence free survival Prognostic Biochemical Recurrence Vs No Recurrence p=0.03 Tissue 20889560
541 MMP-9 intensity Protein Humans Increased expression in Disease Specific Mortality Prognostic Disease Specific Mortality Vs No Mortality p<0.001 Tissue 20889560
542 MMP-9 intensity Protein Humans Increased expression in Overall Mortality Prognostic Overall Mortality Vs No Mortality p<0.001 Tissue 20889560
557 Fructose-bisphosphate aldolase A; Isocitrate dehydrogenase; Citrate synthase; L-Lactate dehydrogenase A; ATP synthase gamma chain; Alpha-enolase; Phosphoglycerate mutase 1; Malate dehydrogenase; Core protein II; Transketolase; 60 kDa heat shock protein; Lamin A; Flotillin 1; Cytokeratin-1; Mimecan; 26S protease regulatory subunit 8; Annexin A2; Protein Humans Upregulated (with Regulation Coefficient): Fructose-bisphosphate aldolase A [1.85]; Isocitrate dehydrogenase [1.79]; Citrate synthase [1.76]; L-Lactate dehydrogenase A [1.75]; ATP synthase gamma chain [1.7]; Alpha-enolase [1.67]; Phosphoglycerate mutase 1 [1.65]; Malate dehydrogenase [1.64]; Core protein II [1.61]; Transketolase [1.59]; 60 kDa heat shock protein [2.13]; Lamin A [2.08]; Flotillin 1 [1.85]; Cytokeratin-1 [1.65]; Mimecan [1.58]; 26S protease regulatory subunit 8 [1.47]; Annexin A2 [1.46]; Prognostic Gleason Score 6 Vs Gleason Score 8 and above p<0.05 Tissue 20977276
558 Prostatic acid phosphatase; Prostate-specific antigen; Protein Humans Downregulated (with Regulation Coefficient): Prostatic acid phosphatase [-1.84]; Prostate-specific antigen [-3.04]; Prognostic Gleason Score 6 Vs Gleason Score 8 and above p<0.05 Tissue 20977276
560 Lamin A Protein Humans Upregulated in GS 8 and above Prognostic Gleason Score 6 Vs Gleason Score 8 and above p<0.05 Tissue 20977276
569 D-Dimer Protein Humans Upregulated in Progressive Disease Prognostic progressive disease (PD) Vs nonprogressive disease (non-PD) p<0.024 Blood 21088161
575 Kininogen-1+ Protein AMBP + Coagulation factor XIII B chain + Complement factor H + Gluthathione peroxidase 3 Protein Humans Differentially Expressed Prognostic Gleason Score 5 vs Gleason Score 7 NA Serum 21166384
576 Protein AMBP; Haptoglobin (R chain) ; Pigment Epithelium-Derived Factor 207 Kininogen-1 Protein Humans Downregulated in Non Organ Confined: [Haptoglobin (R chain) ]; Upregulated in Non Organ Confined: [Protein AMBP; Pigment Epithelium-Derived Factor 207 Kininogen-1] Prognostic Organ Confined vs Non-Organ Confined NA Serum 21166384
578 Kininogen-1+ Protein AMBP + Coagulation factor XIII B chain + Complement factor H +Gluthathione peroxidase 3 Protein Humans Differentially Expressed Prognostic Gleason Score 5 vs Gleason Score 7 NA Serum 21166384
579 Protein AMBP; Haptoglobin (R chain) ; Pigment Epithelium-Derived Factor 207 Kininogen-1 Protein Humans Downregulated in Non Organ Confined: [Haptoglobin (R chain) ]; Upregulated in Non Organ Confined: [Protein AMBP; Pigment Epithelium-Derived Factor 207 Kininogen-1] Prognostic Organ Confined vs Non-Organ Confined NA Serum 21166384
583 β-microseminoprotein (MSMB) Protein Humans increased expression with decreased biochemical recurrence-free survival Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.001 Tissue 21240253
584 SLCO1B1; SLCO1B3; SLCO2A1; SLCO3A1; mRNA Humans Upregulated in CRPC metastases: SLCO1B1 (5.5 fold); SLCO1B3( 3.6 fold); SLCO2A1 (3.2 fold); SLCO3A1 (5.4 fold); Prognostic CRPC metastases versus untreated prostate cancer p<0.053 Tissue 21266523
585 SLCO2B1 (SNP rs12422149) Mutation Humans Increased risk in GA or AA type allele Prognostic Prostate Cancer Specific Mortality No No mortality p<0.05 Blood 21266523
586 SLCO1B3 (SNP rs4149117) Mutation Humans NA Prognostic Prostate Cancer Specific Mortality No No mortality p<0.05 Blood 21266523
588 Annexin A4 (ANXA4); Apolipoprotein A-I (APOA1); ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B); Creatine kinase, brain (CKB); Desmin (DES); Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1); Fibrinogen γ chain (FGG); Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5); Heat shock 60 kDa protein 1 (chaperonin) (HSPD1); Prolyl 4-hydroxylase, β polypeptide (P4HB); Prohibitin (PHB); Serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 1) (SERPINA1); Protein Humans Upregulated in Gleason Score 7(Fold Change) : Annexin A4 (ANXA4) [1.000]; Apolipoprotein A-I (APOA1) [2.691]; ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B) [7.440]; Creatine kinase, brain (CKB) [1.000]; Desmin (DES) [2.059]; Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1) [2.335]; Fibrinogen γ chain (FGG) [7.634]; Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5) [2.339]; Heat shock 60 kDa protein 1 (chaperonin) (HSPD1) [1.000]; Prolyl 4-hydroxylase, β polypeptide (P4HB) [11.540]; Prohibitin (PHB) [1.000]; Serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 1) (SERPINA1) [2.992]; Prognostic Gleason Score 5 Vs Gleason Score 7 p<0.05 Tissue 21305254
589 Albumin (ALB); Rho GDP dissociation inhibitor (GDI) α (ARHGDIA); Keratin 18 (KRT18); Keratin 19 (KRT19); Keratin 8 (KRT8); Protein Humans Downregulated in Gleason Score 7(Fold Change) : Albumin (ALB) [2.155]; Rho GDP dissociation inhibitor (GDI) α (ARHGDIA) [2.571]; Keratin 18 (KRT18) [3.322]; Keratin 19 (KRT19) [4.950]; Keratin 8 (KRT8) [4.950]; Prognostic Gleason Score 5 Vs Gleason Score 7 p<0.05 Tissue 21305254
590 Albumin (ALB); Annexin A4 (ANXA4); Apolipoprotein A-I (APOA1); ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B); Fibrinogen γ chain (FGG); Protein Humans Upregulated in Stage T3 (Fold Change) : Albumin (ALB) [2.684]; Annexin A4 (ANXA4) [1.000]; Apolipoprotein A-I (APOA1) [2.691]; ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B) [1.000]; Fibrinogen γ chain (FGG) [1.000]; Prognostic Stage T2 Vs Stage T3 p<0.05 Tissue 21305254
591 Rho GDP dissociation inhibitor (GDI) α (ARHGDIA); Desmin (DES); Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1); Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5); Keratin 18 (KRT18); Keratin 19 (KRT19); Keratin 8 (KRT8); Protein Humans Downregulated in Stage T3(Fold Change) : Rho GDP dissociation inhibitor (GDI) α (ARHGDIA) [2.165]; Desmin (DES) [8.929]; Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1) [7.407]; Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5) [1.613]; Keratin 18 (KRT18) [3.322]; Keratin 19 (KRT19) [4.950]; Keratin 8 (KRT8) [4.950]; Prognostic Stage T2 Vs Stage T3 p<0.05 Tissue 21305254
601 vascular endothelial growth factor (VEGF) Protein Humans Upregulated in Lymph Node Metastatis Prognostic Lymph Node Metastatis Posititve Lymph Node Metastatis Negative p<0.001 Tissue 21367627
602 matrix metalloproteinase-9 (MMP-9) Protein Humans Upregulated in Lymph Node Metastatis Prognostic Lymph Node Metastatis Posititve Lymph Node Metastatis Negative p<0.001 Tissue 21367627
603 Stromal cell-derived factor-1 (SDF-1) Protein Humans Upregulated in Lymph Node Metastatis Prognostic Lymph Node Metastatis Posititve Lymph Node Metastatis Negative p<0.001 Tissue 21367627
604 Stromal cell-derived factor-1 (SDF-1) Protein Humans Patients with low levels survived longer than those with high levels Prognostic Prostate Cancer Specific Survival VS No Survival Univariate: p<0.001; Multivariate: p=0.017 Tissue 21367627
605 vascular endothelial growth factor (VEGF) Protein Humans Patients with low levels survived longer than those with high levels Prognostic Prostate Cancer Specific Survival VS No Survival Univariate: p<0.001; Multivariate: p<0.001 Tissue 21367627
606 matrix metalloproteinase-9 (MMP-9) Protein Humans Patients with low levels survived longer than those with high levels Prognostic Prostate Cancer Specific Survival VS No Survival p<0.001 Tissue 21367627
641 Ki-67 Protein Humans Upregulated in Black men Prognostic Prostate Cancer in Black Men Vs Prostate Cancer in White Men Univariate: p=0.02; Multivariate: =0.002 Tissue 21519348
642 Norm AR (Androgen Receptor) Protein Humans Upregulated in Black men Prognostic Prostate Cancer in Black Men Vs Prostate Cancer in White Men Univariate: p=0.006; Multivariate: p=0.001 Tissue 21519348
643 Ki-67/lum Protein Humans Upregulated in Black men Prognostic Prostate Cancer in Black Men Vs Prostate Cancer in White Men p=0.022 Tissue 21519348
653 Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) + Biopsy T-stage + Gleason Score Protein Humans Downregulated in Patients with Gleason Score Upgradation Prognostic Gleason Score Upgradation Vs No Gleason Score Upgradation p = 0.024 Serum 21520165
654 Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) + Biopsy T-stage + Gleason Score Protein Humans Downregulated in Patients with Gleason Score Upgradation Prognostic Gleason Score Upgradation Vs No Gleason Score Upgradation NA Serum 21520165
655 enhancer of zeste homologue 2 (EZH2) Protein Humans Progression Vs No Progression Prognostic Progression Free Survival Vs No Progression Free Survival p=0.004 Tissue 21592298
656 minichromosome maintenance protein 7 (MCM7) Protein Humans Progression Vs No Progression Prognostic Progression Free Survival Vs No Progression Free Survival p<0.001 Tissue 21592298
657 Ki-67 Protein Humans Increased expression in patients with Progression Prognostic Progression Free Survival Vs No Progression Free Survival p<0.001 Tissue 21592298
665 MKI67 (Ki-67) + TOP2A (DNA topoisomerase II, alpha) + E2F1 (E2F transcription factor 1) Genes Humans TOP2A, E2F1: Increased expression with earlier Biochemical Recurrence, Prognostic PSA Reccurence Vs No Recurrence for 8 years p=0.001 Tissue 21629784
666 PSA+ Grade + Stage +MKI67 (Ki-67) + TOP2A (DNA topoisomerase II, alpha) + E2F1 (E2F transcription factor 1) Genes Humans TOP2A, E2F1: Increased expression with earlier Biochemical Recurrence, Prognostic PSA Reccurence Vs No Recurrence for 8 years p=0.005 Tissue 21629784
667 NA miRNA Humans Downregulated in Bone Metastatis: Prognostic Primary vs Bone Metastatis p<0.05 Tissue 21647377
668 NA miRNA Humans Upregulated in Bone Metastatis: Prognostic Primary vs Bone Metastatis p<0.05 Tissue 21647377
669 miR-143 miRNA Humans Downregulated in Bone Metastatis: 12.9 fold Prognostic Primary vs Bone Metastatis p=0.012 Tissue 21647377
670 miR-145 miRNA Humans Downregulated in Bone Metastatis: 17.3 fold Prognostic Primary vs Bone Metastatis p=0.014 Tissue 21647377
671 miR-143 miRNA Humans Downregulated in Bone Metastatis Prognostic Bone Metastatis Vs No Bone Metastasis p=0.039 Tissue 21647377
672 miR-145 miRNA Humans Downregulated in Bone Metastatis Prognostic Bone Metastatis Vs No Bone Metastasis p=0.041 Tissue 21647377
679 miR-141 miRNA Humans Upregulated with increasing PSA Prognostic progression Vs No Progression p<0.001 Plasma 21723797
680 Circulating Tumor Cells Others Humans Upregulated with increasing PSA Prognostic progression Vs No Progression p=0.002 Plasma 21723797
681 Lactate Dehydrogenase (LDH) Metabolites Humans Upregulated with increasing PSA Prognostic progression Vs No Progression p= 0.014 Plasma 21723797
682 thrombospondin 1 (THBS1) + C-Reactive Prostien (CRP) + poliovirus receptor-related 1 (PVRL1) + memembrane metallo endopeptidase (MME) +ephrin- A5 (EFNA5) Protein Humans NA Prognostic Overall Survival Vs No Survival (12 months) NA Serum 21741162
683 thrombospondin 1 (THBS1) + C-Reactive Prostien (CRP) + poliovirus receptor-related 1 (PVRL1) + memembrane metallo endopeptidase (MME) +ephrin- A5 (EFNA5) Protein Humans NA Prognostic Overall Survival Vs No Survival (24 months) NA Serum 21741162
684 PVRL1 (poliovirus receptor-related 1); PRG4 (proteoglycan 4); AP (alkaline phosphatase); FSTL1 (follistatin-like 1); Albumin; CEACAM1 (carcinoembryonic antigen related cell adhesion molecule 1); ANPEP (alanyl (membrane) aminopeptidase); CRP (C-reactive protein); Hb (hemoglobin); CADM1a (cell adhesion molecule 1a); POSTN (periostin, osteoblast specific factor); CADM1b (cell adhesion molecule 1b); CP (ceruloplasmin); AZGP1 (alpha-2-glycoprotein 1, zinc-binding). Protein Humans NA Prognostic Overall Survival Vs No Survival PVRL1 (poliovirus receptor-related 1) p= 0.002; CD10 p= 0.004; PRG4 (proteoglycan 4) p = 0.006; AP (alkaline phosphatase) p= 0.007; FSTL1 (follistatin-like 1) p= 0.01; Albumin p= 0.016; CEACAM1 (carcinoembryonic antigen related cell adhesion molecule 1) p = 0.018; ANPEP (alanyl (membrane) aminopeptidase) p=0.02; CRP (C-reactive protein) p= 0.02; Hb (hemoglobin) p=0.022; CADM1a (cell adhesion molecule 1a) p =0.03; POSTN (periostin, osteoblast specific factor) p=0.034; CADM1b (cell adhesion molecule 1b) p=0.035; CP (ceruloplasmin) p =0.046; AZGP1 (alpha-2-glycoprotein 1, zinc-binding) p =0.046. Serum 21741162
687 miR-139-5p; miR-1; miR-133b; miR-133a; miR-143*; miR-145*; miR-143; miR-145; miR-27b, miR-221; miR-222; miR-378; miR-204; miR-141*; miR-32; let-7b; miR-183*, miR-301b; miR-106b; miR-93; miR-25; miR-183; miR-96; miR-425; miR-663 miRNA Humans NA Prognostic group I (good prognosis) from group II (poor prognosis) p=0.0005 Tissue 21765474
695 AMACR mRNA Humans Upregulated in locally advanced cancers Prognostic localized Vs locally advanced cancers p= 0.044 Urine 21788966
696 EZH2 mRNA Humans Upregulated in locally advanced cancers Prognostic localized Vs locally advanced cancers p= 0.022 Urine 21788966
697 EZH2 mRNA Humans Upregulated in Intermediate and further upregulated in High Risk Group Prognostic Low Vs Intermediate Vs High Risk Group High vs low-risk group patients (P = 0.002), intermediate vs low risk group patients (P = 0.044) Urine 21788966
698 PCAT-1 ncRNA Humans Upregulated in a subset of metastatic and high-grade localized (Gleason score ≥7) cancers Prognostic High grade tumor vs. low grade tumor/non-tumor NA Tissue 21804560
699 KBP4; CRKL; PDHB, PRDX3; HYPK; MYL6;KHSRP; ENO1; ANXA5 ; RPLP0; OSTF1; CFL1; TXNDC12 ; PFDN5 ; HRNR; COPS8 ; Protein Humans Upregulated (Atleast 2 fold): [KHSRP; ENO1; ANXA5 ; RPLP0; OSTF1; CFL1; TXNDC12 ; PFDN5 ; HRNR; COPS8;]Downregulated (Atleast 0.5 fold): [KBP4; CRKL; PDHB, PRDX3; HYPK; MYL6;] Prognostic CD44+ Vs CD44- Cells p<0.05 Cell Lines 21820414
700 Cofilin Protein Humans Upregulated in CD44++ Cells Prognostic CD44+ Vs CD44- Cells p<0.01 Cell Lines 21820414
701 Annexin A5 Protein Humans Upregulated in CD44++ Cells Prognostic CD44+ Vs CD44- Cells p<0.05 Cell Lines 21820414
702 Methylation Status of (RARB or GSTP1 or RASSF1) Methylation Humans Hypermethylated in Cancer Prognostic Methylation in Patients with PCa NA Urine 21822036
703 Methylation Status of RARB Methylation Humans Hypermethylated in Cancer Prognostic Methylation in Patients with PCa NA Tissue 21822036
704 Methylation Status of RARB Methylation Humans Hypermethylated in Gleason Score 7 (PMR>=50) Prognostic Gleason Score 6 Vs Gleason Score 7 p=0.01 Urine 21822036
713 α2-macroglobulin (α2M) Protein Humans Downregulated with α2M deficiency (Without α2M deficiency: 252.45±125.07 Vs with α2M deficiency: 12.75±5.60) Prognostic PCa patients without α2M deficiency vs. PCa patients with α2M deficiency p<0.01 Serum 21894431
714 C-reactive protein (CRP) Protein Humans Downregulated with α2M deficiency (without α2M deficiency: 1534.6±1482.8 Vs with α2M deficiency: 173±90.3) Prognostic PCa patients without α2M deficiency vs. PCa patients with α2M deficiency p<0.01 Serum 21894431
715 serum amyloid A (SAA) Protein Humans Downregulated with α2M deficiency (without α2M deficiency: 54.7±44.5 Vs with α2M deficiency: 2.15±1.68) Prognostic PCa patients without α2M deficiency vs. PCa patients with α2M deficiency p<0.01 Serum 21894431
716 interleukin-6 (IL-6) Protein Humans Downregulated with α2M deficiency (without α2M deficiency: 46.50±40.65 Vs with α2M deficiency: 3.38±2.61) Prognostic PCa patients without α2M deficiency vs. PCa patients with α2M deficiency p<0.01 Serum 21894431
720 Katanin p60 Protein Humans Upregulated in PCa Prognostic bone metastasis (Met) Vs No bone metastasis (controls) p<0.05 Bone Marrow (Tissue) 21681775
752 CEP55 Protein Humans Upregulated in Patients with Recurrence Prognostic PSA Reccurence Vs No Recurrence p<0.0001 Tissue 21917134
753 NUF2 Protein Humans Upregulated in Patients with Recurrence Prognostic PSA Reccurence Vs No Recurrence p<0.0001 Tissue 21917134
754 PAGE4 Protein Humans Downregulated in Patients with Recurrence Prognostic PSA Reccurence Vs No Recurrence p=0.0045 Tissue 21917134
755 CEP55 Protein Humans Upregulated with high Gleason Score Prognostic Gleason Score (≤6, (3+4), (4+3), 8-10) For Hazrard Ratio: (p = 0.003) Tissue 21917134
756 NUF2 Protein Humans Upregulated with high Gleason Score Prognostic Gleason Score (≤6, (3+4), (4+3), 8-10) For Hazrard Ratio: (p = 0.002) Tissue 21917134
757 PBK Protein Humans Upregulated with high Gleason Score Prognostic Gleason Score (≤6, (3+4), (4+3), 8-10) For Hazrard Ratio: (p = 0.001) Tissue 21917134
758 TTK Protein Humans Upregulated with high Gleason Score Prognostic f For Hazrard Ratio: (p = 0.002) Tissue 21917134
759 PAGE4 Protein Humans Downregulated with high Gleason Score Prognostic Gleason Score (≤6, (3+4), (4+3), 8-10) For Hazrard Ratio: (p = 0.002) Tissue 21917134
767 OPNa (osteopontin -a ) mRNA Humans Upregulated with high Gleason Score (Median for GS< 7: 0.35, Median for GS ≥ 7: 84.54) Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 p= 0.006 Tissue 21963599
768 OPNb (osteopontin -b ) mRNA Humans Upregulated with high Gleason Score (Median for GS< 7: 3.54, Median for GS ≥ 7: 61.19) Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 p = 0.003 Tissue 21963599
769 OPNa (osteopontin -a ) mRNA Humans Upregulated with high Gleason Score (Median for GS< 7: 112.06, Median for GS ≥ 7: 526.39) Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 p= 0.001 Tissue 21963599
770 miR-7; miR-126; miR-144; miR-144*; miR-335*; miR-374a;miR-374a*; miR-28-3p; miR-542-3p miRNA Humans Upregulated: [miR-7: (3.22 fold); miR-126: (14.45 fold); miR-144 (6.78 fold);miR-144* (12.98 fold); miR-335* (1.39 fold) ; miR-374a (2.43 fold) ; miR-374a (1.16 fold) ; miR-28-3p (1.69 fold); miR-542-3p (3.72 fold)] Prognostic Metastatic Vs Non Metastatic p<0.001 Tissue 21980368
771 miR-7-1*; miR-126*; miR-335; miR-28-5p; miR-339-3p; miR-339-5p; miR-542-5p miRNA Humans Downregulated: [miR-7-1* (8.88 fold); miR-126* (3.46b fold); miR-335 (2,42 fold); miR-28-5p (6.84 fold); miR-339-3p (-1.57 fold); miR-339-5p (5.26 fold); miR-542-5p (13.31 fold)] Prognostic Metastatic Vs Non Metastatic p<0.001 Tissue 21980368
777 Thiobarbituric acid reactive substances (TBARS) Protein Humans Upregulated in Localised and Bone Metastasis Prognostic Controls Vs Localised Vs Bone Metastasis p<0.05 Plasma 21993000
778 Vitamin -C Protein Humans Downregulated in Localised and Bone Metastasis Prognostic Controls Vs Localised Vs Bone Metastasis p<0.05 Serum 21993000
779 Vitamin -E Protein Humans Downregulated in Localised and Bone Metastasis Prognostic Controls Vs Localised Vs Bone Metastasis p<0.05 Serum 21993000
780 Thiobarbituric acid reactive substances (TBARS) Protein Humans Upregulated in PCA (without treatment,), PCA (with Treatment: Goserelin A), and PCA (with treatment : Cytoproterone A.) Prognostic Controls Vs PCA (No Treatment) Vs PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) p<0.05 (Controls Vs PCA (No Treatment) ) & Controls Vs PCA (with Treatment: Goserelin A) & Controls Vs PCA (with Treatment: Cytoproterone A) & PCA (No Treatment) Vs PCA (with Treatment: Cytoproterone A) & PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) Plasma 21993000
781 Vitamin -C Protein Humans Downregulated in PCA (without treatment,), PCA (with Treatment: Goserelin A), and PCA (with treatment : Cytoproterone A.) Prognostic Controls Vs PCA (No Treatment) Vs PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) p<0.05 (Controls Vs PCA (No Treatment) ) & Controls Vs PCA (with Treatment: Goserelin A) & Controls Vs PCA (with Treatment: Cytoproterone A) Serum 21993000
782 Vitamin -E Protein Humans Downregulated in PCA (without treatment,), PCA (with Treatment: Goserelin A), and PCA (with treatment : Cytoproterone A.) Prognostic Controls Vs PCA (No Treatment) Vs PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) p<0.05 (Controls Vs PCA (No Treatment) ) & Controls Vs PCA (with Treatment: Goserelin A) & Controls Vs PCA (with Treatment: Cytoproterone A) & PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) & PCA (with Treatment: Goserelin A) Vs PCA (with no Treatment) Serum 21993000
783 Thiobarbituric acid reactive substances (TBARS) Protein Humans Upregulated in PCA (GS<7, GS=7, GS>7) Prognostic Controls Vs GS<7 Vs GS =7 Vs GS>7 p<0.05 (Controls Vs GS<7) & (Controls Vs GS=7) & (Controls Vs GS>7) Plasma 21993000
784 Vitamin -C Protein Humans Upregulated in PCA (GS<7, GS=7, GS>7) Prognostic Controls Vs GS<7 Vs GS =7 Vs GS>8 p<0.05 (Controls Vs GS<7) & (Controls Vs GS=7) & (Controls Vs GS>7) Serum 21993000
785 Vitamin -E Protein Humans Upregulated in PCA (GS<7, GS=7, GS>7) Prognostic Controls Vs GS<7 Vs GS =7 Vs GS>9 p<0.05 (Controls Vs GS<7) & (Controls Vs GS=7) & (Controls Vs GS>7) Serum 21993000
798 hsa-mir-375 miRNA Humans High expression associated with an increased risk of BCR Prognostic Biochemical Recurrenece p = 0.002 Serum 22052531
799 hsa-mir-375 miRNA Humans High expression with reduced chances of relapse free survival Prognostic Biochemical Recurrenece Univariate: p=0.0001; Multivariate: p=0.0260 Serum 22052531
800 PRKAR1A; LRRN3; PCDH17; TTN; LAIR2; RNASE3; CEACAM6; AZU1; HIST1H4C; PGLYRP1; CEACAM8; LCN2; MPO; CAMP; DEFA1;DEFA1; DEFA1; DEFA3; DEFA1; DEFA1; CTSG; DEFA4; ELA2; mRNA Humans Downregulated (0.6-0.82 fold): [PRKAR1A; LRRN3; PCDH17; TTN;] ; Upregulated (0.6 - 1.36 fold): [LAIR2; RNASE3; CEACAM6; AZU1; HIST1H4C; PGLYRP1; CEACAM8; LCN2; MPO; CAMP; DEFA1e;DEFA1e; DEFA1e; DEFA3; DEFA1e; DEFA1e; CTSG; DEFA4; ELA2;] Prognostic Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - prevaccination p< 0.008 Blood 22071976
801 LTB; OLR1; CEACAM1; ARG1; MYL4; ALAS2; SLPI; SELENBP1; SNCA; AZU1; HMGXB4; RNASE3; HBQ1; MMP9; GYPE; SNCA; EPB42; HP; IFIT1L; BPI; CEACAM6; MPO; OLFM4; HBM; ALAS2; CEACAM8; CA1; HBD; LCN2; CTSG; DEFA1; CAMP; ELA2; DEFA4; DEFA3; DEFA1; DEFA1; DEFA1; DEFA1; mRNA Humans Downregulated: [LTB (1.03 fold)] ; Upregulated (1.04- 2.87 fold): [OLR1; CEACAM1; ARG1; MYL4; ALAS2; SLPI; SELENBP1; SNCAe; AZU1; HMGXB4; RNASE3; HBQ1; MMP9; GYPE; SNCAe; EPB42; HP; IFIT1L; BPI; CEACAM6; MPO; OLFM4; HBM; ALAS2; CEACAM8; CA1; HBD; LCN2; CTSG; DEFA1e; CAMP; ELA2; DEFA4; DEFA3; DEFA1e; DEFA1e; DEFA1e; DEFA1e;] Prognostic Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - Postvaccination p< 0.008 Blood 22071976
803 LRRN3+PCDH17+HIST1H4C+PGLYRP1 mRNA Humans Downregulated: [LRRN3; PCDH17;] ; Upregulated: [HIST1H4C; PGLYRP1;] Prognostic Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - prevaccination p< 0.008 Blood 22071976
804 Methylation of GSTP1 Methylation Humans Hypermethylated in PCa Prognostic negative histology followed by a positive biopsy more than 24 months later NA Tissue 22077694
805 Methylation of APC Methylation Humans Hypermethylated in PCa Prognostic negative histology followed by a positive biopsy more than 24 months later P=0.012 Tissue 22077694
806 Methylation of GSTP1 + APC Methylation Humans Hypermethylated in PCa Prognostic negative histology followed by a positive biopsy more than 24 months later NA Tissue 22077694
807 %p2PSA Protein Humans Upregulated in Gleason Score ≥7 Prognostic Gleason Score ≥7 and Gleason Score <7 p<0.0001 Blood 22078333
808 Prostate Helth Index (phi) Protein Humans Upregulated in Gleason Score ≥7 Prognostic Gleason Score ≥7 and Gleason Score <7 p<0.0001 Blood 22078333
809 %p2PSA Protein Humans Upregulated with GS upgrading Prognostic Gleason sum upgrading from 6 to 7 p<0.0001 Blood 22078333
810 Prostate Helth Index (phi) Protein Humans Upregulated with GS upgrading Prognostic Gleason sum upgrading from 6 to 7 p<0.0001 Blood 22078333
811 %p2PSA Protein Humans Upregulated in Tumor Stage pt3 Prognostic pathological stage pt2 Vs pathological stage pt3 p<0.0001 Blood 22078333
812 Prostate Helth Index (phi) Protein Humans Upregulated in Tumor Stage pt3 Prognostic pathological stage pt2 Vs pathological stage pt3 p<0.0001 Blood 22078333
813 TGFβ1 (transforming growth factor beta 1) mRNA Humans Associated with Prostate cancer specific Survival Prognostic disease specific survival Vs no survival p=0.0 Tissue 22113713
814 (IL-7) Interleukin-7 mRNA Humans Associated with Prostate cancer specific Survival Prognostic disease specific survival Vs no survival p=0.03 Tissue 22113713
815 miRNA - 221 and miRNA-222 miRNA Humans Upregulated in aggressive Prostate Cancer (Aggressive: 20.1 ± 2.4; Non Aggressive: 3.4 ± 0.2) Prognostic Agressive Vs Non - Agressive Prostate Cancer p=0.001 Tissue 22117988
816 ARHI mRNA Humans Downregulated in aggressive Prostate Cancer (Aggressive:9.6 ± 1.2; Non Agressive: 8.3 ± 2.3 ) Prognostic Agressive Vs Non - Agressive Prostate Cancer p=0.001 Tissue 22117988
817 Interleukin-18 (IL-18) Protein Humans Upregulated in BPH and Prostate cancer: [ Controls: 143.97 ± 2.29; BPH: 145.88 ± 1.93; TNM Stage 2: 229.54 ± 3.30; TNM Stage 3: 245.66 ± 4.05; TNM Stage 4: 251.64 ± 4.12] Prognostic Controls Vs BPH Vs TNM T2 stage Vs TNM T3 stage Vs TNM T4 stage p<0.05 (Controls Vs TNM Stage 2,3 and 4 ; BPH Vs TNM Stage 2,3 and 4; TNM Stage 2 Vs TNM Stage 3,4] Serum 22126577
818 Interleukin-10 (IL-10) Protein Humans Upregulated in BPH and Prostate cancer: [ Controls: 2.08 ± 0.27; BPH: 2.15 ± 0.18; TNM Stage 2: 8.03 ± 0.49; TNM Stage 3: 13.06 ± 0.45; TNM Stage 4: 6.32 ± 0.29] Prognostic Controls Vs BPH Vs TNM T2 stage Vs TNM T3 stage Vs TNM T4 stage p<0.05 (Controls Vs TNM Stage 2,3 and 4 ; BPH Vs TNM Stage 2,3 and 4; TNM Stage 2 Vs TNM Stage 3,4] Serum 22126577
819 Interleukin-18 (IL-18) Protein Humans Increased expression in patients with poor survival Prognostic Survival Vs No Survival p<0.001 Serum 22126577
820 Interleukin-10 (IL-10) Protein Humans Increased expression in patients with poor survival Prognostic Survival Vs No Survival p<0.001 Serum 22126577
821 Methylation Status of AIM1 Methylation Humans Decreased hypermethylation in progression Prognostic Time To Progression Univariate: p = 0.02 ; Multivariate: p = 0.05 Tissue 22127895
823 TDRD1 mRNA Humans Upregulated in TMPRSS2-ERG gene fusion (36 fold) compared to benign samples and TMPRSS2-ERG gene fusion compared to non fusion (23 fold). Prognostic Benign Vs TMPRSS2-ERG gene fusion Vs non-fusion TMPRSS2-ERG positive tumors compared to normal (p = 1.77*10^-9) and fusion-negative samples (p = 1.51*10^-9) Tissue 22142399
830 Secreted frizzled-related protein (SFRP)-2 Protein Humans Upregulated in Gleason Grade 5 (PCa: 3.16 ± 0.99; Control: 0.77±0.15) Prognostic Gleason Grade 3,4 Vs Gleason Grade 5 p<0.0001 Tissue 22175903
834 Mutation Status of StAR Mutation Humans Allelic Loss in StAR in Recurrence Prognostic Biochemical Recurrenece (5 years) p=0.00269 Tissue 22213075
835 Mutation Status of HSD17B2 Mutation Humans Allelic Loss in HSD17B2 in Recurrence Prognostic Biochemical Recurrenece (5 years) p=0.031 Tissue 22213075
836 Mutation Status of StAR or HSD17B2 Mutation Humans Allelic Loss in atleast one (HSD17B2 or StaR) in Recurrence Prognostic Biochemical Recurrenece (5 years) p=0.0028 Tissue 22213075
842 breast cancer antiestrogen resistance 1 (BCAR1) Protein Humans Significantly associated with Biochemical Relapse Prognostic Biochemical Recurrence p=0.02 Tissue 22241677
863 sphingosine-1-phosphate (S1P) Protein Humans Downregulated in Stage 2 PCa than Stage 1 PCa Prognostic Stage 1 Vs Stage 2 prostate cancer p<0.001 Plasma 22315056
864 sphingosine-1-phosphate (S1P) Protein Humans Downregulated in Patients with No survival (No Survival: 5.11±0.75 Vs Survival: 7.02±0.22) Prognostic disease specific survival Vs no survival p=0.0439 Plasma 22315056
866 Testosterone Protein Humans Downregulated in Gleason Score 8-9 Prognostic Gleason Sum 5 Vs Gleason Sum 8-9 p=0.0495 Plasma 22315056
867 Testosterone Protein Humans Upregulated in Metastases Prognostic Metastases Vs No Metastases p<0.0001 Plasma 22315056
873 cDNA FLJ51403 ; Elongation Factor 1A (EF-A1) ; Alpha 1B - glycoprotien; Complement component C7; Inter-alpha (Globulin) inhibitor H4; Kininogen 1; Plasma retinol-binding protien; cDNA FLJ77744; Complement C1r subcomponent-like Protein; Ficolin-3 Protein Humans Upregulated: [cDNA FLJ51403 (1.9 fold); Elongation Factor 1A (EF-A1) (1.8 fold); Alpha 1B - glycoprotien (1.1 fold) ; Complement component C7 (1.1 fold) ; Inter-alpha (Globulin) inhibitor H4;(1.1 fold)]; Downregulated: [Kininogen 1 (1.1 fold); Plasma retinol-binding protien (1.2 fold); cDNA FLJ77744 (1.4 fold); Complement C1r subcomponent-like Protein (1.4 fold); Ficolin-3 (1.4 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
874 Inter-alpha-trypsin inhibitor heavy chain H3 + Antithrombin III Protein Humans Upregulated [Inter-alpha-trypsin inhibitor heavy chain H3 (2.0 fold) + Antithrombin III (1.2 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
875 Apliopoprotien A-IV + Complement Component 4B Protein Humans Downregulated [Apliopoprotien A-IV (1.1 fold)+ Complement Component 4B (1.3 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
876 Beta 2-Glycoprotein 1 + Somatomedin- B Protein Humans Downregulated [Beta 2-Glycoprotien 1 (1.1 fold) + Somatomedin- B (1.2 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
877 Alpha-2 HS-glycoprotien chain B + Afamin + Fibronectin 1 Protein Humans Downregulated [Alpha-2 HS-glycoprotien chain B (1.2 fold) + Afamin (1.5 fold)+ Fibronectin 1 (1.6 fold)] Prognostic Non Progressing Vs Progressing Prostate Cancer p ≤0.01 Serum 22355332
878 Elongation Factor 1A (EFA1) ; Zinc-alpha-2-glycoprotien ; Complement Compnent C6; Hemopexin ; Vitamin D-binding protien; cDNA FLJ53698; Histidine-rich glycoprotien; Inter-alpha-trypsin inhibitor heavy chain H1; Inter-alpha-trypsin inhibitor heavy chain H2; N-acetlymuramoyl-L-alanine amidase; Thyroxine-binding globulin Protein Humans Upregulated [Elongation Factor 1A (EFA1) (1.4 fold) ; Zinc-alpha-2-glycoprotien (1.3 fold) ; Complement Compnent C6 (1.2 fold); Hemopexin (1.2 fold); Vitamin D-binding protien (1.1 fold)];Downregulated [cDNA FLJ53698 (1.3 fold); Histidine-rich glycoprotien (1.3 fold); Inter-alpha-trypsin inhibitor heavy chain H1 (1.3 fold); Inter-alpha-trypsin inhibitor heavy chain H2 (1.4 fold); N-acetlymuramoyl-L-alanine amidase (1.4 fold); Thyroxine-binding globulin (1.5 fold)] Prognostic Progressing Vs Metastatic Prostate Cancer p ≤0.01 Serum 22355332
879 Apliopoprotien A-IV + Complement Component 4B Protein Humans Upregulated [Apliopoprotien A-IV (1.3 fold) + Complement Component 4B (1.4 fold)] Prognostic Progressing Vs Metastatic Prostate Cancer p ≤0.01 Serum 22355332
880 Alpha-2 HS-glycoprotien chain B + Afamin + Fibronectin 1 Protein Humans Downregulated [Alpha-2 HS-glycoprotien chain B (1.9 fold) + Afamin (1.9 fold)+ Fibronectin 1 (2.1 fold)] Prognostic Progressing Vs Metastatic Prostate Cancer p ≤0.01 Serum 22355332
881 cDNA FLJ54228 + Alpha-1-antichymotrypsin+ Complement component C9b+ cDNA FLJ58564 + Complement C5+Ceruloplasmin+cDNA FLJ55673 Protein Humans Upregulated [cDNA FLJ54228 (2.2 fold)+ Alpha-1-antichymotrypsin (1.8 fold)+ Complement component C9b (1.4 fold)+ cDNA FLJ58564 (1.3 fold) + Complement C5 (1.3 fold) +Ceruloplasmin (1.2 fold) +cDNA FLJ55673 (1.1 fold)] Prognostic Progressing Vs Metastatic Prostate Cancer p ≤0.01 Serum 22355332
889 Methylation Status of TBX15 Methylation Humans Highly methylated in ERG positive fusion compared to ERG negative fusion Prognostic ERG positive fusion compared to ERG negative fusion in Prostate cancer p<0.01 Tissue 22452941
890 Methylation Status of HOXD3 Methylation Humans Highly methylated in ERG positive fusion compared to ERG negative fusion Prognostic ERG positive fusion compared to ERG negative fusion in Prostate cancer p<0.01 Tissue 22452941
891 Methylation Status of CYP26A1 Methylation Humans Highly methylated in ERG positive fusion compared to ERG negative fusion Prognostic ERG positive fusion compared to ERG negative fusion in Prostate cancer p≤0.041 Tissue 22452941
892 Methylation Status of HOXD3 Methylation Humans Differentially Expressed Prognostic Pathological Stage (pT2 Vs pT3/pT4) p=0.026 Tissue 22452941
893 Methylation Status of TBX15 Methylation Humans Differentially Expressed Prognostic Pathological Stage (pT2 Vs pT3/pT4) p=0.010 Tissue 22452941
894 Methylation Status of HOXD3 Methylation Humans Differentially Expressed Prognostic Gleason score as ≤ 7 Vs 8 and above p<0.001 Tissue 22452941
895 Methylation Status of TBX15 or HOXD3 Methylation Humans Differentially Expressed Prognostic Disease specific survival Vs no survival p=0.044 Tissue 22452941
903 ERG mRNA Humans Upregulated in TMPRSS2-ERG positive fusion cases Prognostic TMPRSS2-ERG positive fusion compared to TMPRSS2-ERG negative fusion in Prostate cancer p<0.0001 Tissue 22505341
904 SPINK1 mRNA Humans Upregulated in TMPRSS2-ERG negative fusion cases Prognostic TMPRSS2-ERG positive fusion compared to TMPRSS2-ERG negative fusion in Prostate cancer p=0.03 Tissue 22505341
905 ERG mRNA Humans Upregulated in TERT positive cases Prognostic TERT positive compared to TERT negative in Prostate cancer p=0.016 Tissue 22505341
906 Fusion status of TMPRSS2-ERG and TERT expression mRNA Humans TMPRSS2–ERG and TERT-negative tumors had significantly lower rate of recurrence Prognostic Biochemical Recurrence Free Survival p=0.025 Urine 22505341
912 Minichromosome Maintenance Complex Protein 2 (MCM2) product scores Protein Humans Upregulated with Increasing Gleason Score Prognostic Gleason Score ≤6 Vs 7 Vs ≥8 p=0.002 Tissue 22554381
914 Ki-67 Protein Humans Upregulated with Increasing Gleason Score Prognostic Gleason Score ≤ 6 Vs 7 Vs ≥ 8 p=0.008 Tissue 22554381
915 Minichromosome Maintenance Complex Protein 2 (MCM2) product scores Protein Humans High in Patients with BCR Prognostic Biochemical Recurrence (Group 1) p=0.001 Tissue 22554381
916 Minichromosome Maintenance Complex Protein 2 (MCM2) product score OR ki-67 Product Score Protein Humans High in Patients with BCR Prognostic Biochemical Recurrence (Group 1) p=0.02 Tissue 22554381
917 Minichromosome Maintenance Complex Protein 2 (MCM2) product score AND ki-67 Product Score Protein Humans High in Patients with BCR Prognostic Biochemical Recurrence (Group 1) p=0.002 Tissue 22554381
922 Methylation Status Of ACTL6B; AEBP1; AMID; CD8A; CRIP1; FLJ30934; FLNC; FMOD; FOXE3; GAS7; GDPD5; HS3ST2; LOC349136; NEUROG1; PLTP; PTGER2; RASGRF2; RUNX3; SIX6; SLC9A3; SPSB4; SRD5A2; SUSD3; SYT10; TMEM74 Methylation Humans Hypermethlated in recurrent prostate cancer : Prognostic recurrent prostate cancer Vs nonrecurrent cancer NA Tissue 22589488
923 Methylation Status Of CHST7; LMX1B; RAFTLIN; RASGRF2; TNFRSF10D; ZNF135 Methylation Humans Methylated with Clinical Recurrence Prognostic clinical recurrence Vs biochemical recurrence NA Tissue 22589488
924 Methylation Status Of ALPL; AMPH; BCDIN3; BCL11B; BRD4; C18orf34; DCAMKL1; FGF5; FLJ42486; JAM2; LHX9; LOC283537; LRAT; PDE4B; POU3F3; PTGS2; RASGRF2; SLC27A6; SLC03A1; SPSB4; STAT3; SYN2; TACR3; TIRAP; WNT11 Methylation Humans Methylated with Systemic Recurrence Prognostic systemic recurrence Vs local recurrence NA Tissue 22589488
926 Methylation Status Of CRIP1; RUNX3; HS3ST2; FLNC; RASGRF2 Methylation Humans Methylated in PCA: Prognostic recurrent prostate cancer Vs nonrecurrent cancer NA Tissue 22589488
927 Methylation Status Of PHLDA3; RASGRF2; TNFRSF10D; ZNF135 Methylation Humans Hypermethlated in recurrent prostate cancer : Prognostic clinical recurrence Vs biochemical recurrence NA Tissue 22589488
928 Methylation Status Of BCL11B; POU3F3; RASGRF2 Methylation Humans Methylated with Clinical Recurrence Prognostic systemic recurrence Vs local recurrence NA Tissue 22589488
941 Mutation Status of KLK3 (-5429 T/G (rs2569733)) Mutation Humans NA Prognostic Biochemical Recurrence Vs no Biochemical Recurrence (5 years) Univariate Analysis: <0.01 ; Multivariate Analysis : p=0.013 Blood 22759231
942 Mutation Status of KLK2 (Arg250Trp (rs198977)) Mutation Humans NA Prognostic Biochemical Recurrence Vs no Biochemical Recurrence (5 years) Univariate Analysis: p=0.025 ; Multivariate Analysis : p=0.044 Blood 22759231
943 Mutation Status of SULT1A1, Arg213His (rs9282861) Mutation Humans NA Prognostic Biochemical Recurrence Vs no Biochemical Recurrence (5 years) Univariate Analysis: 0.014 Blood 22759231
944 Mutation Status of BGLAP, -198 T/C (rs1800247) Mutation Humans NA Prognostic Biochemical Recurrence Vs no Biochemical Recurrence (5 years) Univariate Analysis: <0.01 ; Multivariate Analysis : p=0.020 Blood 22759231
945 Mutation Status of KLK3 + KLK2 + SULT1A1 + BGLAP + Nonogram Mutation Humans NA Prognostic Biochemical Recurrence Vs no Biochemical Recurrence (5 years) p<0.001 Blood 22759231
952 Mutation Status of LEPR (LEPR Gln223Arg) Mutation Humans Increased Risk of High Grade PCa Prognostic LEPR Gln223Arg ( A Vs G mutation) in Patients with High Grade PCa NA NA 22792137
953 Mutation Status of SPP1 (SPP1-66 T>G) Mutation Humans Increased Risk of High Grade PCa Prognostic SPP1 mutaion (SPP1- 66 T>G) in Patients with High Grade PCa NA NA 22792137
954 Mutation Status of IGF1R (IGF1R+3174 G>A) Mutation Humans Increased Risk of High Grade PCa Prognostic IGF1R mutation (IGF1R+3174 G>A) in Patients with High Grade PCa NA NA 22792137
955 Mutation Status of IGFBP3 (IGFBP3-202 A>C) Mutation Humans Increased Risk of High Grade PCa Prognostic IGFBP3 mutation (IGFBP3-202 A>C) in Patients with High Grade PCa NA NA 22792137
956 Mutation Status of FGF2 (FGF2+223 C>T) Mutation Humans Increased Risk of High Grade PCa Prognostic FGF2 mutation (FGF2+223 C>T) in Patients with High Grade PCa NA NA 22792137
957 Mutation Status of IL6 (IL6-597 G>A) Mutation Humans Increased Risk of High Grade PCa Prognostic IL6 mutation (IL6-597 G>A) in Patients with High Grade PCa NA NA 22792137
958 Mutation Status of LEPR (LEPR Gln223Arg) Mutation Humans Increased Risk of High Grade PCa for Metastasis Prognostic LEPR Gln223Arg ( A Vs G mutation) in Patients with High Grade PCa With Metastasis NA NA 22792137
959 Mutation Status of SPP1 (SPP1-66 T>G) Mutation Humans Increased Risk of High Grade PCa for Metastasis Prognostic SPP1 mutaion (SPP1- 66 T>G) in Patients with High Grade PCa With Metastasis NA NA 22792137
960 Mutation Status of FGF2 (FGF2+223 C>T) Mutation Humans Increased Risk of High Grade PCa for Metastasis Prognostic FGF2 mutation (FGF2+223 C>T) in Patients with High Grade PCa With Metastasis NA NA 22792137
964 Soluble interleukin-6 Receptor (sIL-6R) Protein Humans Upregulated in higher Gleason Score (Without Gleason Score Upgrading: 65.62±23.87 Vs With Gleason Score Upgrading: 94.63±33.31) Prognostic Gleason Score Upgrading Vs No Gleason Score Uprading p=0.024 Serum 22866141
965 Soluble interleukin-6 Receptor / Interleukin-6 ((sIL-6R/IL-6) Protein Humans Upregulated in higher Gleason Score (Without Gleason Score Upgrading: 9.23±5.78 Vs With Gleason Score Upgrading: 15.61±4.94) Prognostic Gleason Score Upgrading Vs No Gleason Score Uprading p=0.011 Serum 22866141
968 GADD45B; CDKN1A; NLRP1; ERBB3; FMO5; SERINC2; AMFR; DPP4; PGC; YWHAE; EHF; TF; TNFSF10; EIF5A; TGM4; mRNA Humans Upregulated in Relapse: [GADD45B (4.86 fold); CDKN1A (2.65 fold); NLRP1 (1.57 fold)]; Downregulated in Relapse: [ERBB3 (0.55 fold); FMO5 (0.55 fold); SERINC2 (0.43 fold); AMFR (0.41 fold); DPP4 (0.40 fold); PGC (0.38 fold); YWHAE (0.34 fold); EHF(0.33 fold); TF (0.33 fold); TNFSF10 (0.31 fold); EIF5A (0.15 fold); TGM4 (0.03 fold);] Prognostic Relpase Vs No Relapse p<0.05 Tissue 22870216
969 hsa-miR-375; hsa-miR-96; hsa-miR-892b; hsa-miR-378; hsa-miR-302b; hsa-miR-548c-3p; hsa-miR-124; hsa-miR-141; hsa-miR-875-5p; hsa-miR-409-3p; hsa-miR-548a-3p; hsa-miR-623; hsa-miR-520d-5p; hsa-miR-489 miRNA Humans Upregulated in PCa: [hsa-miR-375 (8 fold); hsa-miR-96 (45.3 fold); hsa-miR-892b (9.9 fold); hsa-miR-378 (9.2 fold); hsa-miR-302b (45.3 fold); hsa-miR-548c-3p (2.8 fold); hsa-miR-124 (4.6 fold); hsa-miR-141 (6.5 fold); hsa-miR-875-5p (4.6 fold) ;hsa-miR-548a-3p (2.8 fold); hsa-miR-520d-5p (2.6 fold); hsa-miR-489 (7.5 fold)]; Downregulated in PCa: [ hsa-miR-409-3p (7 fold); hsa-miR-623 (2.6 fold); ] Prognostic LowRisk(LR) Vs Metastatic CRPC p<0.0001 Serum 22887127
970 miR-375; miR-141; miR-378*; miRNA Humans Upregulated in Primary Tumors: [miR-375 and miR-141]; Downregulated in Primary Tumors: [miR-378*] Prognostic Normal Vs Primary Tumor p<0.0001 Tissue 22887127
971 miR-375; miR-141; miR-378*; miR-409-3p miRNA Humans Upregulated in Low Risk PCa: [miR-375 ; miR-141]; Downregulated in Low Risk PCa: [miR-378*, miR-409-3p] Prognostic Normal Vs Low Risk Prostate Cancer miR-375; miR-141; miR-378*[p<0.0001]; miR-409-3p [p=0.004] Tissue 22887127
972 Prostate Specific Antigen (PSA) Protein Humans Downregulated with Increased BMI: [BMI <23: 9.49±3.46 Vs BMI >25: 6.28±1.36] Prognostic BMI Group <23 Vs BMI Group >25 p=0.001 Serum 22901185
976 RhoC score Protein Humans 10-point increase in the RhoC score reduced the subsequent risk of PSA failure by about 6% Prognostic Time to PSA Failure p=0.009 Tissue 22935975
977 RhoC score Protein Humans Decreased in Cases Prognostic Time to PSA Failure p=0.009 Tissue 22935975
979 ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004; genes or ncRNA Humans Upregulated: C19orf46-002, RSRC2-017 get upregulated with fold change >1.2; Downregualted: Others get downregulated with Fold Change < 1.1 Prognostic Metastatic Vs Primary p<0.05 Tissue 22956952
981 ACOT11-001; AOX1-001; C19orf46-002; C8orf84-001; COCH-202; CTA-55I10.1;001; DMD-024; FGF10-002 ;FGFR2-008; FGFR2-016; GABRE-006; GNAL-001; GNAO1-002; HEATR8-006; ISL1-002; NR2F2-202; PCP4-004; PDE5A-005; PDZRN4-202; RSRC2-017; TGM4-001; TSPAN2-001; ABCC4-004; ALK-001; ATP1A1-002; NAMPT-006; NAMPT-007; RP11-627G23.1-004; genes or ncRNA Humans NA Prognostic Biochemical Recurrence p<0.005 Tissue 22956952
982 EGFR Protein Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival p= 0.01 Tissue 22977195
983 EGFR mRNA Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival p= 0.005 Tissue 22977195
984 PTEN Protein Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival p= 0.02 Tissue 22977195
985 PTEN mRNA Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival p= 0.0003 Tissue 22977195
986 PTEN mRNA Humans Overexpressed for Progression Free Survival Prognostic Overall Survival p= 0.02 Tissue 22977195
987 EGFR + PTEN mRNA Humans Overexpressed for Progression Free Survival Prognostic Progression Free Survival NA Tissue 22977195
990 FLIP Protein Humans NA Prognostic PSA Failure Vs Non Failure p<0.05 Tissue 23028678
991 Sp1 Protein Humans NA Prognostic PSA Failure Vs Non Failure p<0.05 Tissue 23028678
992 Sp3 Protein Humans NA Prognostic PSA Failure Vs Non Failure p<0.05 Tissue 23028678
993 FLIP + Sp1 + Sp3 + Gleason Score Protein Humans NA Prognostic PSA Failure Vs Non Failure p<0.05 Tissue 23028678
994 Ras-related GTP binding D (RRAGD) + polyglutamine binding protein 1 (PQBP1) +histone cluster 1, H2bg (HIST1H2BC)+ aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) +tripartite motif-containing 22 (TRIM22) + RNA binding protein with multiple splicing (RBPMS) + heat shock 22 kDa protein 8 (HSPB8) mRNA Humans Upregulated: [histone cluster 1, H2bg (HIST1H2BC) (1.88 fold); polyglutamine binding protein 1 (PQBP1) (2.08 fold)]; Downregulated: [Ras-related GTP binding D (RRAGD) (0.45 fold); aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) (0.49 fold) ; tripartite motif-containing 22 (TRIM22) (0.54 fold) ; RNA binding protein with multiple splicing (RBPMS) (0.49 fold) + heat shock 22 kDa protein 8 (HSPB8) (0.44 fold)] Prognostic Biochemical relapse Vs No biochemical Relpase p<0.002 Tissue 23028830
995 Ras-related GTP binding D (RRAGD) + polyglutamine binding protein 1 (PQBP1) +histone cluster 1, H2bg (HIST1H2BC)+ aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) +tripartite motif-containing 22 (TRIM22) + RNA binding protein with multiple splicing (RBPMS) + heat shock 22 kDa protein 8 (HSPB8) + Cell Type Hetrogenity + Gleason Score mRNA Humans Upregulated: [histone cluster 1, H2bg (HIST1H2BC) (1.88 fold); polyglutamine binding protein 1 (PQBP1) (2.08 fold)]; Downregulated: [Ras-related GTP binding D (RRAGD) (0.45 fold); aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) (0.49 fold) ; tripartite motif-containing 22 (TRIM22) (0.54 fold) ; RNA binding protein with multiple splicing (RBPMS) (0.49 fold) + heat shock 22 kDa protein 8 (HSPB8) (0.44 fold)] Prognostic Biochemical relapse Vs No biochemical Relpase p<0.002 Tissue 23028830
996 GPX1 mRNA Humans Upregulated in Metatstasis Prognostic Relpase Vs No Relapse p<0.001 Blood 23046102
997 SOD2 mRNA Humans Upregulated in Metatstasis Prognostic Relpase Vs No Relapse p=0.01 Blood 23046102
998 AR mRNA Humans Differentially Expressed Prognostic Relpase Vs No Relapse p=0.001 Blood 23046102
999 Cyclin B mRNA Humans Differentially Expressed Prognostic Relpase Vs No Relapse p=0.007 Blood 23046102
1000 bFGF mRNA Humans Differentially Expressed Prognostic Relpase Vs No Relapse p=0.004 Blood 23046102
1001 2 or more out of (GPX1; SOD2; AR; Cyclin B; bFGF) mRNA Humans Differentially Expressed Prognostic Relpase Vs No Relapse p<0.001 Blood 23046102
1002 ABL2+SEMA4D+ITGAL+C1QA+TIMP1+CDKN1A mRNA Humans NA Prognostic low-risk group Vs high-risk group p<0.05 Blood 23059047
1022 TMPRSS2-ERG (v-ets erythroblastosis virus E26 oncogene homolog) >= 10 mRNA Humans NA Prognostic Gleason Score <7 Vs Gleason score ≥ 7 p<0.001 Urine 23201468
1023 TMPRSS2-ERG mRNA Humans NA Prognostic Tumor Stage (T3-T4) p = 0.023 Urine 23201468
1024 Serum PSA Protein Humans NA Prognostic PCa Vs No PCA group p<0.001 Serum 23201468
1025 Serum PSA Protein Humans NA Prognostic Gleason Score <7 Vs Gleason score ≥ 7 p = 0.003 Serum 23201468
1026 Serum PSA Protein Humans NA Prognostic Tumor Stage (T3-T4) p = 0.002 Serum 23201468
1031 miR-30d miRNA Humans Shorter Survival Time in High miRNA-30d group Prognostic Biochemical Recurrence p = 0.026 (BCR); p =0.04 (Univariate); 0.003 (multivariate) Tissue 23231923
1035 BMI1 Protein Humans Upregulated with Advanced Stage PCa (stage 2: 3.91±.60 Vs Stage 3: 8.55 ±1.95; Stage 4: 10.84 ± 2.44) Prognostic Stage 2 Vs Stage 3 Vs Stage 4 Prostate Cancer p< 0.001 Serum 23308129
1040 Aminopeptidase N (APN) Protein Humans NA Prognostic Recurrence Free Survival Univariate: p=0.002; Mutlivariate: p=0.017 Tissue 23322201
1041 Aminopeptidase N (APN) Protein Humans NA Prognostic Cancer Specific Survival Univariate: p=0.017; Mutlivariate: p=0.049 Tissue 23322201
1045 Early Growth Response 1 (Egr1) mRNA Humans Downregulated in Relapse (0.784 fold) Prognostic Relpase Vs No Relapse p = 0.017 Tissue 23342084
1055 Circulating Tumor Cells (CTC) Others Humans Upregulated in mRCPC (CTC count >=3) Prognostic Locally Advanced Prostate Cancer (LaPC) Vs Metastatic Disease p < 0.001 Blood 23358719
1056 Circulating Tumor Cells (CTC) Others Humans Upregulated in patients with Lower Overall Survival (CTC count >=3) Prognostic Overall Survival p = 0.001 Blood 23358719
1064 miR-141 miRNA Humans Upregulated in Bone Metastasis Prognostic Patients with Bone Metastasis Vs No Bone Metastasis p<0.001 Serum 23377530
1075 Methylation Status of APC Methylation Humans Hypermethylated in early stages of PCa Prognostic Stage 1 & 2 Vs Stage 3 & 4 p<0.049 Tissue 23431474
1076 3-hydroxy-3-methylglutaryl coenzyme A synthase ( HMGCS2 ); aldehyde dehydrogenase 1 family, member A3 ( ALDH1A3 ); chromosome 6 open reading frame 115 ( C6orf115 ); hydroxysteroid (11-beta) dehydrogenase 2 ( HSD11B2 ); anterior gradient homolog 2 (Xenopus laevis) ( AGR2 ); S100 calcium binding protein P ( S100P ); dehydrogenase/reductase (SDR family) member 2 ( DHRS2 ); monoamine oxidase B ( MAOB ); thymidine phosphorylase ( TYMP ); monoamine oxidase A ( MAOA ); sequestosome 1 ( SQSTM1 ); tropomyosin 1 (alpha) ( TPM1 ); cathepsin D ( CTSD ); growth differentiation factor 15 ( GDF15 ); arginase, type II ( ARG2 ); glutaminase ( GLS ); arylacetamide deacetylase-like 1 ( AADACL1 ); aldehyde dehydrogenase 4 family, member A1 ( ALDH4A1 ); solute carrier family 12 (potassium/chloride transporters), member 7 ( SLC12A7 ); spermatogenesis associated, serine-rich 2-like ( SPATS2L ); N-acylsphingosine amidohydrolase (acid ceramidase) 1 ( ASAH1 ); calpain 2, (m/II) large subunit ( CAPN2 ); acyl-CoA thioesterase 9 ( ACOT9 ); keratin 18 ( KRT18 ); epoxide hydrolase 1, microsomal (xenobiotic) ( EPHX1 ); glutathione S-transferase kappa ( GSTK1 ); aldo-keto reductase family 1, member C2 ( AKR1C2 ); acyl-CoA synthetase long-chain family member 3 ( ACSL3 ); mannosidase, beta A, lysosomal ( MANBA ); vesicle-associated membrane protein 8 (endobrevin) ( VAMP8 ); retinol saturase (all-trans-retinol 13,14-reductase) ( RETSAT ); occludin ( OCLN ); sulfide dehydrogenase like ( SQRDL ); acyl-CoA dehydrogenase, C-2 to C-3 short chain ( ACADS ); microtubule associated monoxygenase, calponin and LIM domain containing 1 ( MICAL1 ); 3-hydroxyisobutyryl-CoA hydrolase ( HIBCH ); abhydrolase domain containing 11 ( ABHD11 ); acyl-CoA synthetase long-chain family member 4 ( ACSL4 ); superoxide dismutase 2, mitochondrial ( SOD2 ); fucosidase, alpha-L- 1, tissue ( FUCA1 ); sideroflexin 3 ( SFXN3 ); carnitine palmitoyltransferase 2 ( CPT2 ); Protein Humans Upregulated in LNCAP-SF [3-hydroxy-3-methylglutaryl coenzyme A synthase ( HMGCS2 ); ( 9.2394 fold) aldehyde dehydrogenase 1 family, member A3 ( ALDH1A3 ); ( 8.1484 fold) chromosome 6 open reading frame 115 ( C6orf115 ); ( 6.6899 fold) hydroxysteroid (11-beta) dehydrogenase 2 ( HSD11B2 ); ( 5.4227 fold) anterior gradient homolog 2 (Xenopus laevis) ( AGR2 ); ( 5.0377 fold) S100 calcium binding protein P ( S100P ); ( 4.92 fold) dehydrogenase/reductase (SDR family) member 2 ( DHRS2 ); ( 4.5974 fold) monoamine oxidase B ( MAOB ); ( 4.3792 fold) thymidine phosphorylase ( TYMP ); ( 3.8776 fold) monoamine oxidase A ( MAOA ); ( 3.8563 fold) sequestosome 1 ( SQSTM1 ); ( 3.8075 fold) tropomyosin 1 (alpha) ( TPM1 ); ( 3.5117 fold) cathepsin D ( CTSD ); ( 3.3074 fold) growth differentiation factor 15 ( GDF15 ); ( 3.2564 fold) arginase, type II ( ARG2 ); ( 3.2251 fold) glutaminase ( GLS ); ( 3.2099 fold) arylacetamide deacetylase-like 1 ( AADACL1 ); ( 3.1698 fold) aldehyde dehydrogenase 4 family, member A1 ( ALDH4A1 ); ( 3.0362 fold) solute carrier family 12 (potassium/chloride transporters), member 7 ( SLC12A7 ); ( 3.0201 fold) spermatogenesis associated, serine-rich 2-like ( SPATS2L ); ( 2.9743 fold) N-acylsphingosine amidohydrolase (acid ceramidase) 1 ( ASAH1 ); ( 2.9654 fold) calpain 2, (m/II) large subunit ( CAPN2 ); ( 2.9387 fold) acyl-CoA thioesterase 9 ( ACOT9 ); ( 2.9016 fold) keratin 18 ( KRT18 ); ( 2.8839 fold) epoxide hydrolase 1, microsomal (xenobiotic) ( EPHX1 ); ( 2.8828 fold) glutathione S-transferase kappa ( GSTK1 ); ( 2.8356 fold) aldo-keto reductase family 1, member C2 ( AKR1C2 ); ( 2.8239 fold) acyl-CoA synthetase long-chain family member 3 ( ACSL3 ); ( 2.8157 fold) mannosidase, beta A, lysosomal ( MANBA ); ( 2.813 fold) vesicle-associated membrane protein 8 (endobrevin) ( VAMP8 ); ( 2.7515 fold) retinol saturase (all-trans-retinol 13,14-reductase) ( RETSAT ); ( 2.7151 fold) occludin ( OCLN ); ( 2.7082 fold) sulfide dehydrogenase like ( SQRDL ); ( 2.7062 fold) acyl-CoA dehydrogenase, C-2 to C-3 short chain ( ACADS ); ( 2.6711 fold) microtubule associated monoxygenase, calponin and LIM domain containing 1 ( MICAL1 ); ( 2.6382 fold) 3-hydroxyisobutyryl-CoA hydrolase ( HIBCH ); ( 2.5805 fold) abhydrolase domain containing 11 ( ABHD11 ); ( 2.5752 fold) acyl-CoA synthetase long-chain family member 4 ( ACSL4 ); ( 2.5729 fold) superoxide dismutase 2, mitochondrial ( SOD2 ); ( 2.536 fold) fucosidase, alpha-L- 1, tissue ( FUCA1 ); ( 2.5286 fold) sideroflexin 3 ( SFXN3 ); ( 2.5136 fold) carnitine palmitoyltransferase 2 ( CPT2 ); ( 2.5117 fold) Prognostic LNCAP Cell Lines Vs LNCaP-SF (androgen independent) NA Cell Lines 23443136
1077 semenogelin I ( SEMG1 ); Cyclin-dependent kinase 1 ( CDC2 ); thymidine kinase 1, soluble ( TK1 ); semenogelin II ( SEMG2 ); barrier to autointegration factor 1 ( BANF1 ); cDNA FLJ16186 ( cDNA FLJ16186 ); polo-like kinase 1 ( PLK1 ); cyclin-dependent kinase 2 ( CDK2 ); insulin-like growth factor binding protein 2, 36kDa ( IGFBP2 ); stathmin 1 ( STMN1 ); ribonucleotide reductase M2 ( RRM2 ); S100 calcium binding protein A13 ( S100A13 ); GINS complex subunit 3 (Psf3 homolog) ( GINS3 ); neural cell adhesion molecule 2 ( NCAM2 ); thyroid hormone receptor interactor 13 ( TRIP13 ); ribonucleotide reductase M1 ( RRM1 ); nucleolar pre-rRNA processing protein ( ESF1 ); stathmin-like 2 ( STMN2 ); H3 histone, family 3A ( H3F3A ); GINS complex subunit 4 (Sld5 homolog) ( GINS4 ); H2A histone family, member Z ( H2AFZ ); DNA (cytosine-5-)-methyltransferase 1 ( DNMT1 ); ATPase family, AAA domain containing 2 ( ATAD2 ); SCD6 homolog B (S. cerevisiae) ( LSM14B ); chromosome 13 open reading frame 33 ( C13orf33 ); karyopherin alpha 2 (RAG cohort 1, importin alpha 1) ( KPNA2 ); Nuclear autoantigenic sperm protein (histone-binding) ( NASP ); acireductone dioxygenase 1 ( ADI1 ); histone cluster 1, H4a ( HIST1H4A ); lamin B1 ( LMNB1 ); 3-hydroxybutyrate dehydrogenase, type 2 ( BDH2 ); phosphorylase, glycogen, liver ( PYGL ); PDZ binding kinase ( PBK ); histone cluster 1, H1b ( HIST1H1B ); histone acetyltransferase 1 ( HAT1 ); Ras association (RalGDS/AF-6) domain family member 3 ( RASSF3 ); nitrogen fixation 1 homolog (S. cerevisiae) ( NFS1 ); programmed cell death 4 (neoplastic transformation inhibitor) ( PDCD4 ); H2A histone family, member Y ( H2AFY ); ligase I, DNA, ATP-dependent ( LIG1 ); structural maintenance of chromosomes 4 ( SMC4 ); topoisomerase (DNA) II beta 180kDa ( TOP2B ); nucleus accumbens associated 1, BEN and BTB (POZ) domain containing ( NACC1 ); structural maintenance of chromosomes 2 ( SMC2 ); DEAH (Asp-Glu-Ala-His) box polypeptide 36 ( DHX36 ); Metastasis-associated protein 1 ( MTA1 ); Protein Humans Downregulated in LNCAP-SF [semenogelin I ( SEMG1 ); ( 0.076735 fold) Cyclin-dependent kinase 1 ( CDC2 ); ( 0.081925 fold) thymidine kinase 1, soluble ( TK1 ); ( 0.083392 fold) semenogelin II ( SEMG2 ); ( 0.10883 fold) barrier to autointegration factor 1 ( BANF1 ); ( 0.17609 fold) cDNA FLJ16186 ( cDNA FLJ16186 ); ( 0.19531 fold) polo-like kinase 1 ( PLK1 ); ( 0.20362 fold) cyclin-dependent kinase 2 ( CDK2 ); ( 0.22407 fold) insulin-like growth factor binding protein 2, 36kDa ( IGFBP2 ); ( 0.22637 fold) stathmin 1 ( STMN1 ); ( 0.24713 fold) ribonucleotide reductase M2 ( RRM2 ); ( 0.25054 fold) S100 calcium binding protein A13 ( S100A13 ); ( 0.2628 fold) GINS complex subunit 3 (Psf3 homolog) ( GINS3 ); ( 0.26922 fold) neural cell adhesion molecule 2 ( NCAM2 ); ( 0.26951 fold) thyroid hormone receptor interactor 13 ( TRIP13 ); ( 0.27195 fold) ribonucleotide reductase M1 ( RRM1 ); ( 0.27289 fold) nucleolar pre-rRNA processing protein ( ESF1 ); ( 0.27757 fold) stathmin-like 2 ( STMN2 ); ( 0.28292 fold) H3 histone, family 3A ( H3F3A ); ( 0.28744 fold) GINS complex subunit 4 (Sld5 homolog) ( GINS4 ); ( 0.28965 fold) H2A histone family, member Z ( H2AFZ ); ( 0.2989 fold) DNA (cytosine-5-)-methyltransferase 1 ( DNMT1 ); ( 0.3037 fold) ATPase family, AAA domain containing 2 ( ATAD2 ); ( 0.30571 fold) SCD6 homolog B (S. cerevisiae) ( LSM14B ); ( 0.30649 fold) chromosome 13 open reading frame 33 ( C13orf33 ); ( 0.3127 fold) karyopherin alpha 2 (RAG cohort 1, importin alpha 1) ( KPNA2 ); ( 0.31541 fold) Nuclear autoantigenic sperm protein (histone-binding) ( NASP ); ( 0.32372 fold) acireductone dioxygenase 1 ( ADI1 ); ( 0.33027 fold) histone cluster 1, H4a ( HIST1H4A ); ( 0.33313 fold) lamin B1 ( LMNB1 ); ( 0.33412 fold) 3-hydroxybutyrate dehydrogenase, type 2 ( BDH2 ); ( 0.33637 fold) phosphorylase, glycogen, liver ( PYGL ); ( 0.33849 fold) PDZ binding kinase ( PBK ); ( 0.34986 fold) histone cluster 1, H1b ( HIST1H1B ); ( 0.35951 fold) histone acetyltransferase 1 ( HAT1 ); ( 0.36643 fold) Ras association (RalGDS/AF-6) domain family member 3 ( RASSF3 ); ( 0.37213 fold) nitrogen fixation 1 homolog (S. cerevisiae) ( NFS1 ); ( 0.37728 fold) programmed cell death 4 (neoplastic transformation inhibitor) ( PDCD4 ); ( 0.37993 fold) H2A histone family, member Y ( H2AFY ); ( 0.38303 fold) ligase I, DNA, ATP-dependent ( LIG1 ); ( 0.38796 fold) structural maintenance of chromosomes 4 ( SMC4 ); ( 0.38871 fold) topoisomerase (DNA) II beta 180kDa ( TOP2B ); ( 0.38889 fold) nucleus accumbens associated 1, BEN and BTB (POZ) domain containing ( NACC1 ); ( 0.39627 fold) structural maintenance of chromosomes 2 ( SMC2 ); ( 0.3968 fold) DEAH (Asp-Glu-Ala-His) box polypeptide 36 ( DHX36 ); ( 0.39825 fold) Metastasis-associated protein 1 ( MTA1 ); ( 0.39986 fold) ] Prognostic LNCAP Cell Lines Vs LNCaP-SF (androgen independent) NA Cell Lines 23443136
1079 PCA3 mRNA Humans Upregulated with High Gleason Score Prognostic Low Gleason Score Vs high Gleason Score (≥7) p=0.02 Urine 23515404
1080 TMPRSS2:ERG mRNA Humans Upregulated with High Gleason Score Prognostic Low Gleason Score Vs high Gleason Score (≥7) p=0.02 Urine 23515404
1081 PCA3 + TMPRSS2:ERG mRNA Humans Upregulated with High Gleason Score Prognostic Low Gleason Score Vs high Gleason Score (≥7) NA Urine 23515404
1084 PCA3 + TMPRSS2:ERG + PSA mRNA Humans Upregulated with High Gleason Score Prognostic Low Gleason Score Vs high Gleason Score (≥7) NA Urine 23515404
1087 miR-183 miRNA Humans Upregulated in Prostate Cancer Prognostic Tumor Stage pT2 Vs pT3 p<0.05 Tissue 23538390
1088 miR-183 miRNA Humans Upregulated in Prostate Cancer Prognostic Overall Survival p<0.05 Tissue 23538390
1091 miR-141 miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1092 miR-375 miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1093 miR-151-3p miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1094 miR-126 miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1095 miR-16 miRNA Humans Downregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1096 miR-205 miRNA Humans Downregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1097 PSA + miR141 + mir-151-3p + mir-16 miRNA Humans Upregulated in metastatic castration-resistant PCa (mCRPC) Prognostic localized (local) prostate cancer (PCa) Vs metastatic castration-resistant PCa (mCRPC) p < 0.001 Plasma 23574937
1098 miR-423-3p miRNA Humans Upregulated with High Gleason Score Prognostic Gleason Score < 7 Vs Gleason Score ≥ 8 p = 0.002 Plasma 23574937
1099 miR-205 miRNA Humans Downregulated with High Gleason Score Prognostic Gleason Score < 7 Vs Gleason Score ≥ 8 p = 0.004 Plasma 23574937
1100 miR-205 miRNA Humans Upregulated in Biochemical Recurrence Prognostic Biochemical recurrence p = 0.006 Plasma 23574937
1101 miR-423-3p miRNA Humans Downregulated in Biochemical Recurrence Prognostic Biochemical recurrence p<0.001 Plasma 23574937
1102 miR-151-3p miRNA Humans Downregulated in Biochemical Recurrence Prognostic Biochemical recurrence p<0.001 Plasma 23574937
1103 Apolipoprotein B Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.01 Serum 23582881
1104 Biotinidase Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p= 0.041 Serum 23582881
1105 Cell adhesion molecule 1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p= 0.046 Serum 23582881
1106 Complement factor H Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p= 0.025 Serum 23582881
1107 Ceruloplasmin Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.041 Serum 23582881
1108 Carboxypeptidase M Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.001 Serum 23582881
1109 Intercellular adhesion molecule 1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.041 Serum 23582881
1110 Galectin-3-binding protein Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.009 Serum 23582881
1111 Serum paraoxonase/arylesterase 1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.011 Serum 23582881
1112 Poliovirus receptor-related protein 1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.046 Serum 23582881
1113 Thrombospondin-1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.022 Serum 23582881
1114 Transmembrane 9 superfamily member 3 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.037 Serum 23582881
1121 Asporin; Cartilage oligomeric matrix Protein (COMP); Versican; EMILIN 3; Protein Humans Upregulated in Agressive Prostate Cancer (Fold Change); [Asporin (2.14 fold); Cartilage oligomeric matrix Protein (COMP) (100 fold) ; Versican (100 fold) ; EMILIN 3 ( 6 fold); Prognostic Agressive Vs Non Agressive Prostate Cancer Asporin (p=0.00016) ; Cartilage oligomeric matrix Protein (COMP) (p = 0.00228) ; Versican ( 0.03367) ; EMILIN 3 (0.04983); Tissue 23716368
1122 Acid ceramidase Protein Humans Downregulated in Agressive Prostate Cancer 0.18 Fold Prognostic Agressive Vs Non Agressive Prostate Cancer p = 0.04983 Tissue 23716368
1136 Aminoadipic acid Metabolites Humans Increased in Patients with Recurrence Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p =0.031 Tissue 23737455
1137 Gluconic acid Metabolites Humans Decreased in Patients with Recurrence Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p =0.036 Tissue 23737455
1138 Maltotriose Metabolites Humans Decreased in Patients with Recurrence Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p =0.006 Tissue 23737455
1139 Aminoadipic acid Metabolites Humans Increased in Patients with Recurrence Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p =0.048 Tissue 23737455
1141 let-7a; let-7b; let-7c, miR-515-3p; miR515-5p; miR-181b; miR-146b; miR-361 miRNA Humans Upregulated: [let-7a - 1.7 fold; let-7b 3.7 fold; let-7c 3.0 fold, miR-515-3p 3.2 fold; miR515-5p 3.2 fold;] Downregulated: [miR-181b 1.8 fold; miR-146b 1.7 fold; miR-361 1.7 fold] Prognostic Clinical progression free survival (CPFS) Vs. clinical failure (CF) p<0.05 Tissue 23798998
1148 C-Reactive Protein (CRP) Protein Humans Higher levels associated with shorter biochemical failure-free survival (Both for patients with Post- radical Prostatectomy and Definitive Radiotherapy) Prognostic Biochemical Failure Free survival p = 0.009 Serum 23818401
1151 Histidine; Glycine; Alanine; Kynurenine; Glutamate; Glycerol 3-phosphate (G3P); Betaine; Pipecolate 2-methylbutyrylcarnitin; Isobar: 15-methylpalmitate; 2-methylpalmitate; Threonine; Cytidine 50-diphosphocholine; Valine; Myristoleate (14:1n5); S-adenosylhomocysteine (SAH); Phosphate; Choline; 2-aminobutyrate 2-hydroxypalmitate; Glycerol; Adenine; 2-hydroxystearate; Deoxycarnitine; Fumarate; Docosadienoate (22:2n6); Metabolites Humans Increased with Upgraded Gleason Score Prognostic Gleason Score Upgrading [6 to 7 (3+4) to 7(4+3) to 8] p<0.05 Tissue 23824564
1152 Adenosine 50 -diphosphate (ADP); Citrate; Palmitoyl-sphingomyelin; Metabolites Humans Decreased with Upgraded Gleason Score Prognostic Gleason Score Upgrading [6 to 7 (3+4) to 7(4+3) to 8] p<0.05 Tissue 23824564
1153 5,6-dihydrouracil +choline phosphate+ glycerol + methylpalmitate Metabolites Humans Differentially Expressed Prognostic Organ Confined Vs Non Orgnan Confined p<0.05 Tissue 23824564
1154 7-HOCA+ pregnen-diol disulfate +mannosyl tryptophan Metabolites Humans Differentially Expressed Prognostic Progression Free Survival (5 years) Vs No Progression Free Survival (5 years) p<0.05 Tissue 23824564
1155 LASP1 + IQGAP3+ NFIB+ S1PR4+ THBS2+ANO7+ PCDH7 + MYBPC1+ EPPK1+ TSBP+ PBX1+ NUSAP1+ ZWILCH+ UBE2C+ CAMK2N1+ RABGAP1+ PCAT-32 + GLYATL1P4/PCAT-80 + TNFRSF19 mRNA Humans Differentially Expressed Prognostic Metastasis Vs No Metastasis p<0.01 Tissue 23826159
1159 Peptide ID: [1004; 2663; 5650; 7228; 9483; 9504; 10193; 10442; 10471; 10502; 17993] Protein Humans Upregulated in PCa [mean(case)/mean(control)]: Downregulated in PCa [mean(control)/mean (case)]: [] Prognostic Localised Vs Advanced Prostate Cancer p=0.0055 Plasma 23826311
1170 miR-141 miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.007 Serum 23846169
1171 miR-146b-3p miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.008 Serum 23846169
1172 miR-194 miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.044 Serum 23846169
1173 miR-146b-3p miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.02 Serum 23846169
1174 miR-194 miRNA Humans Upregulated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.029 Serum 23846169
1178 SLCO2B1 rs12422149 (GG allele) Mutation Humans NA Prognostic Time to Progression p =0.028 Blood 23896625
1184 Bone Sialoprotein Protein Humans Upregulated in Bone Metastatis (BM: 38.7 ±19.3; NBM: 9.1 ± 5.8) Prognostic Bone Metastatis Vs No Bone Metastatis p<0.05 Tissue 23904377
1185 Methylation Status of AOX1 (High vs. Low) Methylation Humans Hypermethylated in Prostate Cancer Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1186 Methylation Status of AOX1 (as continous variable) Methylation Humans Hypermethylated in Prostate Cancer Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1187 Methylation Status of C1orf114 (as continous variable) Methylation Humans Lower Methylation in Patients with Longer Survival Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1188 Methylation Status of C1orf114 (High vs. Low) Methylation Humans Lower Methylation in Patients with Longer Survival Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1189 Methylation Status of GAS6 (as continous variable) Methylation Humans Hypermethylated in Prostate Cancer Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1190 Methylation Status of GSTP1 Methylation Humans Hypermethylated in Prostate Cancer Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1191 Methylation Status of HAPLN3 (as continous variable) Methylation Humans Hypermethylated in Prostate Cancer Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1192 Methylation Status of HAPLN3 (High vs. Low) Methylation Humans Hypermethylated in Prostate Cancer Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1193 Methylation Status of KLF8 (High vs. Low) Methylation Humans Hypermethylated in Prostate Cancer Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1194 Methylation Status of KLF8 (as continuous variable) Methylation Humans Hypermethylated in Prostate Cancer Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1195 Methylation Status of MOB3B Methylation Humans Hypermethylated in Prostate Cancer Prognostic Biochemical recurrence P < 0.001 Tissue 23918943
1196 Methylation Status of AOX1/C1orf114/HAPLN3 Methylation Humans Lower Methylation in Patients with Longer Survival Prognostic Biochemical recurrence NA Tissue 23918943
1197 Methylation Status of AOX1/C1orf114/HAPLN3 Methylation Humans Lower Methylation in Patients with Longer Survival Prognostic Biochemical recurrence NA Tissue 23918943
1208 RNASEL [D541E variant: GG] Mutation Humans Expressed in patients with High Risk of PCa Prognostic High Risk with GG phenotype Vs High Risk with (TG and TT phenotype) p≤ 0.001 Blood 24046815
1209 RNASEL [R462Q variant: AA] Mutation Humans Expressed in patients with High Risk of PCa Prognostic High Risk with AA phenotype Vs High Risk with (AA and GA phenotype) p≤ 0.001 Blood 24046815
1210 Copy Number Variation: Deletion of 2p24.3 Mutation Humans Deletion found in Hispanic patients with High Risk PCa Prognostic High Risk Vs Low Risk p = 0.007 Blood 24054869
1218 Methylation Status of APC Methylation Humans Hypermethylated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.02 Tissue 24086370
1219 Methylation Status of GSTP1 Methylation Humans Hypermethylated in patients with Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.02 Serum 24086370
1220 Semaphorin 4F (SF4) mRNA Humans Upregulated (high levels) had increased risk of biochemical recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.0002 Tissue 24097862
1223 Prostate Specific Membrane Antigen (PSMA) Protein Humans Upregulted in Lethal PCa Prognostic Lethal Vs Non Lethal Prostate Cancer p< 0.01 Tissue 24130224
1232 N-terminal propeptide of collagen type I (PINP) Protein Humans Upregulated in Bone Metastatis Prognostic Bone Metastatis Vs No Bone Metastatis P < 0.001 Serum 24179387
1239 cutaneous fatty acid-binding protein (C-FABP) Protein Humans Upregulated in PCa Prognostic Low Vs Moderate Vs High Gleason Score p<0.05 Tissue 24189640
1244 N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) Protein Humans Upregulated with High Tumor Stage Prognostic Tumor Stage pT2 Vs pT3 Vs pT4 p= 0.004 Tissue 24240687
1245 N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) Protein Humans Upregulated with High Gleason Score Prognostic Gleason Score 3 Vs 4 Vs 5 p=0.028 Tissue 24240687
1246 N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) Protein Humans Increased in Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p = 0.0038; Multivariate: p =0.036 Tissue 24240687
1249 Lactate Dehydrogenase [LDH] Protein Humans NA Prognostic Overall Survival Vs No Survival Univariate: p < 0.001; Multivariate: p =0.023 Blood 24255071
1250 Lactate Dehydrogenase [LDH] Protein Humans NA Prognostic Overall Survival Vs No Survival Univariate: p = 0.006 Blood 24255071
1253 Osteopontin (OPN) Protein Humans Upregulated in PCa: [Localised PCa: 613.6; Metastaic PCa: 1024] Prognostic Localised Vs Metastatic Prostate Cancer p = 0.003 Urine 24266816
1254 Forkhead Box A1 [FOXA1] mRNA Humans Increased in shorter time to Biochemical Recurrence Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 0.028 Tissue 24292680
1256 Discs Large Homolog 7 [DLG7] mRNA Humans Upregulated in PCa (log 2 PCa/Normal): [] Prognostic Progression Vs No Progression NA Tissue 24349376
1260 Claudin 7 mRNA Humans Downregulated in DU145 and PC-3 Prognostic DU145, PC-3 Vs CAHPV-10 DU145 (p=0.02); PC-3 (p<0.001) Cell Lines 24358122
1262 α-catenin mRNA Humans Downregulated in DU145 and PC-3 Prognostic DU145, PC-3 Vs CAHPV-10 p<0.001 Cell Lines 24358122
1264 β-catenin mRNA Humans Upregulated in DU145 and PC-3 Prognostic DU145, PC-3 Vs CAHPV-10 DU145 (p=0.006); PC-3 (p=0.001) Cell Lines 24358122
1268 Claudin 7 Protein Humans Downregulated in CAHPV-10 Prognostic CAHPV-10 Vs PC-3 p < 0.01 Cell Lines 24358122
1271 ITGA3; ITGB1; TLN1; VCL; ITGA1; FLNC; Protein Humans Differentially Expressed Prognostic LNCaP Cell Lines Vs PC-3 Cell Lines p<0.05 Cell Lines 24371517
1288 F3 mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.001 Tissue 24394557
1289 WNT5B mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.004 Tissue 24394557
1290 VGLL3 mRNA Humans NA Prognostic Overall Survival Vs No Survival p<0.0001 Tissue 24394557
1291 c-MAF-a mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.008 Tissue 24394557
1292 CTGF mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.008 Tissue 24394557
1293 AMACR mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.009 Tissue 24394557
1294 MUC1 mRNA Humans NA Prognostic Overall Survival Vs No Survival p=0.025 Tissue 24394557
1295 F3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p<0.0001 Tissue 24394557
1296 WNT5B mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p<0.0001 Tissue 24394557
1297 VGLL3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.014 Tissue 24394557
1298 c-MAF-a mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.036 Tissue 24394557
1299 CTGF mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.023 Tissue 24394557
1300 IGFBP3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.013 Tissue 24394557
1301 c-MAF-b mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.019 Tissue 24394557
1302 EZH2 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.018 Tissue 24394557
1303 AMACR mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival p=0.049 Tissue 24394557
1304 VGLL3 + IGFBP3 + F3 mRNA Humans NA Prognostic Overall Survival Vs No Survival Univariate: [p<0.0001;] Multivariate:[Group2: p=0.013 Group 1: p<0.0001] Tissue 24394557
1305 Clinical Parameters + VGLL3 + IGFBP3 + F3 mRNA Humans NA Prognostic Overall Survival Vs No Survival NA Tissue 24394557
1306 VGLL3 + IGFBP3 + F3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival Group2: [Univariate: p= 0.002; Multivariate: 0.030]; Group 1: p<0.0001 Tissue 24394557
1307 Clinical Parameters + VGLL3 + IGFBP3 + F3 mRNA Humans NA Prognostic PCa Specific Survival Vs No PCa Specific Survival NA Tissue 24394557
1308 C2orf43 [SNP: rs13385191] Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.05 Blood 24411283
1309 PDLIM5 [SNP: rs17021918] Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.01 Blood 24411283
1310 JAZF1 [SNP: rs10486567] Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.001 Blood 24411283
1311 LMTK2 [SNP: rs6465657] Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.02 Blood 24411283
1312 MSMB [SNP: rs10993994] Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.02 Blood 24411283
1313 SNP: rs7127900 Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.01 Blood 24411283
1314 SNP: rs11672691 Mutation Humans Increased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.007 Blood 24411283
1315 KLK3 [SNP: rs2735839] Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.002 Blood 24411283
1316 FRK [SNP: rs171866: AA versus gg/gA] Mutation Humans Increased risk of Progression Prognostic Progression Vs No Progression During ADT p=0.015 Blood 24448834
1317 DAB2 [SNP: rs268091: GC/CC versus GG] Mutation Humans Increased risk of Progression Prognostic PCa Specific Mortality Vs No Mortality During ADT p=0.012 Blood 24448834
1318 DAB2 [SNP: rs268091: CC versus GG/GC] Mutation Humans Increased risk of Progression Prognostic PCa Specific Mortality Vs No Mortality During ADT p=0.031 Blood 24448834
1319 EXOC4: [SNP: rs1149558: TT versus CC/CT] Mutation Humans Increased risk of Progression Prognostic PCa Specific Mortality Vs No Mortality During ADT p=0.014 Blood 24448834
1320 EXOC4: [SNP: rs1149558: TT versus CC/CT] Mutation Humans Increased risk of Progression Prognostic All Cause Mortality Vs No Mortality during ADT p=0.005 Blood 24448834
1325 Monoclonal Antibody MIB-1 [Ki-67] Protein Humans Increased with increased risk of death Prognostic PCa Specific Mortality Vs No Mortality p<0.001 Tissue 24486077
1326 Monoclonal Antibody MIB-1 [Ki-67] Protein Humans Increased with increased risk of death Prognostic Progression Vs No Progression p<0.001 Tissue 24486077
1332 UAP1+ PDLIM5+ IMPDH2+ HSPD1+ PCA3+ TMPRSS2+ ERG+ GAPDH+ B2M+age+sPSA level mRNA Humans NA Prognostic Gleason Score <7 Vs Gleason Score ≥ 7 NA Urine + Plasma 24512523
1338 PCAT18 LncRNA Humans Upregulated in metastatic Prostatic Cancer Prognostic Localised Vs Metastatic Prostate Cancer p<0.001 Tissue 24519926
1347 Bone Alkaline Phosphatase [BAP] Protein Humans NA Prognostic Overall Survival Vs No Survival p<0.001 Serum 24565955
1348 C-terminal of type 1 collagen [CICP] Protein Humans NA Prognostic Overall Survival Vs No Survival p <0.001 Serum 24565955
1349 Pyridinoline [PYD] Protein Humans NA Prognostic Overall Survival Vs No Survival p <0.001 Serum 24565955
1350 N-telopeptides of type 1 collagen [NTx] Protein Humans NA Prognostic Overall Survival Vs No Survival p <0.001 Serum 24565955
1351 miR-221 miRNA Humans Downregulation in high-risk prostate cancer Prognostic Cancer Related Death Vs No Cancer Related Death p<0.0001 Tissue 24607843
1352 ERG Protein Humans NA Prognostic Histopathological Progression For ERG Positive Vs ERG Negative samples p<0.0001 Tissue 24630684
1353 ERG Protein Humans NA Prognostic Active Survillence (AS) Progression For ERG Positive Vs ERG Negative samples p<0.0001 Tissue 24630684
1354 COMT [SNP: rs11705619: T>C] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.041 Blood 24682418
1355 COMT [SNP: rs165849: A>G] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.047 Blood 24682418
1356 COMT [SNP: rs9332377: C>T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.017 Blood 24682418
1357 CYP1B1 [SNP: rs1800440: A>G] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.016 Blood 24682418
1358 NQO1 [SNP: rs2917670: G>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.039 Blood 24682418
1359 NQO2 [SNP: rs10223369: C>T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.002 Blood 24682418
1360 NQO2 [SNP: rs1143684: T>C] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.030 Blood 24682418
1361 NQO2 [SNP: rs6920900 G>C] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.007 Blood 24682418
1362 SULT2B1 [SNP: rs12460535: G>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.017 Blood 24682418
1363 SULT2B1 [SNP: rs2665582: G>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.037 Blood 24682418
1364 COMT [ SNP: rs16982844: C>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Blood 24682418
1365 CYP1B1: [SNP: rs1800440: A>G] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.0009 Blood 24682418
1366 SULT2B1: [SNP: rs10426628: G>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.025 Blood 24682418
1367 SULT2B1: [SNP: rs12460535: G>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.028 Blood 24682418
1368 SULT2B1: [SNP: rs2665582: G>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.07 Blood 24682418
1369 Hyaluronan-Mediated Motility Receptor (HMMR) Metabolites Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure Univariate: p=0.028; Multivariate: p=0.04 Tissue 24668563
1370 hsa-miR-337-3p; hsa-miR-330-3p; hsa-miR-339-3p; hsa-miR-124; hsa-miR-218; hsa-miR-128; hsa-miR-10a; hsa-miR-199b-5p; hsa-miR-200b; hsa-miR-15b; miRNA Humans NA Prognostic High Vs Intermediate Vs Low risk p<0.05 Blood 24661838
1371 CCND1 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.042 Tissue 24708576
1372 HMMR Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure Univariate: p=0.005 Multivariate; p=0.008 Tissue 24708576
1373 HOXC6 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.05 Tissue 24708576
1374 IGF1 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure Univariate: p=0.039 Multivariate; p=0.015 Tissue 24708576
1375 MAP4K4 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.024 Tissue 24708576
1376 MKI67 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.026 Tissue 24708576
1377 SIAH2 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure p=0.016 Tissue 24708576
1378 SMAD4 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure Univariate: p=0.01 Multivariate; p=0.016 Tissue 24708576
1379 HMMR+ SIAH2+ SMAD4 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure (3 years) p=0.052 Tissue 24708576
1380 HMMR+ SIAH2+ SMAD4 Protein Humans NA Prognostic Biochemical Failure Vs No Biochemical Faliure (5 years) p=0.024 Tissue 24708576
1381 BTG2; CDC37L1; COL15A1; COL3A1; EIF2D; FDPS; HIST1H1C; HIST1H2BG; IFT57; IGFBP3; ITPR1; LBH; LOC284801; MARCH5; MED4; MEMO1; MXI1; PTN; RPL23AP53; SACM1L; SIRT1; SNORA20; SRSF3; SYNM; mRNA Humans Poor score with decreased BCR Survival Prognostic Biochemical recurrence Vs No Biochemical Recurrence p = 1.45E-21; Validation: p=2.85e-3 Tissue 24713434
1382 miR-598; miR-105; miR-767-5p; miR-24; miR-342-3p; miR-125a-5p; miR-27a; miR-194; miR-454; miR-26b; miR-146a miR-99b; miR-455-3p; miR-301a; miR-9; miR-200a; miR-1267 miR-205 miR-95 miR-200a-5p; miR-200b; miR-203; miR-34a; miR-375; miR-191; miR-100; miR-135b; miR-429 miRNA Humans Upregulated in docetaxel-resistant cell lines: [miR-598; miR-105; miR-767-5p; miR-24; miR-342-3p; miR-125a-5p; miR-27a; miR-194; miR-454; miR-26b; miR-146a miR-99b; miR-455-3p; miR-301a];Downreegulated in docetaxel-resistant cell lines: [miR-9; miR-200a; miR-1267 miR-205 miR-95 miR-200a-5p; miR-200b; miR-203; miR-34a; miR-375; miR-191; miR-100; miR-135b; miR-429] Prognostic PC3 Cell Line Vs PC3Rx Cell Line (docetaxel-resistant sublines) p≤0.001 Cell Lines 24714754
1383 miR-30e-3p; miR-191-3p; miR-30a-5p; miR-152; miR-34b; miR-301b; miR-100; miR-301a; miR-99a; miR-151-3p; miR-30a-3p; miR-146b-5p; miR-210; miR-15a-3p; miR-135b; miR-200b; miR-590-3p; miR-429; miR-590-5p; miR-20b; miR-200c; miR-200a; miR-25; miR-146a; miR-196b; miR-489; miR-96; miR-486-5p; miRNA Humans Upregulated in docetaxel-resistant cell lines: [miR-30e-3p; miR-191-3p; miR-30a-5p; miR-152; miR-34b; miR-301b; miR-100; miR-301a; miR-99a; miR-151-3p; miR-30a-3p; miR-146b-5p; miR-210; miR-15a-3p;]Downregulated in docetaxel-resistant cell lines: [miR-135b; miR-200b; miR-590-3p; miR-429; miR-590-5p; miR-20b; miR-200c; miR-200a; miR-25; miR-146a; miR-196b; miR-489; miR-96; miR-486-5p;] Prognostic DU145 Cell Line Vs DU145Rx Cell Line(docetaxel-resistant sublines) p≤0.001 Cell Lines 24714754
1393 Testosterone Hormone Humans Increased levels in patients with Higher overall Survival Prognostic Overall Survival Vs No Survival p=0.018 Plasma 24722180
1399 Methylation status of GABRE + miR-224 +miR-452 (as continous value ) miRNA + Methylation Humans Hypermethylated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence Cohort 1: Univariate: p<0.001; Multivariate: p= 0.019 Cohort 2: Univariate: p<0.001; Multivariate: p=0.008 Tissue 24737792
1400 Methylation status of GABRE + miR-224 +miR-452 (High vs. Low ) miRNA + Methylation Humans Hypermethylated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence Cohort 1: Univariate: p<0.001; Multivariate: p= 0.019 Cohort 2: Univariate: p<0.001; Multivariate: p=0.008 Tissue 24737792
1401 GABRE + miR-224 +miR-452 mRNA + miRNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1402 GABRE RNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1403 miR-224 miRNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1404 miR-452 miRNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1405 OAZ2 mRNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1406 GABRE + miR-224 +miR-452+OAZ2 mRNA + miRNA Humans Downregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Tissue 24737792
1407 MIR605 [SNP: rs2043556: GG] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1: p= 0.006 Cohort 1+2: p=0.01;Multivariate: Cohort 1:p = 0.005 Cohort 1+2: p=0.01 Blood 24740842
1408 MIR605 [SNP: rs2043556: AG/GG vs. AA] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1: p= 0.04 Cohort 1+2: p=0.02 Blood 24740842
1409 MIR605 [SNP: rs2043556: GG vs. AA/AG] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1: p= 0.02 Cohort 1+2: p=0.03;Multivariate: Cohort 1:p = 0.004 Cohort 1+2: p=0.01 Blood 24740842
1410 MTRR [SNP: rs9332: CT] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1: p= 0.008 Cohort 1+2: p=0.01 Blood 24740842
1411 MTRR [SNP: rs9332: CT/TT vs. CC] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1: p= 0.04 Cohort 1+2: p=0.05 Blood 24740842
1412 CDON [SNP: rs3737336: CC] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1: p= 0.05 Cohort 1+2: p=0.01;Multivariate: Cohort 1:p = 0.03 Cohort 2: p = 0.04 Cohort 1+2: p=0.003 Blood 24740842
1413 CDON [SNP: rs3737336: CC vs. TT/TC] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1+2: p=0.02;Multivariate: Cohort 1: p = 0.03; Cohort 1+2: p=0.007 Blood 24740842
1414 POSTN; ASPN; LAMB2; SERPH; CSPG2; ENTP1; SE1L1; ITAV; FOLH1; STIM1; PTK7; ICOSL; SPP2A; CD276; KLK3; ZA2G; FBN1; CD38; CNTP2; AMPN; FAM3B; RNT2; NAAA; PPAP; GSLG1; TSN1; DPP4; ST14; Protein Humans Upregulated in Agressive PCa; Downregulated in Agressive PCa: [] Prognostic Agressive Vs Non Agressive PCa NA Tissue 24741114
1415 TIMP1; CLUS; MFAP4; AOC3; CADM1; HYOU1; FSTL1; KLK11; NBL1; GOLM1; VTNC; CERU; A1AG2; LYVE1; A1AG1; Protein Humans Upregulated in Metastatic PCa;Downregulated in Non Metastatic PCa: [] Prognostic Metastatic Vs Non Metastatic Prostate Cancer NA Tissue 24741114
1417 NAAA Protein Humans Downregulated in GS >7 Prognostic Gleason Score ≤ 7 and Gleason Score >7 p <0.05 Tissue 24741114
1418 PTK7 Protein Humans Upregulated in GS >7 Prognostic Gleason Score ≤ 7 and Gleason Score >7 p <0.01 Tissue 24741114
1419 NAAA+ PTK7 Protein Humans NAAA: Downregulated in GS >7; PTK7: Upregulated in GS >7 Prognostic Gleason Score ≤ 7 and Gleason Score >7 p <0.05 Tissue 24741114
1424 miR-7; miR-221; miR-222 miRNA Humans Upregulated in PC-3 Cell Lines: [ miR-7(11.3 fold); miR-222 (8.6 fold); miR-221 (8.6 fold)] Prognostic LNCaP Cell Lines Vs PC-3 Cell Lines p<0.05 Cell Lines 24760272
1425 miR-7; miR-221; miRNA Humans Upregulated in Early Castration Resistant Acquisition Prognostic Early Vs Late Castration-resistant acquisition (≤20 months and ≥60 months) miR-7: p=0.034; miR-221: p=0.036; Blood 24760272
1428 DAB2IP Protein Humans Reduced in lower FFBF (Freedom From Biochemical Faliure) Prognostic Freedom From Biochemical Failure Vs Biochemical Failure p=0.04 Tissue 24867541
1429 miR-19a miRNA Humans Upregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1430 miR-19b miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1431 miR-345 miRNA Humans Downregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1432 miR-519c-5p miRNA Humans Downregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1433 miR-19a miRNA Humans Upregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1434 miR-19b miRNA Humans Upregulated in Cases Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1435 miR-345 miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1436 miR-519c-5p miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1437 miR_19a+ miR_345+ miR_519c_5p miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1438 miR_19b+miR_345+ miR_519c_5p miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1439 miR_19a + miR_19b + miR_345 + miR_519c_5p miRNA Humans NA Prognostic Gleason Score ≥7 or Gleason Score =6 p<0.05 Tissue 24893170
1440 MUC1 Protein Humans Increased with Increased mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.02 Tissue 24909936
1441 p53 Protein Humans Increased with Increased mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.005 Tissue 24909936
1442 AZGP1 Protein Humans Increased with Decreased mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.04 Tissue 24909936
1443 MUC1 + p53+ AZGP1 Protein Humans Increased with Increased mortality Prognostic PCa Specific Mortality Vs No Mortality NA Tissue 24909936
1445 miR-1 miRNA Humans Downregulated in Recurrent PCa Prognostic Recurrence Vs No Recurrence p = 0.036 Tissue 24967583
1446 miR-133b miRNA Humans Downregulated in Recurrent PCa Prognostic Recurrence Vs No Recurrence p = 0.012 Tissue 24967583
1447 miR-1 + miR-133b miRNA Humans Downregulated in Recurrent PCa Prognostic Recurrence Vs No Recurrence p = 0.012 Tissue 24967583
1455 N-terminal telopeptide of type I collagen (NTx) Protein Humans NA Prognostic Gleason Score p< 0.001 Serum 24992524
1456 N-terminal telopeptide of type I collagen (NTx) Protein Humans NA Prognostic Prostate Cancer Stage p = 0.007 Serum 24992524
1457 Brachyury Protein Humans Increases with increasing Gleason Score Prognostic Gleason Score GS <7 Vs GS = 7 Vs GS >7 p = 0.027 Tissue 25009296
1462 Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in Stage T3-T4 Prognostic stage T1-T2 Vs Stage T3-T4 p=0.004 Tissue 25057439
1463 High Mobility Group Box 1 (HMGB1) Protein Humans Upregulated in Stage T3-T5 Prognostic stage T1-T2 Vs Stage T3-T4 p=0.009 Tissue 25057439
1464 High Mobility Group Box 1 (HMGB1) + Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in Stage T3-T6 Prognostic stage T1-T2 Vs Stage T3-T4 p=0.007 Tissue 25057439
1465 Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in Distant Metastases Prognostic Distant Metastases Vs No Distant Metastases p=0.013 Tissue 25057439
1466 High Mobility Group Box 1 (HMGB1) Protein Humans Upregulated in Distant Metastases Prognostic Distant Metastases Vs No Distant Metastases p=0.019 Tissue 25057439
1467 High Mobility Group Box 1 (HMGB1) + Receptor for advanced glycation end products (RAGE) Protein Humans Upregulated in Distant Metastases Prognostic Distant Metastases Vs No Distant Metastases p=0.026 Tissue 25057439
1468 High Mobility Group Box 1 (HMGB1) + Receptor for advanced glycation end products (RAGE) Protein Humans Increased Coexpression in patients with Decreased overall Survival Prognostic Overall Suvival Vs No Survival p=0.047 Tissue 25057439
1470 miR-135a miRNA Humans Downregulated in GS ≥ 8 Prognostic Glesaon Score ≥ 8 and Gleason Score <8 p<0.01 Tissue 25065599
1471 miR-135a miRNA Humans Downregulated in Stage pT3a Prognostic Stage pT3a Vs Stage pT2c p<0.05 Tissue 25065599
1472 PTEN Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.0011 Tissue 25075204
1473 CCND1 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.036 Tissue 25075204
1474 SMAD4 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.0035 Tissue 25075204
1475 PTEN + CCND1 +SMAD4 + SSP1 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p = 0.00000456 Tissue 25075204
1476 pS6 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.021 Tissue 25075204
1477 pPRAS40 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p=0.019 Tissue 25075204
1478 CCND1 +SMAD4 + SSP1 + pS6 + pPRAS40 Protein Humans NA Prognostic Lethal Outcome Vs No Lethal Outcome p = 0.000013 Tissue 25075204
1481 miR-21 miRNA Humans Downregulated in GS ≥ 8 (Benign: 0.636 ± 0.048; malignant: 0.521 ± 0.027) Prognostic Gleason Score ≥ 8 Vs Gleason Score < 8 p=0.004 Tissue 25075250
1482 miR-21 miRNA Humans Downregulated in Metastatis (No Metastasis: 0.667 ± 0.037; Metastatis: 0.463 ± 0.027) Prognostic Metastatic Vs Non Metastatic Prostate Cancer p<0.0001 Tissue 25075250
1483 miR-30c miRNA Humans Downregulated in Metastatis (No Metastasis: 0.514 ± 0.029; Metastatis: 0.354 ± 0.032) Prognostic Metastatic Vs Non Metastatic Prostate Cancer p= 0.0003 Tissue 25075250
1484 miR-219 miRNA Humans Downregulated in Metastatis (No Metastasis: 0.532 ± 0.028; Metastatis: 0.448 ± 0.029) Prognostic Metastatic Vs Non Metastatic Prostate Cancer p= 0.039 Tissue 25075250
1485 miR-21 miRNA Humans Downregulated in Patients who suvived (Survival : 0.636 ± 0.039; No Survival: 0.507 ± 0.03) Prognostic Survival Vs No Survival p= 0.009 Tissue 25075250
1486 miR-30c miRNA Humans Downregulated in Patients who suvived (Survival : 0.500 ± 0.031; No Survival: 0.406 ± 0.028) Prognostic Survival Vs No Survival p= 0.024 Tissue 25075250
1487 miR-30c miRNA Humans Downregulated in Patients With Recurrence (No Recurrence : 0.609 ± 0.036; recurrence: 0.415 ± 0.051) Prognostic PSA Recurrence Vs No Recurrence p= 0.003 Tissue 25075250
1488 let-7c miRNA Humans Downregulated in Patients With Recurrence (No Recurrence : 0.703 ± 0.098; recurrence: 0.963 ± 0.06) Prognostic PSA Recurrence Vs No Recurrence p=0.0266 Tissue 25075250
1489 Interleukin-1β (IL-1β) Protein Humans Increased in patients with Biochemical Recurrence Prognostic Recurrence Vs No Recurrence p=0.02 Tissue 25075566
1490 Interferon β (IFNβ) Protein Humans Decreased in patients with Biochemical Recurrence Prognostic Recurrence Vs No Recurrence p=0.008 Tissue 25075566
1491 Interleukin-1β (IL-1β) + Interferon β (IFNβ) Protein Humans Interleukin-1β (IL-1β): Increased in patients with Biochemical Recurrence; Interferon β (IFNβ): Decreased in patients with Biochemical Recurrence Prognostic Recurrence Vs No Recurrence p=0.004 Tissue 25075566
1495 mir-27b miRNA Humans Decreased in patients with shorter progression free interval Prognostic Progression Vs No Progression p=0.0346 Tissue 25115396
1496 miR-1290 miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p<0.0008 Plasma 25129854
1497 miR-1246 miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p<0.0008 Plasma 25129854
1498 miR-375 miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p<0.0008 Plasma 25129854
1499 miR-1290 + miR-375 + PSA + ADT miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p= 0.0016 Plasma 25129854
1500 miR-1290 + miR-375 miRNA Humans NA Prognostic High Risk vs Low Risk (Survival) p<0.05 Plasma 25129854
1501 tPSA Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7) p < 0.001 Serum 25139197
1502 p2PSA Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7) p < 0.001 Serum 25139197
1503 %p2PSA Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7) p < 0.001 Serum 25139197
1504 Prostate Health Index (PHI) Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Single adverse pathologic characteristic (pT3 disease or pathologic Gleason score I7) p < 0.001 Serum 25139197
1505 tPSA Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7) p < 0.001 Serum 25139197
1506 p2PSA Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7) p < 0.001 Serum 25139197
1507 %p2PSA Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7) p < 0.001 Serum 25139197
1508 Prostate Health Index (PHI) Protein Humans Upregulated in patients with Grade pT3 or GS ≥ 7 Prognostic Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7) p < 0.001 Serum 25139197
1515 YWHAZ Protein Humans NA Prognostic Gleason Score ≤ 6 Vs Gleason Score 7 (3+4) Vs Gleason Score 7 (4+3) Vs Gleason Score ≥ 8 p<0.001 Tissue 25156059
1516 YWHAZ Protein Humans Increased expression in patients with PCa specific death Prognostic High Risk vs Low Risk (Survival) Univariate: p=0.004; Multivariate: p = 0.015 Tissue 25156059
1517 YWHAZ Protein Humans Increased expression in patients with Castration Resistant Prostate Cancer (CRPC) Prognostic Castration Resistant Prostate Cancer (CRPC) Vs No CRPC Univariate: p=0.005; Multivariate: p = 0.008 Tissue 25156059
1518 YWHAZ Protein Humans Increased expression in patients with PSA Relapse Prognostic High Risk vs. Low Risk (Relapse Univariate: p=0.005; Multivariate: p = 0.019 Tissue 25156059
1523 Oligophrenin-1 (OPHN1) Protein Humans Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold) Prognostic Gleason Score 6-7 Vs Gleason Score 8-9-10 univariate: p=0.0011; Multivariate: 0.0038 Tissue 25170626
1524 Oligophrenin-1 (OPHN1) Protein Humans Upregulated in Prostate Cancer (Tumor/nonneoplastic prostate (T/N ratio): > 3 fold) Prognostic Stage pT2 Vs Stage pT3 univariate: p=0.0099; Multivariate: 0.0104 Tissue 25170626
1527 Yin Yang 1 (YY1) Protein Humans Downregulated in PCa Prognostic High Grade cancer Vs Low grade Cancer P<0.0001 Tissue 25174820
1528 Death Receptor 5 Protein Humans Downregulated in PCa Prognostic High Grade cancer Vs Low grade Cancer P<0.0001 Tissue 25174820
1532 cytoplasmic-nuclear factor erythroid 2-related factor 2 (c-Nrf-2) Protein Humans Upregulated in Malignant Tissue Prognostic Biochemical Failure Free Survival Vs No Survival Univariate: p=0.28; Multivariate: p=0.019 Tissue 25175169
1533 cytoplasmic-nuclear factor erythroid 2-related factor 2 (c-Nrf-2) Protein Humans Upregulated in Malignant Tissue Prognostic Overall Survival Vs No Survival Univariate: p=0.28; Multivariate: p=0.019 Tissue 25175169
1536 E Cadherin Protein Humans Downregulated in patients with early relapse Prognostic Biochemical Relapse Vs No Biochemical Relapse for external beam radiotherapy treated (EBRT) p=0.02 Tissue 25227682
1537 Ki-67 Protein Humans Upregulated in patients with early relapse Prognostic Early Relapse Vs No Relapse EBRT cohort: p=0.0006; PADT Cohort: p=0.0004 Tissue 25227682
1553 miR-221 miRNA Humans Downregulated in Recurrent Cases (Recurrent Median: 0.25; Control Median: 0.46) Prognostic Recurrence Vs No Recurrence Regulation: p=0.0002; Univariate: p=0.02; Multivariate: p=0.05 Tissue 25252191
1554 miR-21 miRNA Humans Downregulated in Recurrent Cases (Recurrent Median: 1.01; Control Median: 1.54) Prognostic Recurrence Vs No Recurrence p=0.0149 Tissue 25252191
1555 miR-141 miRNA Humans Downregulated in Recurrent Cases (Recurrent Median: 0.39; Control Median: 0.81) Prognostic Recurrence Vs No Recurrence p<0.0001 Tissue 25252191
1557 Chondroitin Sulfate Protein Humans Upregulated in Prostate Cancer Prognostic Progression Vs No Progression p=0.0001 Tissue 9815775
1560 Versican Protein Humans Upregulated in Prostate Cancer Prognostic Progression Vs No Progression p=0.0003 Tissue 9563891
1562 WISP1 Protein Humans Increased with decreased BCR survival Prognostic Biochemical recurrence Vs No Biochemical Recurrence Cohort 1: p = 0.028;Cohort 3: p= 0.042 Tissue 31069142
1563 WISP1 Protein Humans Upregulated with increasing Stage Prognostic pTNM 2 Vs pTNM 3 Vs pTNM 4 p<0.05 Tissue 31069142
1564 WISP1 mRNA Humans Upregulated in Metastatic PCa Prognostic Primary Vs Metastatis Prostate Cancer p=0.03 Tissue 31069142
1566 TMEFF2 mRNA Humans Upregulated in PCa (Log 2 Median Centered Intensity) Prognostic Primary/Localised Vs Metastatic/CRPC Prostate Cancer p<0.05 Tissue 31060542
1567 TMEFF2 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p<0.0001 Tissue 31060542
1569 BUB1B; CDC45; CDK1; CENPI; CLSPN; ERCC6L; EXO1; NCAPG; NUSAP1; RAD51; RRM2; mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p<0.05 Tissue 31060542
1570 BUB1B+CDC45+CDK1+CENPI+CLSPN+ERCC6L+EXO1+NCAPG+NUSAP1+RAD51+RRM2 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p<0.05 Tissue 31060542
1571 Osteopontin (OPN) Protein Humans increased with decreased BRFS Prognostic Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival p < 0.036 Tissue 31059955
1572 Glucose Transporter 1 (GLUT1) Protein Humans increased with decreased BRFS Prognostic Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival p < 0.001 Tissue 31059955
1573 Glucose Transporter 1 (GLUT1) Protein Humans increased with decreased DMFS Prognostic Distant Metastasis Free Survival Vs Distant Metastasis Free Survival p = 0.045 Tissue 31059955
1574 RNASEL (SNP: rs635261) Mutation Humans NA Prognostic PCa-specific mortality Vs No PCa-specific mortality p= 0.002 Blood 25273821
1575 XRCC1 (SNP: rs915927) Mutation Humans NA Prognostic PCa-specific mortality Vs No PCa-specific mortality p=0.009 Blood 25273821
1576 AKT1 (SNP: rs2494750) Mutation Humans NA Prognostic PCa-specific mortality Vs No PCa-specific mortality p=0.016 Blood 25273821
1577 (Intergenic) KLK3–KLK2: [SNP: rs2735839] Mutation Humans NA Prognostic Gleason Score ≤ 6 Vs Gleason Score ≥ 8 p=0.002 Blood 25274378
1578 JAZF1 [SNP: rs10486567] Mutation Humans NA Prognostic Gleason Score ≤ 6 Vs Gleason Score ≥ 8 p=0.012 Blood 25274378
1579 (Intergenic) LILRB2–LILRA3 [SNP: rs103294] Mutation Humans NA Prognostic Gleason Score ≤ 6 Vs Gleason Score ≥ 8 p=0.024 Blood 25274378
1580 (Intergenic) KLK3–KLK2: [SNP: rs2735839] (AG/GG) Mutation Humans NA Prognostic Gleason Score 7 (3+4) Vs Gleason Score 7 (4+3) p=0.0002 Blood 25274378
1581 (Intergenic) KLK3–KLK2: [SNP: rs2735839] (AG+AA/GG) Mutation Humans NA Prognostic Gleason Score 7 (3+4) Vs Gleason Score 7 (4+3) p=0.0005 Blood 25274378
1582 Ki-67 Protein Humans NA Prognostic Distant Metastatis Vs No Distant Metastatis p<0.0001 Tissue 25294917
1583 Cox-2 Protein Humans Upregulation Prognostic Distant Metastatis Vs No Distant Metastatis p=0.04 Tissue 25294917
1584 p16 Protein Humans NA Prognostic Distant Metastatis Vs No Distant Metastatis p=0.0065 Tissue 25294917
1585 MDM2 Protein Humans NA Prognostic Distant Metastatis Vs No Distant Metastatis p=0.036 Tissue 25294917
1594 Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA] Protein Humans Upregulated in GS ≤ 7 Prognostic Gleason Score <7 and Gleason Score ≤7 p<0.0001 Blood 25454615
1602 Vascular endothelial growth factor A (VEGF-A) Protein Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.016 Tissue 26268996
1603 Vascular endothelial growth factor A (VEGF-A) + Vascular endothelial growth factor Receptor (VEGFR-2) Protein Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.006 Tissue 26268996
1604 Full Length Androgen Receptor (AR-FL) mRNA Humans NA Prognostic Progression-free survival Vs No Progression-free survival p=0.0003 Plasma 31055861
1610 mir-145 miRNA Humans Downregulated in Gleason Score Upgradation (Without Upgradation: -0.4831 Vs Upgradation: -1.1202) Prognostic Gleason Score Upgradation Vs No Upgradation p=0.03 Tissue 31045265
1611 mir-221 miRNA Humans Downregulated in Recurrence (Recurrence: −1.7170 Vs No Recurrence: − 0.9129) Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.04 Tissue 31045265
1612 IL2RB [SNP: rs84460; C vs T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.006 Blood 31035590
1613 SMAD3 [SNP: rs7162912; G vs T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.0001 Blood 31035590
1614 FOXO3 [SNP: rs7762395 C Vs T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.002 Blood 31035590
1615 FOXO3 [SNP: rs2153960 C Vs T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Blood 31035590
1616 SMAD3 [SNP: rs9302242; A vs G] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.005 Blood 31035590
1617 IL4R [SNP: rs1805011; A vs C] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.003 Blood 31035590
1618 IL4R [SNP: rs3024586; A vs G] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.003 Blood 31035590
1619 CCL5 [SNP: rs2280789 C Vs T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Blood 31035590
1620 MMP9 [SNP: rs3918262; A Vs G] Mutation Humans NA Prognostic Overall Survival Vs No Overall Survival p=0.001 Blood 31035590
1621 VEGFR2 [SNP: rs7692791; C Vs T] Mutation Humans NA Prognostic Overall Survival Vs No Overall Survival p=0.001 Blood 31035590
1622 VEGFR2 [SNP: rs2034967; C Vs T] Mutation Humans NA Prognostic Overall Survival Vs No Overall Survival p=0.00000008 Blood 31035590
1624 KIF20A mRNA Humans Upregulated in prostate cancer tissues compared with HR: 2.060 Pathways include: Kinesins, Aurora B signaling, Polo-like kinase 1 (PLK1) pathway, M phase pathway, MHC class II antigen presentation Prostate Cancer Vs No Prostate Cancer Diagnostic 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis NA NA 0.8406 (95% CI: 0.6603-0.8256) NA p < 0.0001 1623 NA No NA NA Not validated on independent patient dataset 31031850 2019 CDK1 NA Expression Based mRNA Tissue Humans normal tissues Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1625 CCNB1 mRNA Humans Upregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.0166 Tissue 31031850
1626 BUB1 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1627 CENPA mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1628 AURKB mRNA Humans Upregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p =0.0002662 Tissue 31031850
1629 CCNB2 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.001469 Tissue 31031850
1630 BIRC5 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p =0.0001304 Tissue 31031850
1631 AURKA mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1632 BUB1B mRNA Humans Upregulated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1633 TTK mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1634 KIF20A mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1636 CDKN3 mRNA Humans Upregulated in prostate cancer tissues compared with HR: 2.451 Pathways include: T cell receptor regulation of apoptosis Biochemical recurrence Vs No Biochemical Recurrence Prognostic 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis NA NA 0.6493 NA p =0.0002558 1635 NA No NA NA Not validated on independent patient dataset 31031850 2019 KIF2C NA Expression Based mRNA Tissue Humans normal tissues Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1637 NCAPG mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p < 0.0001 Tissue 31031850
1638 CDCA8 mRNA Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p =0.0001771 Tissue 31031850
1639 miR-3162-5p miRNA Humans NA Prognostic Gleason grades 4+5 and 5 Vs Gleason grade 4 p=0.04 Tissue 31018918
1646 NLR (neutrophil to lymphocyte ratio) Others Humans Upregulated in TRAMP Prognostic Overall Survival Vs No Survival p=0.0 Blood 30962764
1647 PLR (Platelet to lymphocyte ratio) Others Humans Upregulated in PCa Prognostic Overall Survival Vs No Survival p=0.0 Blood 30962764
1648 LMR (lymphocyte to monocyte ratio) Others Humans Downregulated in PCa Prognostic Overall Survival Vs No Survival p=0.0 Blood 30962764
1649 Neutrophil Others Humans NA Prognostic Overall Survival Vs No Survival p=0.006 Blood 30962764
1650 Monocyte Others Humans NA Prognostic Overall Survival Vs No Survival p=0.006 Blood 30962764
1651 NLR (neutrophil to lymphocyte ratio) Others Humans NA Prognostic Progression Free Survival Vs No Progression Free Survival p=0.0 Blood 30962764
1652 NLR (neutrophil to lymphocyte ratio) Others Humans NA Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p=0.002 Blood 30962764
1653 LMR (lymphocyte to monocyte ratio) Others Humans NA Prognostic Progression Free Survival Vs No Progression Free Survival p=0.0 Blood 30962764
1654 Monocyte Others Humans NA Prognostic Progression Free Survival Vs No Progression Free Survival p=0.006 Blood 30962764
1655 miR‐28; miR‐100; miR‐942; miR‐28‐3p miRNA Humans NA Prognostic Low Grade Vs High Grade Prostate Cancer miR‐28: p=0.016; miR‐100: p=0.025; miR‐942: p=0.025; miR‐28‐3p: p=0.038 Plasma 30958910
1656 miR‐708; miR‐1298; miR‐886‐3p; miR‐374; miR‐376c; miR‐202; miR‐128a; miR‐185 miRNA Humans NA Prognostic Low Grade Vs High Grade Prostate Cancer miR‐708: p<0.001; miR‐1298: p=0.001; miR‐886‐3p:p=0.01; miR‐374:p=0.017; miR‐376c: p=0.031; miR‐202: p=0.035; miR‐128a: p=0.039; miR‐185: p=0.041 Plasma 30958910
1660 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Downregulated in PCa Prognostic Normal Prostate Vs T2 PCa Vs T3+T4 PCa p<0.001 Tissue 30911973
1661 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Upregulated in PCa Prognostic Normal Prostate Vs Gleason Score 6 Vs GS 7 VS GS 8 Vs GS 9+GS10 p<0.001 Tissue 30911973
1662 SNHG6 (small nucleolar RNA host gene 6) LncRNA Humans Upregulated in PCa Prognostic Disease Free Survival Vs No Disease Free Survival p=0.0365 Tissue 30911973
1676 tPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1677 fPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1678 p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1679 %fPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1680 %p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1681 PHI Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1682 tPSA+ fPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1683 tPSA+ %fPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1684 fPSA + p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1685 %fPSA + %p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1686 PSA + %fPSA + %p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1692 sE-Cadherin Protein Humans Upregulated in PCa Prognostic Gleason Pattern 3 Vs 4 Vs 5 p=0.02 Serum 25967040
1693 sE-Cadherin Protein Humans Downregulated in PCa Prognostic Gleason Upgrade Vs No Gleason Upgrade p=0.03 Serum 25967040
1711 ERG Protein Humans Upregulated in PCa (Tissue, Serum) Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p=0.04 Tissue 26172920
1712 SPINK1 Protein Humans Upregulated in PCa (Tissue, Urine) Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p=0.004 Tissue 26172920
1713 ERG; SPINK1 Protein Humans Upregulated in PCa (Tissue, Urine) Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p=0.003 Tissue 26172920
1716 TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 AA vs GG] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.032 Blood 26238235
1717 TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 AG/AA Vs GG] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.002 Blood 26238235
1718 TNKS2 (Tankyrase 2) [SNP: rs1539042 CG Vs GG] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.032 Blood 26238235
1719 TNKS2 (Tankyrase 2) [SNP: rs1539042 CG/CC Vs GG] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.02 Blood 26238235
1721 FOXM1 (Forkhead Box M1) Protein Humans NA Prognostic Low & Intermediate Risk Vs High Risk p<0.001 Tissue 30719174
1722 FOXM1 (Forkhead Box M1) Protein Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p=0.022; Multivariate: p=0.035 Tissue 30719174
1724 CRIP3 Methylation Humans Upregulated in PCa Prognostic Reclassification (Progression Vs No Progression) p=0.017 Urine 30777394
1725 miR-24+miR-30c+ Methylation Status of CRIP3 miRNA + DNA (Gene) Humans Increased in shorter BCR-free survival Prognostic Reclassification (Progression Vs No Progression) Univariate: p=0.008; Multivariate: p=0.017 Urine 30777394
1727 HA: Hyaluronic acid Metabolites Humans NA Prognostic High Risk Vs Intermediate Risk PCa p=0.0214 Serum 30516927
1732 SERPINA5; MFSD2A; ACSL6; MCF2; EMX2; HOXB8; CLDN2; AKR1B1; SPINK2; CYP19A1; mRNA Humans Differentially Expressed [Log Fold Change: SERPINA5: (-6.78954); MFSD2A (− 5.97025); ACSL6: (− 4.99597); MCF2: (−5.26855); EMX2: (− 6.79059); HOXB8: (− 6.24965); CLDN2: (−7.91887); AKR1B1: (− 3.87736); SPINK2: (−7.41992); CYP19A1: (−5.40444;] Prognostic High Risk Vs Low Risk PCa p=0.00822 Tissue 30286759
1741 Methylation Status of cg12799885 Methylation Humans Hypermethylated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p=0.025 Tissue 30866497
1742 Methylation Status of DOCK2 Methylation Humans Hypermethylated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p < 0.001; Multivariate: p=0.004 Tissue 30866497
1743 Methylation Status of GRASP Methylation Humans Hypermethylated in PCa Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p < 0.001; Multivariate: p=0.037 Tissue 30866497
1744 Methylation Status of HIF3A Methylation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p=0.005 Multivariate: p =0.027 Tissue 30866497
1745 Methylation Status of PFKP Methylation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p=0.001 Multivariate: p=0.028 Tissue 30866497
1746 Methylation Status of TPM4 Methylation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p=0.038; Tissue 30866497
1749 Neutrophil to Lymphocyte Ratio (NLR) Others Humans NA Prognostic Cancer Specific Survival Vs No Survival p=0.011 Blood 30800682
1750 Neutrophil to Lymphocyte Ratio (NLR) Others Humans Upregulated in PCa: Fold change mean(BPH: 1.470; PCa: 54.384) Prognostic Overall Survival Vs No Overall Survival p=0.017 Blood 30800682
1751 Tyrosine+Methylguanine+Isoleucine+Hypoxanthine+Maleic Acid +Xanthurenic acid 3+ LPC(18:0e)+LPC(22:3)+SM(d16:1/14:0)+DG(16:0/24:6)+SM(d16:1/24:3)+TG(15:0/16:1/18:2)+TG(16:0/18:1/18:2)+TG(18:1/18:1/18:1)+TG(18:0/18:1/22:5)+LPI(16:0) +Cer(d18:1/24:1) +Leucine+Glucose+Inosine Lipid Humans Upregulated in PCa: Fold change mean(BPH: 1.365; PCa: 10.108) Prognostic Biochemical recurrence Vs No Biochemical Recurrence NA Serum 30758971
1752 Gleason score+age,+pre-operative PSA +pathological stage+Tyrosine+Methylguanine+Isoleucine+Hypoxanthine+Maleic Acid +Xanthurenic acid 3+ LPC(18:0e)+LPC(22:3)+SM(d16:1/14:0)+DG(16:0/24:6)+SM(d16:1/24:3)+TG(15:0/16:1/18:2)+TG(16:0/18:1/18:2)+TG(18:1/18:1/18:1)+TG(18:0/18:1/22:5)+LPI(16:0) +Cer(d18:1/24:1) +Leucine+Glucose+Inosine Lipid Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence NA Serum 30758971
1753 5-hmC (5-hydroxymethylcytosin)+ ERG negative Protein Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: p=0.01; Multivariate: p=0.003 Tissue 30818754
1754 AZGP1; C0S; H3K18Ac; H3K4Me2; Ki67; p53; PML Protein Humans NA Prognostic Biochemical Relapse Vs No Biochemical Relapse AZGP1 p= 0.03; C0S: p=0.01; H3K18Ac: p=0.04; H3K4Me2: p=0.05; Ki67: p=0.02; p53: p=0.002; PML: p=0.03 Tissue 30288742
1755 AZGP1; Ki67; PML Protein Humans NA Prognostic Metastatic Relapse Vs No Relapse AZGP1: p=0.002; Ki67: p=0.04; PML:p=0.04 Tissue 30288742
1756 AZGP1 Protein Humans NA Prognostic Prostate Cancer Specific Death Vs No Death p=0.002 Tissue 30288742
1757 AZGP1+Ki67 Protein Humans NA Prognostic Metastatic Relapse Vs No Relapse Discovery: Univariate: p=0.03; Multivariate: p=0.04 Tissue 30288742
1758 AZGP1+Ki67 Protein Humans NA Prognostic Prostate Cancer Specific Death Vs No Death Discovery: Univariate: p=0.005; Multivariate: p=0.03;Validation: Univariate: p=0.05 Tissue 30288742
1761 CGA (chromogranin A) Protein Humans NA Prognostic Progression Free Survival Vs No Progression Free Survival p=0.0416 Serum 30286478
1767 miR-1825 miRNA Humans Downregulated in PCa Prognostic Stage T1-T2 Vs Stage T3-T4 p<0.05 Serum 30324582
1768 let-7b miRNA Humans Upregulated in PCa Prognostic Stage T1-T2 Vs Stage T3-T4 p<0.05 Serum 30324582
1769 miR-205 miRNA Humans Downregulated in PCa Prognostic Bone Metastasis Vs No Bone Metastasis p<0.05 Serum 30324582
1822 BUB1 mRNA Humans Methylated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1823 TPX2 mRNA Humans Methylated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1824 NCAPG mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1825 UBE2C mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1826 MELK mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1827 CCNA2 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1828 CCNB1 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1829 CDK1 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1830 E2F2 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1831 DLGAP5 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1832 TMEM206 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1833 CDKN3 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1834 SHMT2 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1835 SRD5A2 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1836 CSRP1 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1837 PGM5 mRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1838 NFIB mRNA Humans Downregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p<0.05 Tissue 30616540
1842 MT1IP (Metallothionein 1I, pseudogene (MT1IP), transcript variant 1); TRPT1 (tRNA phosphotransferase 1 (TRPT1), transcript variant 6); CHFR (Checkpoint with forkhead and ring finger domains, E3 ubiquitin protein ligase (CHFR), transcript variant 2); ZNF830 (Zinc finger protein 830); REXO1L2P (RNA exonuclease one homolog (S. cerevisiae)-like 2); SLC25A21 (SLC25A21 antisense RNA 1); mRNA Humans Differentially Expressed Prognostic Tumor Stage T1C Vs T2 p<0.05 Tissue 30890858
1843 FXR2 (Fragile X mental retardation, autosomal homolog 2); GADD45GIP1 (Growth arrest and DNA-damage-inducible, gamma interacting protein 1); STX4 (Syntaxin 4, transcript variant 1); CALCOCO2 (Calcium binding and coiled-coil domain 2, transcript variant 1); BEST4 (Bestrophin 4); URI1 (Prefoldin-like chaperone, transcript variant 3); DCP2 (Decapping mRNA 2, transcript variant 3); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2 Vs T2a p<0.05 Tissue 30890858
1844 RASSF4 (Ras association (RalGDS/AF-6) domain family member 4); SIRPA (Signal-regulatory protein alpha (SIRPA), transcript variant 3); COMP (Cartilage oligomeric matrix protein); SOD3 (Superoxide dismutase 3, extracellular); DIDO1 (Death inducer-obliterator 1, transcript variant 3); PRELP (Proline/arginine-rich end leucine-rich repeat protein, transcript variant 1); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2a Vs T2b p<0.05 Tissue 30890858
1845 BGN (Homo sapiens biglycan); RASSF4 (Ras association (RalGDS/AF-6) domain family member 4); USP21 (Ubiquitin-specific peptidase 21, transcript variant 3); NR1D1 (Nuclear receptor subfamily 1 group D, member 1); ANGPTL2 (Angiopoietin-like 2); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2b Vs T2c p<0.05 Tissue 30890858
1846 SMAP2 (Small ArfGAP2 (SMAP2), transcript variant 2); TMSA (Prothymosin, alpha (PTMA), transcript variant 1); YY1AP1 (YY1 associated protein 1 (YY1AP1), transcript variant 6); DOCK9 (Dedicator of cytokinesis 9 (DOCK9), transcript variant 2); KITLG (KIT ligand (KITLG), transcript variant b); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2c Vs T3a p<0.05 Tissue 30890858
1847 FAM133DP (Family with sequence similarity 133 member D pseudogene); SAMM50 (Sorting and assembly machinery component 50 homolog, protein coding); OR4F13P (Olfactory receptor family 4 subfamily F member 13 pseudogene); mRNA Humans Differentially Expressed Prognostic Tumor Stage T3a Vs T3b p<0.05 Tissue 30890858
1848 IKZF3 (IKAROS family zinc finger 3 (Aiolos), transcript variant 12); USP13 (Ubiquitin-specific peptidase 13 (isopeptidase T-3)); CLASP1 (Cytoplasmic linker associated protein 1, transcript variant 3); CEP112 (Centrosomal protein 112kDa, transcript variant 3); TSEN15 (tRNA splicing endonuclease subunit, transcript variant 1); FLVCR2 (Feline leukemia virus subgroup C cellular receptor family, member 2,transcript variant 2); GOLGA8B (Golgin A8 family, member B, transcript variant 1); ZNF438 (Zinc finger protein 438, transcript variant 1); SCARNA22 (Small Cajal body-specific RNA 22); LPPR1 (Lipid phosphate phosphatase-related protein type 1, transcript variant 2); PTGFR (Prostaglandin F receptor (FP), transcript variant 1); NREP (Neuronal regeneration related protein, transcript variant 1); mRNA Humans Differentially Expressed Prognostic Tumor Stage T2c Vs T3/4 p<0.05 Tissue 30890858
1854 miR-424 miRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p=0.043 Tissue 30345533
1855 miR-572 miRNA Humans Upregulated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p= 0.031 Tissue 30345533
1856 miR-572+ miR-424 miRNA Humans Upregulated in PC3 and DU145 Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p= 0.031 Tissue 30345533
1857 miR-572+ miR-424+ miR-1 + miR133b miRNA Humans Downregulated in Recurrent PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p= 0.031 Tissue 30345533
1865 Methlyation Status of APC Methylation Humans Methylated in PCa Prognostic Gleason Grade 1 Vs Gleason Grade 2-5 p<0.01 Tissue 30373654
1866 Methlyation Status of GSTP1 Methylation Humans Methylated in PCa Prognostic Gleason Grade 1 Vs Gleason Grade 2-5 p<0.01 Tissue 30373654
1867 Methlyation Status of RARβ2 Methylation Humans Methylated in PCa Prognostic Gleason Grade 1 Vs Gleason Grade 2-5 p<0.01 Tissue 30373654
1868 Methlyation Status of miR-34b/c Methylation Humans Methylated in Gleason Grade 2-5 Prognostic Gleason Grade 1 Vs Gleason Grade 2-5 p<0.01 Tissue 30373654
1869 Methlyation Status of APC Methylation Humans Methylated in Gleason Grade 2-5 Prognostic Low & Intermediate Risk Vs High Risk p<0.01 Tissue 30373654
1870 Methlyation Status of APC Methylation Humans Methylated in Gleason Grade 2-5 Prognostic Low & Intermediate Risk Vs High Risk p<0.05 Tissue 30373654
1871 Promoter methylation of: miR-193b+ miR-34b/c Methylation Humans Methylated in Gleason Grade 2-5 Prognostic Prostate Cancer Specific Survival Vs No Survival p=0.017 Tissue 30373654
1872 Methlyation Status of APC Methylation Humans Methylated in High Risk Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p=0.044 Tissue 30373654
1873 Promoter methylation of: GSTP1 Methylation Humans Methylated in High Risk Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p=0.017 Tissue 30373654
1874 Methlyation Status of miR-34b/c Methylation Humans Methylated in PCa Prognostic Biochemical Recurrence Vs No Biochemical Recurrence p=0.017 Tissue 30373654
1876 PD-L2 (Programmed death ligand 2) mRNA Humans Methylated in PCa Prognostic Biochemical Recurrence Free Survival Vs No Biochemical Recurrence Free Survival p=0.01 Tissue 30321406
1877 PD-L2 (Programmed death ligand 2) mRNA Humans Methylated in PCa Prognostic Distant Metastatic Free Survival Vs No DMFS Survival p=0.01 Tissue 30321406
1878 PD-L2 (Programmed death ligand 2) mRNA Humans Upregulated in PCa: []; Downregulated in PCa: [] Prognostic Prostate Cancer Specific Survival Vs No PCSS Survival p<0.001 Tissue 30321406
1879 Testosterone Protein Humans Decreased in Biochemical Recurrence Free Survival Prognostic Progression Free Survival Vs No Progression Free Survival p=0.037 Serum 30446464
1880 Testosterone Protein Humans Decreased in Biochemical Recurrence Free Survival Prognostic Progression Free Survival Vs No Progression Free Survival p=0.0028 Serum 30446464
1881 Testosterone Protein Humans Decreased in Biochemical Recurrence Free Survival Prognostic Overall Survival Vs No Overall Survival p=0.043 Serum 30446464
1894 ASAP1 DNA (Copy Number variations) Humans NA Prognostic Gleason Grade 4 in Gleason Score 7 p<0.01 Tissue 30611450
1895 HDAC9 DNA (Copy Number variations) Humans NA Prognostic Gleason Grade 4 in Gleason Score 7 p<0.01 Tissue 30611450
1896 CHD1 DNA (Copy Number variations) Humans NA Prognostic Gleason Grade 4 in Gleason Score 7 p<0.01 Tissue 30611450
1897 RB1 DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic Gleason Grade 4 in Gleason Score 7 p<0.01 Tissue 30611450
1898 PTEN DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic Gleason Grade 4 in Gleason Score 7 p<0.01 Tissue 30611450
1899 MYC DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic Gleason Grade 4 in Gleason Score 7 p<0.01 Tissue 30611450
1900 ASAP1 DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic GP3 in GS7 Vs GP3 in GS6 p<0.01 Tissue 30611450
1901 HDAC9 DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic GP3 in GS7 Vs GP3 in GS6 p<0.01 Tissue 30611450
1902 CHD1 DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic GP3 in GS7 Vs GP3 in GS6 p<0.01 Tissue 30611450
1903 RB1 DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic GP3 in GS7 Vs GP3 in GS6 p<0.01 Tissue 30611450
1904 PTEN DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic GP3 in GS7 Vs GP3 in GS6 p<0.01 Tissue 30611450
1905 MYC DNA (Copy Number variations) Humans Upregulated in Agressive PCa Prognostic GP3 in GS7 Vs GP3 in GS6 p<0.01 Tissue 30611450
1906 AFP; AKR1C1; AKR1C3; AKR1C4; C1orf229; C5orf28; C5orf34; CCNE1; DNMT1; E2F3; ENSA; FBXO4; G6PD; KPNA2; LETM2; LGSN; MRPS30; OPLAH; OR4K15; OR4L1; PAIP1; SKP1; SPEF2; WDR70; ZNF124; ZNF280A; ZNF324B; ZNF669; ZNF695; mRNA Humans Upregulated in Agressive PCa Prognostic Primary Prostate Cancer Vs Metastatic Prostate Cancer p<0.05 Tissue 30401717
1907 ANO7; NSA2; BOK; PDE8B; CECR6; PER3; CNNM1; PPP1R7; CNTNAP3; SCAMP1; COX15; SEMA4G; DMGDH; SLC7A8; DUSP1; TMEM18; EPHA7; TRIM8; FAM20C; TSLP; FOXC1; WDR41; ZNF658; GABRG3; GLB1L3; GLOD4; KCNMB1; LOC100128239; LOXL4; MTERFD2; NCAM1; NDN; mRNA Humans Upregulated in Agressive PCa Prognostic Primary Prostate Cancer Vs Metastatic Prostate Cancer p<0.05 Tissue 30401717
1908 ADAM12; AURKA; AURKB; C7orf49; CDCA8; CENPF; CIT; DNMT3B; DYRK2; FANCD2; FGD1; GDAP1; GPI; GTSE1; HNRNPUL1; IPO9; KIF23; LIG1; NCAPH; NHSL1; PEG10; SKP2; TMEM65; TOP2A; TPX2; UBE2T; mRNA Humans Upregulated in Agressive PCa Prognostic Primary Prostate Cancer Vs Metastatic Prostate Cancer p<0.05 Tissue 30401717
1909 ALDH1A3; APH1B; ATAD1; CTBS; CTSO; DHRS7; ESR1; FOXC1; MEIS2; NR4A1; PDE8B; RPS27L; SEC62; SPCS3; ZMAT1; mRNA Humans Upregulated in Metastatic PCa Prognostic Primary Prostate Cancer Vs Metastatic Prostate Cancer p<0.05 Tissue 30401717
1911 HSP27 Protein Humans Upregulated in Metastatic PCa Prognostic Survival Vs No Survival p=0.007 Tissue 30396985
1912 Prohibitin Protein Humans Upregulated in Metastatic PCa Prognostic Survival Vs No Survival p<0.001 Tissue 30396985
1913 ALDH6A1 Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Survival Vs No Survival p<0.001 Tissue 30396985
1914 Prohibitin+ HSP27+ALDH6A1 Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);]Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Survival Vs No Survival NA Tissue 30396985
1915 Prohibitin+ HSP27 Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);] Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Survival Vs No Survival NA Tissue 30396985
1916 Prohibitin+ALDH6A1 Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Survival Vs No Survival NA Tissue 30396985
1918 CAV1; MAGEA11; CALM1; CALR; TP53; FHL2; EGFR; APP; JUN; SMAD3; SMAD2; ESR1; RB1; HIPK3; BRCA1; SMAD1; GNB2L1; XRCC6; UBE2I; HDAC1; CDC2; AES; STAT3; IL6ST; APPBP2; PCAF; REPS2; FLNA; RAF1; MYC; MAPK1; TRAF6; CCND1; SMARCA4; HLA-B; TRAF2; RANBP9; PIAS4; GSK3B; TRIM29; FOS; IDE; SRC; PXN; SLC25A4; SP1; NR5A1 YWHAG; AKT1; CCNE1; Protein Humans Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);]Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] Prognostic Prostate Cancer Vs Lymph Node Metastasis NA Tissue 22654636
1931 let-7a* miRNA Humans Upregulated in PCa Prognostic Disseminated PCa VS Localised PCa p=0.012 Serum 25786615
1932 miR-200b* miRNA Humans Upregulated in PCa Prognostic Disseminated PCa VS Localised PCa p=0.028 Serum 25786615
1933 miR-210 miRNA Humans Upregulated in PCa Prognostic Disseminated PCa VS Localised PCa p=0.01 Serum 25786615
1934 miR-297 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.038 Serum 25786615
1935 miR-375 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.014 Serum 25786615
1936 miR-501-3p miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.028 Serum 25786615
1937 miR-562 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.03 Serum 25786615
1938 miR-616 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa p=0.05 Serum 25786615
1939 let-7a*+ miR-210 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa NA Serum 25786615
1940 let-7a*+ miR-210+ miR-562 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa NA Serum 25786615
1941 let-7a*+ miR-210+ miR-562+ miR-616 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa NA Serum 25786615
1942 let-7a*+ miR-210+ miR-562+ miR-616+ miR-297 miRNA Humans Upregulated in PCa [mean PC/mean]: (2.34 fold) Prognostic Disseminated PCa VS Localised PCa NA Serum 25786615
1968 Methylation status of ACTL6B Methylation Humans Differentially Methylated between PCa and Normal Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1969 Methylation status of AEBP1 Methylation Humans Differentially Methylated between PCa and Normal Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0021 Tissue 22589488
1970 Methylation status of AMID Methylation Humans Differentially Methylated between PCa and Normal Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1971 Methylation status of CD8A Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1972 Methylation status of CRIP1 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0037 Tissue 22589488
1973 Methylation status of FLJ30934 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1974 Methylation status of FLNC Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1975 Methylation status of FMOD Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1976 Methylation status of FOXE3 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1977 Methylation status of GAS7 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1978 Methylation status of GDPD5 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1979 Methylation status of HS3ST2 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1980 Methylation status of LOC349136 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1981 Methylation status of NEUROG1 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1982 Methylation status of PLTP Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1983 Methylation status of PTGER2 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1984 Methylation status of RASGRF2 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1985 Methylation status of RUNX3 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1986 Methylation status of SIX6 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1987 Methylation status of SLC9A3 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1988 Methylation status of SPSB4 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0008 Tissue 22589488
1989 Methylation status of SRD5A2 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1990 Methylation status of SUSD3 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0014 Tissue 22589488
1991 Methylation status of SYT10 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0001 Tissue 22589488
1992 Methylation status of TMEM74 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Recurrent prostate cancer Vs nonrecurrent cancer <0.0005 Tissue 22589488
1993 Methylation status of CHST7 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Clinical recurrence vs. biochemical recurrence <0.0050 Tissue 22589488
1994 Methylation status of LMX1B Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Clinical recurrence vs. biochemical recurrence <0.0021 Tissue 22589488
1995 Methylation status of PHLDA 3 Methylation Humans Hypermethlated in Recurrent prostate cancer Prognostic Clinical recurrence vs. biochemical recurrence <0.0772 Tissue 22589488
1996 Methylation status of RAFTLIN Methylation Humans Differentially Methylated in Clinical recurrence Prognostic Clinical recurrence vs. biochemical recurrence <0.0050 Tissue 22589488
1997 Methylation status of RASGRF2 Methylation Humans Differentially Methylated in Clinical recurrence Prognostic Clinical recurrence vs. biochemical recurrence <0.0015 Tissue 22589488
1998 Methylation status of TNFRSF10D Methylation Humans Differentially Methylated in Clinical recurrence Prognostic Clinical recurrence vs. biochemical recurrence <0.0008 Tissue 22589488
1999 Methylation status of ZNF135 Methylation Humans Differentially Methylated in Clinical recurrence Prognostic Clinical recurrence vs. biochemical recurrence <0.0061 Tissue 22589488
2000 Methylation status of ALPL Methylation Humans Differentially Methylated in Clinical recurrence Prognostic Systemic recurrence vs. local recurrence <0.0182 Tissue 22589488
2001 Methylation status of AMPH Methylation Humans Differentially Methylated in Clinical recurrence Prognostic Systemic recurrence vs. local recurrence <0.0021 Tissue 22589488
2002 Methylation status of BCDIN3 Methylation Humans Differentially Methylated in Clinical recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2003 Methylation status of BCL11B Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2004 Methylation status of BRD4 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0038 Tissue 22589488
2005 Methylation status of C18orf34 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2006 Methylation status of DCAMKL1 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2007 Methylation status of FGF5 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2008 Methylation status of FLJ42486 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2009 Methylation status of JAM2 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2010 Methylation status of LHX9 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2011 Methylation status of LOC283537 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2012 Methylation status of LRAT Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0034 Tissue 22589488
2013 Methylation status of PDE4B Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2014 Methylation status of POU3F3 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2015 Methylation status of PTGS2 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0153 Tissue 22589488
2016 Methylation status of RASGRF2 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0002 Tissue 22589488
2017 Methylation status of SLC27A6 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0017 Tissue 22589488
2018 Methylation status of SLC03A1 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2019 Methylation status of SPSB4 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2020 Methylation status of STAT3 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0017 Tissue 22589488
2021 Methylation status of SYN2 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0001 Tissue 22589488
2022 Methylation status of TACR3 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0086 Tissue 22589488
2023 Methylation status of TIRAP Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0003 Tissue 22589488
2024 Methylation status of WNT11 Methylation Humans Methylated in systemic Recurrence Prognostic Systemic recurrence vs. local recurrence <0.0011 Tissue 22589488